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ABSTRACT
The conclusions from randomized clinical trials (RCT) rely on the primary endpoint (PE), which is
chosen at the design stage of the study; thus, it is of utmost importance to select it appropriately. In
RCT, there should generally be only one PE, and it should be able to provide the most clinically relevant
and scientific evidence regarding the potential efficacy of the new treatment.
Composite endpoints (CE) consist of the union of two or more outcomes and are often used in RCT.
When the focus is time-to-event analysis, CE refer to the elapse time from randomization until the first
component of the CE. In oncology trials, for instance, progression-free survival is defined as the time
to disease progression or death.
The decision on whether to use a CE versus a single component as the PE is controversial. The
advantages and drawbacks regarding the use of CE have been extensively discussed in the literature.
Gómez and Lagakos develop a statistical methodology to evaluate the convenience of using a relevant
endpoint RE versus a CE consisting of the union of the RE plus another additional endpoint (AE). Their
strategy is based on the value of the asymptotic relative efficiency (ARE), which relates the efficiency
of using the logrank test based on the RE versus the efficiency based on the CE. The ARE is expressed
as a function of the marginal laws of the time to each component RE and AE, the probabilities of ob-
serving each component in the control group, the hazard ratios measured by each component of the
CE between the two treatment groups, and the correlation between components.
This thesis explores, elaborates on, implements and applies the ARE method. We have also devel-
oped a new online platform named Comp ARE that facilitates the practical use of this method. The
ARE method has been applied to cardiovascular studies. We have made further progress into the the-
oretical meaning of the ARE and have explored how to handle the probability and the hazard ratio of a
combination of endpoints.
In cardiovascular trials, it is common to use CE. We systematically examine the use of CE in this
field by means of a literature search and the discussion of several case studies. Based on the ARE
methodology, we provide guidelines for the informed choice of the PE.
We prove that the usual interpretation of the ARE as the ratio of sample sizes holds and that it can
be applied to evaluate the efficiency of the RE versus the CE. Furthermore, we carry out a simulation
study to empirically check the proximity between the ratio of finite sample sizes and the ARE.
We discuss how to derive the probabilities and hazard ratios when they come from a combination
of several components. Furthermore, it is shown that the combined hazard ratio (HR*) is, in general,
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not constant over time, even if the hazard ratio of the marginal components are. This non-constant
behaviour might have a strong influence on the interpretation of treatment effect and on sample size
assessment. We evaluate the behaviour of the HR* in respect to the marginal parameters, and we study
its departure from constancy, depending on different scenarios.
This thesis has implemented the ARE methodology on the online platform Comp ARE . Clinicians
and biostatisticians can use Comp ARE to study the performance of different endpoints in a variety of
scenarios. Comp ARE has an intuitive interface and it is a convenient tool for better informed deci-
sions regarding the PE. Results from different parameter settings are shown immediately by means of
tables and plots. Comp ARE is extended to quantify specific values for the combined probability and
hazard ratios. When the user cannot anticipate some of the needed parameters, Comp ARE provides
a range of plausible values. Moreover, the departure from constancy of a combined hazard ratio can
be explored by visualizing its shape over time. Sample size computations are implemented as well.
RESUMEN
Los eventos compuestos consisten en la unión de dos o más eventos, y son utilizados usualmente en
ensayos clínicos aleatorizados. A menudo, los análisis se basan en el tiempo hasta que se produce
el evento de interés; en ese caso hablaríamos del tiempo hasta el primero de los componentes. En
ensayos oncológicos, por ejemplo, la supervivencia libre de progresión se define como el tiempo hasta
la progresión o la muerte.
La decisión entre utilizar un evento compuesto o un componente de este como variable principal
es controvertida. Gómez y Lagakos desarrollan una metodología estadística para evaluar la convenien-
cia de utilizar un evento relevante frente a un evento compuesto consistente en la unión del evento
relevante más un evento adicional. Su estrategia se basa en el valor de la eficiencia relativa asintótica
(ARE, usando el acrónimo en inglés), la cual relaciona la eficiencia de utilizar el test logrank basado
en el evento relevante frente a la eficiencia basada en el evento compuesto. La ARE se expresa en fun-
ción de las leyes marginales correspondientes al tiempo hasta cada componente relevante y adicional,
las probabilidades de observar cada componente en el grupo control, los hazard ratios medidos para
cada componente del evento compuesto entre los dos grupos de tratamiento y la correlación entre los
componentes.
Esta tesis explora, profundiza, implementa y aplica la metodología ARE. También hemos creado
una nueva plataforma en línea, Comp ARE , que facilita el uso práctico de esta metodología.
Examinamos sistemáticamente el uso de eventos compuestos en ensayos cardiovasculares a partir
de una búsqueda en la literatura existente y discutimos diferentes casos. Basándonos en la metodología
ARE, aportamos guías para la elección informada de la variable principal.
Probamos que la interpretación usual de la ARE como el ratio de los tamaños de muestra se sus-
tenta y puede ser aplicado para evaluar la eficiencia del evento relevante frente al evento compuesto.
Asimismo, llevamos a cabo una simulación para estudiar empíricamente cuán cerca está el ratio de
tamaños de muestra finitos de la ARE.
Discutimos cómo derivar las probabilidades y hazard ratios cuando provienen de una combi-
nación de varios componentes. También mostramos que el hazard ratio combinado es, en general,
no constante a lo largo del tiempo, incluso cuando los hazard ratios de los componentes marginales
lo son. Este comportamiento no constante puede tener una gran influencia en la interpretación del
efecto del tratamiento y en el cálculo de los tamaños de muestra. Evaluamos el comportamiento del
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hazard ratio combinado respecto a los parámetros marginales y lo estudiamos para diferentes esce-
narios.
En esta tesis se ha implementado la metodología ARE en la plataforma en línea Comp ARE . Clíni-
cos y bioestadísticos pueden utilizar Comp ARE para estudiar el comportamiento de diferentes even-
tos en un gran abanico de escenarios. Comp ARE contiene una interfaz intuitiva y es una herramienta
conveniente para tomar una mejor decisión informada sobre la variable principal. Los resultados
provenientes de diferentes escenarios son mostrados instantáneamente a partir de tablas y gráficos.
Comp ARE se ha ampliado para cuantificar valores específicos para la probabilidad combinada y el
hazard ratio. Cuando el usuario no puede anticipar alguno de los parámetros necesarios, Comp ARE
facilita un rango de valores posibles. Asimismo, el hazard ratio puede ser explorado visualizando su
forma a lo largo del tiempo y, por lo tanto, proporciona una ayuda gráfica para posibles desviaciones
de proporcionalidad de los hazards. Cálculos sobre el tamaño de muestra también han sido imple-
mentados en la plataforma.
RESUM
Els esdeveniments compostos consisteixen en la unió de dos o més esdeveniments, i són utilitzats
usualment en assajos clínics aleatoritzats. Sovint, les anàlisis es basen en el temps fins que es produeix
l’esdeveniment d’interès; en aquest cas parlaríem del temps fins al primer dels components. En as-
sajos oncològics, per exemple, la supervivència lliure de progressió es defineix com a temps fins a la
progressió o la mort.
La decisió entre utilitzar un esdeveniment compost o un component d’aquest com a variable prin-
cipal és controvertida. Gómez i Lagakos desenvolupen una metodologia estadística per avaluar la
conveniència d’utilitzar un esdeveniment rellevant enfront d’un esdeveniment compost consistent
en la unió de l’esdeveniment rellevant més un esdeveniment addicional. La seva estratègia es basa
en el valor de l’eficiència relativa asimptòtica (ARE, fent servir l’acrònim en anglès), la qual relaciona
l’eficiència d’utilitzar la prova logrank basada en l’esdeveniment rellevant enfront de l’eficiència basada
en l’esdeveniment compost. L’ARE s’expressa com a funció de les lleis marginals corresponents al
temps fins a cada component rellevant i addicional, les probabilitats d’observar cada component en
el grup control, els hazard ratios mesurats per a cada component de l’esdeveniment compost entre els
dos grups de tractament i la correlació entre els components.
Aquesta tesi explora, aprofundeix, implementa i aplica la metodologia ARE. També hem creat una
nova plataforma en línia, Comp ARE , que facilita l’ús pràctic d’aquesta metodologia.
Examinem sistemàticament l’ús d’esdeveniments compostos en assajos cardiovasculars a partir
d’una recerca en la literatura existent i en discutim diferents casos. Basant-nos en la metodologia ARE,
aportem guies per a l’elecció informada de la variable principal.
Provem que la interpretació usual de l’ARE com la ràtio de les mides mostrals se sustenta i pot ser
aplicada per avaluar l’eficiència de l’esdeveniment rellevant enfront de l’esdeveniment compost. A
més, portem a terme una simulació per estudiar empíricament com n’està, de prop, la ràtio de mides
mostrals finites respecte de l’ARE.
Discutim com es poden derivar les probabilitats i els hazard ratios quan provenen d’una combi-
nació de diversos components. També mostrem que el hazard ratio combinat és, en general, no con-
stant al llarg del temps, fins i tot quan els hazard ratios dels components marginals ho són. Aquest
comportament no constant pot tenir una gran influència en la interpretació de l’efecte del tractament
i en el càlcul de les mides mostrals. Avaluem el comportament del hazard ratio combinat respecte dels
paràmetres marginals i l’estudiem per a diferents escenaris.
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En aquesta tesi també s’ha implementat la metodologia ARE en la plataforma en línia Comp ARE .
Clínics i bioestadístics poden utilitzar Comp ARE per estudiar el comportament de diferents esdeveni-
ments en un gran ventall d’escenaris. Comp ARE conté una interfície intuïtiva i és una eina convenient
per prendre una decisió informada millor sobre la variable principal. Els resultats provinents de difer-
ents escenaris són mostrats instantàniament a partir de taules i gràfics. Comp ARE s’ha ampliat per
quantificar valors específics per a la probabilitat combinada i el hazard ratio. Quan l’usuari no pot
anticipar algun dels paràmetres necessaris, Comp ARE facilita un rang de valors possibles. A més, el
hazard ratio pot ser explorat visualitzant-ne la forma al llarg del temps i, per tant, proporciona una
ajuda gràfica per a possibles desviacions de la proporcionalitat dels hazards. Càlculs sobre la mida
mostral també han estat implementats en la plataforma.
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INTRODUCTION. STATE OF THE ART AND MAIN
OBJECTIVES
1.1 Background
The broad aim of clinical drug development is to find out whether a treatment can be shown to be si-
multaneously safe and effective, to the extent that the risk-benefit relationship is acceptable. At phase
III of treatment development, randomized clinical trials (RCTs) are commonly designed to demon-
strate or confirm any therapeutic benefit (ICH, E8, E9).36 The conclusions from RCTs rely on the pri-
mary endpoint, which is chosen at the design stage of the study, and thus it is of utmost importance
to select it appropriately. In these trials, there should generally be only one primary endpoint, and
it should be able to provide the most clinically relevant and convincing evidence directly related to
the primary objective of the trial. In two-arm clinical trials, primary endpoint observations from con-
trol and treatment group are compared in order to provide scientific evidence regarding the potential
efficacy of the new treatment after a follow-up period (see Figure 1.1).
Composite endpoints (CEs), also referred as combined outcomes, consist of the union of two or
more outcomes and are often used as the primary endpoint in RCTs. Many trials measure dichoto-
mous (binary) endpoints and combine them into a single composite outcome which is considered to
have occurred if any of the individual outcomes is observed (Meinert, 2012; Neaton, 2005).44, 46 For ex-
ample, in the HIV field, the binary composite endpoint consisting of the observation of CD4 cell count
< 250 cel l s/µL or need for antiretroviral therapy (ART) is used as primary endpoint to prove treatment
efficacy (Reynolds, 2012).58 Total scores and health indices, based on rating scales, are also referred to
as composite endpoints (Chi, 2005).6 For instance, the Hamilton Depression Rating Scale (HAMD) is
based on multiple items and is a composite endpoint commonly used in depression trials.
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TOTAL PATIENTS
(Population)
Treatment
group
Random Allocation:
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Primary endpoint
results
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Follow-up period:
Primary endpoint
results
Figure 1.1: Scheme of a randomized confirmatory clinical trial.
When the focus is time-to-event analysis, composite endpoints use the time from randomization
until the time that the first CE component occurs. For example, progression-free survival is defined
as a time to disease progression or death in cancer studies. In cardiovascular trials, it is common to
use CEs as primary endpoints. They usually incorporate either terminal outcomes such as death from
any cause or cardiovascular death, and non-terminal outcomes such as myocardial infarction, stroke
and hospitalization. Time to the composite endpoint Major Adverse Cardiovascular Event (MACE), for
example, is generally defined as the time to cardiovascular death, myocardial infarction, target vessel
revascularization or stroke, whichever occurs first.
1.2 Main arguments in favor and cautions in the use of composite
endpoints in clinical trials
The decision on whether to use a composite endpoint versus a single component as the primary end-
point in RCTs is controversial. The pros and cons regarding the use of CE have been extensively dis-
cussed in the literature, as described in depth by the European Network for Health Technology Assess-
ment (EUnetHTA, 2013)13 guidelines. We summarize the main arguments discussed by several authors
(see Table 1.1).
Main arguments in favor
Although a simple endpoint has the advantage of simplicity, one of the major arguments for using
CEs is the need to combine multiple measurements into a single CE when a single primary variable
cannot be selected from several outcomes that are associated with the primary objective, as stated
in the guidelines for the International Conference on Harmonisation of Technical Requirements for
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Use of composite endpoints
Main arguments in favor
Combination of several outcomes of equal importance in one primary endpoint
Net clinical treatment benefit estimation
Multiplicity is adequately addressed without type I error adjustments
Avoids the problem of bias associated to competing risks
Event rate incrementation
Cautions
Need for homogeneity between components (similar clinical importance and expected effects)
Improvement can be driven by less important components
Interpretation problems regarding the the global effect of the CE
Multiplicity adjustments when reporting component results
Significance of CE does not imply significance of components
Including inappropriate components may lead to a loss of power in the CE
Table 1.1
Registration of Pharmaceutical for Human Use (ICH).36 Composite endpoints may help investigators
who are having difficulty in deciding which outcome to select as primary endpoint, especially when
they are of equal importance (Ferreira-González, 2007; Freemantle, 2003; Ross, 2007)15, 19, 59 or when
no single event alone could be considered an adequate primary endpoint. Composite endpoints can
also be useful when an outcome is considered a poor surrogate for the principal outcome of the study.
As stated in Amir 2012,2 progression free survival (PFS), a CE consisting of death and progression,
might sometimes be a valid surrogate for overall survival (OS), due to the high correlation between
them. Hence, PFS would be an alternative to testing the overall clinical effect of treatment.
The problem of multiple comparisons (multiplicity) is also addressed. Since only one outcome is
used as the primary endpoint for statistically testing the treatment effect, there is no need to adjust for
the type I error (Kleist, 2006; Wittkop, 2010).39, 80
Another major argument is to avoid the problem of competing risks, especially when the target
of a treatment is to reduce non-fatal events for diseases in which a fatal event might preclude their
observation (Cook, 2007). Thus, endpoints which do not include the mortality component are prob-
lematic, since patients who died before the endpoint of interest are likely to not have the same risk as
the survivors.
One more rational argument is that the use of CE assures higher event rates. The improvement
of treatments and population health in the society fortunately leads to declining event rates. Conse-
quently, a larger number of patients or longer follow-up period is needed in order to detect treatment
differences. Using CEs for a fixed sample size and follow-up period, the number of outcome observa-
tions (event rates) increases, and this might hopefully lead to an increase in the statistical efficiency of
the trial.
Cautions
Despite the rationale of using a composite endpoint as described above, several authors have cau-
tioned against their use and interpretation since they do not always prove useful and informative for
clinical decision making (Montori, 2005).45 It is well established that a CE in an RCT should only be
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used if the individual components are clinically meaningful and of similar importance to the patient
(Tomlinson, 2010);72 the expected effects on each component are similar based on biological plausi-
bility; and the more important clinical components should -at the very least- not be affected negatively
(Kleist, 2007).38
Composite endpoints can be used to describe an overall disease process (van Leth, 2003)76 or a
complex disease. However, the interpretation of the global effect of a CE might be confounding when
components are quite heterogeneous and do not move along the same lines as each other (Freemantle,
2003).19 Moreover, the treatment benefit with a CE in which the component endpoints have very dif-
ferent clinical importance can be problematic, because the treatment might have beneficial effects for
only the less important endpoints and thus give a misleading impression (Neaton, 2005).46 As stated in
Ferreira-González (2007),14 the main results of their systematic review show that less important com-
ponents had higher event rates and larger treatment effects, whereas the most important components
(mainly mortality outcomes) provided the lowest event rate and showed the smallest treatment effects.
As several authors propose, the results of each CE component should be reported individually.
They should be presented as secondary outcomes, and report the primary CE results that clearly fol-
low the CONSORT guidelines.8 Some methodologies take into consideration the importance of the
CE components, such as those based on priority ranking outcomes (Rauch, 2014).54 These methods
consider endpoints of different scale levels that assign higher weight to the most clinically relevant
endpoints. In Pocock (2012),52 the authors propose using the "win ratio", a measure that takes into
account the clinical importance of each component. However, this method does not actually use the
precise times from randomization to event occurrence, but only considers whether the outcome is
observed sooner in one patient than in another patient with a similar profile.
It has also been discussed that statistical treatment significance on the CE does not imply statisti-
cal treatment significance for each component. One way to overcome this problem is to analyze all the
composite components separately. However, this would lead to a problem of multiplicity. Consistency-
adjusted methods for type I error are proposed to test the efficacy of both the CE and the main compo-
nent (Rauch, 2014)57 although it comes with a loss in power. Another strategy is to test the superiority
of the CE and the non-inferiority of each one of the components in order to guarantee the overall clin-
ical relevance of the result (Rauch, 2013).55
Another rationale in literature for using CE instead of a single event as primary endpoint is the
reduction in sample size due to the increase of the event rates (Tomlinson, 2010).72 Hence, investiga-
tors hoping to increase the efficiency of the test can be tempted to add endpoints that will give them
a higher number of observed events, such as hospitalizations. In the case of time-to-event endpoints,
this increase is expected to be achieved by including component endpoints that occur with higher
frequency and/or earlier than the main events of interest (Freemantle, 2003).19 However, it has been
discussed (Montori, 2005)45 and demonstrated in Gómez and Lagakos (2013)27 that adding inappro-
priate components to the relevant endpoint might actually lead to a loss of power in detecting the true
treatment differences, consequently leading to a larger chance of failure in detecting any real effect of
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the treatment under study.
Another crucial aspect is referred to the joint probability law of the CE. It is the basis for computing
the needed sample size in order to detect a prespecified treatment effect size for a specified nominal
α-level for a given power. However, due to the complexity of the composite endpoint definition, a
straightforward derivation of the associated joint distribution cannot be based solely on the marginal
laws of their multiple single endpoints. The final law for the composite endpoint and, hence, the ef-
ficient evaluation of the treatment effect are influenced by: the distribution of every component of
the composite endpoint, the probability of observing the outcome in the control group, the expected
treatment effects given by the hazard ratio between the two treatment groups, the correlation between
the components and, to a lesser extent, the joint distribution between the components.
In the following sections we describe how to assess the statistical treatment effect in clinical trials
that involve time-to-event analysis, and the statistical methodology developed by Gómez and Lagakos
(2013) for deciding when it would be more appropriate to use a CE instead of a single endpoint.
1.3 Testing the statistical treatment effect of the Primary Endpoint
1.3.1 The logrank test
The logrank test, also known as the Mantel-Cox test, is commonly used in time-to-event analysis for
comparing treatment effects between groups. Assume that we have a two-arm study that involves
either a random assignment to an active (X = 1) or a control treatment (X = 0) that aims to prove
the efficacy of the new active treatment. The effect of treatment is evaluated based on the time T ( j )
to an endpoint E , where the superscript j indicates the treatment group ( j = 0 for the control group
and j = 1 for the treatment group). Let λ( j )(t ) and S( j )(t ) denote the hazard and survival functions of
T ( j ) ( j = 0,1), respectively. The null hypothesis of no treatment effect is given by H0 : S(0)(t ) = S(1)(t ),
or equivalently by H0 : HR(t ) = λ(1)(t )/λ(0)(t ) = 1, where HR(t ) is the hazard ratio. The alternative
hypothesis that the new treatment improves survival is given by Ha : HR(t )< 1.
Consider the observed failure times t1 < t2 < ·· · < tl . At each time ti (i = 1,2, . . . , l ) we observe d (0)i
events and R(0)i individuals at risk in group 0 (control), and d
(1)
i events and R
(1)
i individuals at risk in
group 1 (treatment).
Group Observed to fail at ti (events) Not fail at ti At risk
Control d (0)i R
(0)
i −d (0)i R(0)i
Treatment d (1)i R
(1)
i −d (1)i R(1)i
Total di Ri −di Ri
Table 1.2
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Note that conditioned on the four marginal totals, d (1)i defines the whole table (1.2). Under the null
hypothesis H0 of no treatment effect, d
(1)
i follows a hypergeometric distribution. That is:
P (d (1)i = d)=
(
di
d
)(
Ri −di
R(1)i −d
)
/
(
Ri
R(1)i
)
,
where d takes values d =max(0,di −R(0)i ), . . . ,mi n(di ,R(1)i ).
Therefore, the mean Ei and variance Vi of d
(1)
i under H0 are:
Ei =
(
R (1)i
Ri
)
di ,
Vi = Ri−R
(1)
i
Ri−1 ·R
(1)
i
(
di
Ri
)(
1− diRi
)
.
The logrank test is constructed by comparing the observed event minus the expected number of events
in one group. In our case, we denote:
O =∑li=1 d (1)i (total failures in group 1),
E =∑li=1 Ei ,
V =∑li=1 Vi ,
and define the logrank statistic as: Z = O−Ep
V
=
∑l
i=1(d
(1)
i −Ei )√∑l
i=1 Vi
.
It is known that under the null hypothesis H0 of no treatment effect, the test statistic Z follows a stan-
dard normal distribution (Z ∼ N (0,1)) (Cox, 1972),9 or equivalently Z 2 ∼ χ21. Hence, we would reject
the null hypothesis in favor of the alternative for large values of Z .
1.3.2 Testing treatment effect using the relevant endpoint and the composite endpoint
Consider that the effect of treatment is to be evaluated based on the time T ( j )R to a relevant event ER ,
where the superscript j indicates the treatment group ( j = 0 for the control group and j = 1 for the
treatment group). Assume now that an additional endpoint EA is considered as a component of the
primary endpoint and the composite endpoint E∗ = ER∪EA is to be used instead, in order to prove the
efficacy of the new treatment. The effect of treatment would then be evaluated with the time T ( j )∗ to
E∗, where T
( j )
∗ =min{T ( j )R ,T
( j )
A }, and T
( j )
A stands for the time to EA for each group. We will also assume
that end-of-study censoring at time τ is the only non-informative censoring cause for both groups; this
assumption indirectly implies that the censoring mechanism is the same for both groups.
Let λ˜( j )k (t )(k =R, A) denote a marginal or cause-specific hazard for the relevant endpoint(k =R) or
the additional endpoint (k = A), such that λ˜( j )k (t )= λ
( j )
k (t ) are the marginal hazards of T
( j )
k when there
are no competing causes, and λ˜( j )k (t ) = λ
( j )
C k (t ) denote the cause-specific hazards of T
( j )
k when either
T ( j )R is a competing cause for T
( j )
A , or T
( j )
A is a competing cause for T
( j )
R .
If we were to use the relevant endpoint as primary endpoint in a clinical trial, the treatment effect
would be tested with the logrank test, being the null hypothesis of no effect given by H0 : HRR (t ) =
λ˜(1)R (t )/λ˜
(0)
R (t ) = 1 and the alternative that the new treatment improves survival by Ha : HRR (t ) < 1.
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Analogously, if we were to use the composite endpoint as primary endpoint, the treatment effect would
be tested with the logrank test to compare H∗0 : HR∗(t )=λ(1)∗ (t )/λ(0)∗ (t )= 1 versus H∗a : HR∗(t )< 1.
1.4 The Asymptotic Relative Efficiency (ARE) of two tests
A statistical test is more efficient against another if for a given significance level the former leads to a
higher power. However, for any fixed alternative to a null hypothesis, say H0 : θ = θ0, the power of any
test will typically go to 1 if the number of observations is sufficiently large (Noether, 1954).48 Pitman
defines a sequence of alternatives hypotheses around the null with asymptotic power converging to
some number less than 1, as n →∞, to compare the efficiency of two tests. Pitman alternatives are
given by:
Ha,n : θn = θ0+k/
p
n, for any fixed k.
Since these alternatives change with n they form a sequence of alternatives. And since θn → θ0 as
n →∞, it is called a sequence of local alternatives or contiguous alternatives to the null.
Assume we have two tests based on statistics T1n and T2n which follow a normal distribution
N (µ1n(θ),σ21n(θ)) and N (µ2n(θ),σ
2
2n(θ)), respectively. We want to test the null hypothesis H0 : θ = θ0
against the alternatives Ha,1n : θ1n = θ0 + k1/pn1 and Ha,2n : θ2n = θ0 + k2/pn2 for T1n and T2n , re-
spectively, with k1 > 0 and k2 > 0. The power of T1n and T2n for a given statistical significance α is,
respectively, given by:
Π1n(θ1n)= P (T1n ≥ zα|Ha,1n),
Π2n(θ2n)= P (T2n ≥ zα|Ha,2n),
where zα is the standard normal quantile corresponding to the right tail probability α.
We define the relative efficiency of T2n with respect to T1n as the ratio of sample sizes n1/n2 that are
required to achieve the same power for the same alternative hypothesis for a given significance level
(Lehmann and Romano, 2005).41 For large values of n, Pitman defines the asymptotic relative efficiency
as:
ARE(T2n ,T1n)= n1
n2
= lim
n→∞
µ
′
2n(θ0)/σ2n(θ0)
µ
′
1n(θ0)/σ1n(θ0)
= lim
n→∞
R22n(θ0)
R21n(θ0)
,
where µ
′
i n(θ0) = ∂µi n(θ0)/∂θ for i = (1,2) and R21n(θ0), R22n(θ0) are called the efficacies of the test T1n
and T2n , respectively. Therefore, the ARE(T2n ,T1n) is given by the limit of the ratio of the efficacies of
the two tests, which is equivalent to the limit of the corresponding ratio n1/n2.
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1.5 The ARE method by Gómez and Lagakos
Gómez and Lagakos (2013) develop a statistical methodology that helps to decide between using a
relevant endpoint ER instead of a composite endpoint E∗, consisting of the union of ER plus another
additional endpoint EA , to evaluate the effect of a treatment. Their strategy is based on using the value
of the asymptotic relative efficiency to assess the efficiency of the logrank test ZR , which is based on
the relevant endpoint, and comparing it with the efficiency of the logrank test Z∗, which is based on
the composite endpoint.
Endpoints ER and EA may or may not include terminating events, also called fatal events. This
leads to four different censoring situations, referred to as Cases 1, 2, 3 and 4 (see Table 1.3):
Case 1: Neither of the two endpoints (ER , EA) includes a terminating event. We observe T
( j )
k (k =
R, A) if Ek occurs before the right-censoring time τ.
Case 2. The relevant endpoint does not include a terminating event while the additional endpoint
does. Hence, we observe T ( j )R if T
( j )
R <min{T
( j )
A ,τ}, and we observe T
( j )
A if T
( j )
A < τ.
Case 3. The relevant endpoint includes a terminating event, but the additional endpoint does not.
Thus, we observe T ( j )R if T
( j )
R < τ, and we observe T
( j )
A if T
( j )
A <min{T
( j )
R ,τ}.
Case 4. Both endpoints include a terminating event. We observe T ( j )R if T
( j )
R <min{T
( j )
A ,τ}, and we
observe T ( j )A if T
( j )
A <min{T
( j )
R ,τ}.
Relevant endpoint Additional endpoint
Case 1 NT NT
Case 2 NT T
Case 3 T NT
Case 4 T T
Table 1.3: Four possible combinations depending on whether the relevant endpoint or the additional endpoint
includes a terminating event (T). NT stands for non-terminating event.
Consider the marginal or cause-specific hazard function λ˜(0)R (t ) of the relevant endpoint in the
control group as fixed and define a sequence of alternatives Ha,n that consist of instantaneous haz-
ard functions that are close enough to λ˜(0)R (t ); for instance, by taking λ˜
(1)
R,n(t )= λ˜(0)R (t )eg (t )/
p
n for some
g (t ) function. Logrank ZR is asymptotically N (0,1) under the null hypothesis of no treatment dif-
ference (H0 : HRR (t ) = λ˜(1)R (t )/λ˜(0)R (t ) = 1); and under the sequence of alternatives Ha,n it is asymp-
totically normal with unit variance and mean µR given in equation (1.1)(Schoenfeld, 1983).64 Anal-
ogously, the hypothesis of no treatment effect when using the composite endpoint E∗ is stated as
H∗0 :λ
(1)
∗ (t )/λ
(0)
∗ (t )=HR∗(t )= 1, and the sequence of alternatives H∗a,n : HR∗,n(t )= eg∗(t )/
p
n for a given
function g∗(t ). The statistic Z∗ is asymptotically N (0,1) under H∗0 and asymptotically normal with unit
variance and mean µ∗ given in equation (1.2) under the sequence H∗a,n . The asymptotic means of ZR
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and Z∗, called the non-centrality parameters, are given by:
µR =
∫∞
0 g (t )p(t )[1−p(t )]PrH0 {U ≥ t }λ˜(0)R (t )d t√∫∞
0 p(t )[1−p(t )]PrH0 {U ≥ t }λ˜(0)R (t )d t
, (1.1)
µ∗ =
∫∞
0 g∗(t ))p∗(t )[1−p∗(t )]PrH∗0 {U∗ ≥ t }λ
(0)
∗ (t )d t√∫∞
0 p∗(t )[1−p∗(t )]PrH∗0 {U∗ ≥ t }λ
(0)
∗ (t )d t
, (1.2)
where U = min{TR ,τ} (in Cases 1 and 3), U = min{TR ,TA ,τ} (in Cases 2 and 4) and U∗ = min{T∗,τ}
denote the observed outcome; τ denotes the censoring time; p(t ) = PrH0 {X = 1|U ≥ t } and p∗(t ) =
PrH∗0 {X = 1|U∗ ≥ t } are the null probabilities that someone at risk at time t is in treatment group
1; PrH0 {U ≥ t } and PrH∗0 {U∗ ≥ t } are the null probabilities that someone is still at risk at time t and
PrH0 {U ≥ t }λ˜(0)R (t ) and PrH∗0 {U∗ ≥ t }λ
(0)
∗ (t ) correspond to the probabilities, under the null hypothesis,
of observing events ER and E∗, respectively, at time t .
To evaluate the difference in efficiency between using the logrank test with the relevant endpoint
based on ZR versus with the composite endpoint based on Z∗, Gómez and Lagakos base their strategy
on the behavior of the ARE of Z∗ versus ZR given by:
ARE(Z∗, ZR )=
(
µ∗
µR
)2
, (1.3)
where µR and µ∗ are to be replaced by expressions (1.1) and (1.2).
Gómez and Lagakos derive an expression of the ARE based on parameter values that can be an-
ticipated at the design stage of a clinical trial. Next, we describe the assumptions established and the
anticipatable1 parameters needed to compute ARE .
1.5.1 Assumptions
Censoring
The end-of-study censoring at time τ (τ= 1 without loss of generality) is the only non-informative
censoring cause for both groups. This assumption implies that the censoring mechanism is the same
for both groups.
Proportional hazards
The hazard ratios between T (0)R and T
(1)
R and between T
(0)
A and T
(1)
A are constant, that is, HRR(t ) =
λ˜(1)R (t )/λ˜
(0)
R (t ) =HRR and HRA(t ) = λ˜(1)A (t )/λ˜(0)A (t ) =HRA for all t . Note that although we are assuming
that the hazard functions λ˜( j )R (t ) and λ˜
( j )
A (t ) ( j = 0,1) are proportional, this does not imply the pro-
portionality of hazards λ(0)∗ (t ) and λ
(1)
∗ (t ) for the composite endpoint T∗ (see Figure 1.2). Indeed, the
hazard ratio is only constant for specific scenarios, as we will describe further in another chapter of
this thesis.
1Anticipatable: capable of being anticipated (Source: http://www.collinsdictionary.com).
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Figure 1.2: Hazard ratios HRR , HRA and HR∗ of the relevant, additional and composite endpoint; and survival
functions S(0)∗ (t ) and S
(1)
∗ (t ) of the composite endpoint for each group. Marginal Weibull distributions are assumed
for the times to the relevant and additional endpoints.
Copula assumptions
We can approach the bivariate distribution (TR ,TA) by decoupling the joint survival of (TR ,TA) into
univariate components using a copula model. Gómez and Lagakos consider a Frank Archimedean
survival copula (Trivedi PK and Zimmer DM, 2005),73 given by:
C (tR , tA ;θ)=−1
θ
log
{
1+ (e
−θtR −1)(e−θtA −1)
e−θ−1
}
,
where θ(−∞< θ <∞) is an association parameter between TR and TA . Perfect positive and negative
dependence between marginals are achieved when θ tends to ∞ and −∞, respectively. When θ tends
to 0, TR and TA are close to being independent. Other copulas could also be considered (Plana-Ripoll
and Gómez, 2015).51 The association parameter θ is biunivocally related to Spearman’s rank correla-
tion ρ(−1< ρ < 1) given by ρ = ρ(θ)= 1− 12θ [ 1θ
∫ θ
0
t
e t−1 d t − 2θ2
∫ θ
0
t 2
e t−1 d t ].
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Spearman’s correlation
The spearman rank correlation ρ between TR and TA is given by (Schweizer, 1981):66
ρ(TR ,TA)= 12
∫ +∞
0
∫ +∞
0
(F (tR , tA)−FR (tR )FA(tA))dFR (tR )dFA(tA), (1.4)
where FR (tR ) and FA(tA) are the distribution functions of TR and TA , respectively, and F (tR , tA) is the
joint distribution function of (TR ,TA).
The joint survival probability is given by:
S(tR , tA)= P (TR > tR ,TA > tA)= 1−FR (tR )−FA(tA)+F (tR , tA)= SR (tR )+S A(tA)−1+F (tR , tA), (1.5)
where SR (tR )= 1−FR (tR ) and S A(tA)= 1−FA(tA) are the survival functions of TR and TA , respectively.
It follows from (1.5)
F (tR , tA)= S(tR , tA)−SR (tR )−S A(tA)+1,
and
F (tR , tA)−FR (tR )FA(tA)= S(tR , tA)−SR (tR )−S A(tA)+1−(1−SR (tR ))(1−S A(tA))= S(tR , tA)−SR (tR )S A(tA).
Hence from (1.4), we can express ρ(TR ,TA) in terms of the survival functions as follows:
ρ(TR ,TA)= 12
∫ +∞
0
∫ +∞
0
(S(tR , tA)−SR (tR )S A(tA))dSR (tR )dS A(tA). (1.6)
We can also define ρ in terms of the survival copula CS(SR (tR ),S A(tA))= S(tR , tA) as:
ρ(TR ,TA)= 12
∫ +∞
0
∫ +∞
0
(CS(SR (tR ),S A(tA))−SR (tR )S A(tA))dSR (tR )dS A(tA).
If we make the substitution u = SR (tR ) and v = SR (tA), the ρ(TR ,TA) simplifies to:
ρ(TR ,TA)= 12
∫ 1
0
∫ 1
0
(CS(u, v)−uv)dud v.
Spearman’s ρ can be as well defined in terms of the probability of concordance and discordance of
two vectors (Nelsen, 2006).47 Let (TR1,TA1), (TR2,TA2) and (TR3,TA3) be three independent random
vectors with common joint distribution function F (tR , tA). The population version of ρ is defined to
be proportional to the probability of concordance minus the probability of discordance for the two
vectors (TR1,TA1) and (TR2,TA3) as:
ρ(TR ,TA)= 3(P [(TR1−TR2)(TA1−TA3)> 0]−P [(TR1−TR2)(TA1−TA3)< 0]).
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Joint distribution of (T ( j )R , T
( j )
A )
Assuming equal association parameter θ for groups 0 and 1, the joint survival and joint density for
(T ( j )R , T
( j )
A ) (j=0,1) are given by:
S( j )(R,A)(tR , tA ;θ)=−
1
θ
log
{
1+ (e
−θS( j )R (tR )−1)(e−θS( j )A (tA)−1)
e−θ−1
}
f ( j )(R,A)(tR , tA ;θ)=
θe−θ(S
( j )
R (tR )+S
( j )
A (tA))
(1−e−θ)e−2θS( j )(R,A)(tR ,tA ;θ)
[ f ( j )R (tR )][ f
( j )
A (tA)], (1.7)
where S( j )R (tR ) and f
( j )
R (tR ), S
( j )
A (tA) and f
( j )
A (tA) are the survival and marginal densities of T
( j )
R and T
( j )
A ,
respectively. The survival function of T ( j )∗ =mi n{T ( j )R ,T
( j )
A } is given by:
S( j )∗ (t ;θ)= P (T ( j )∗ > t )= P (T ( j )R > t ,T
( j )
A > t )=C (S
( j )
R (t ),S
( j )
A (t );θ)= S
( j )
(R,A)(t , t ;θ).
Marginal laws of T ( j )R and T
( j )
A
Regarding the marginal laws of T ( j )R and T
( j )
A , the Weibull distributions are chosen since they are
widely used in survival analysis due to their flexibility, allowing decreasing, constant and increasing
hazard functions. Hence, for both treatment groups ( j = 0,1) the survival function is given by
S( j )k (t )= exp{−(t/b
( j )
k )
β
( j )
k } (k =R, A),
where b( j )k and β
( j )
k are the scale and shape parameters, respectively, for T
( j )
k . The shape parameters
are chosen equal for both groups, that is β(0)k = β(1)k = βk , so that the assumption of proportionality of
the hazards holds.
Denoting by pR and p A the probabilities of observing ER and EA in group 0, respectively, they are
related to the marginal law of T (0)R ,T
(0)
A and the bivariate law of (T
(0)
R ,T
(0)
A ) as follows:
pR =
Pr{T
(0)
R < 1}= 1−S(0)R (1) Cases 1,3
Pr{T (0)R <min{T (0)A ,1}}=
∫ 1
0
∫∞
u f
(0)
(R,A)(u, v ;θ)d vdu Cases 2,4
p A =
Pr{T
(0)
A < 1}= 1−S(0)A (1) Cases 1,2
Pr{T (0)A <min{T (0)R ,1}}=
∫ 1
0
∫∞
v f
(0)
(R,A)(u, v ;θ)dud v Cases 3,4 ,
where f (0)(R,A)(u, v ;θ) is the joint density of (T
(0)
R ,T
(0)
A ) and is defined in (1.7).
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The scale parameters b(0)k (k =R, A) are derived as follows:
Case 1: b(0)k = 1(− log(1−pk ))1/βk .
Case 2: The scale parameter b(0)R is a function of the joint density f
(0)
(R,A)(·, ·;θ), and it is found as the
solution of equation pR =
∫ 1
0
∫∞
u f
(0)
(R,A)(u, v ;θ)d vdu. The scale parameter b
(0)
A is a function of p A and
βA , and it is given by b
(0)
A = 1(− log(1−p A))1/βA .
Case 3: b(0)R = 1(− log(1−pR ))1/βR and b
(0)
A is a function of the joint density f
(0)
(R,A)(·, ·;θ) and it is found as
the solution of equation p A =
∫ 1
0
∫∞
v f
(0)
(R,A)(u, v ;θ)dud v .
Case 4: The scale parameters b(0)k are functions of the joint density f
(0)
(R,A)(·, ·;θ) and are found as the
simultaneous solution of equations pR =
∫ 1
0
∫∞
u f
(0)
(R,A)(u, v ;θ)d vdu and p A =
∫ 1
0
∫∞
v f
(0)
(R,A)(u, v ;θ)dud v .
The scale parameters b(1)R , b
(1)
A are computed so that the assumption of proportionality of the haz-
ards holds, that is, b(1)R and b
(1)
A are such that HRR =
λ(1)R (t )
λ(0)R (t )
and HRA = λ
(1)
A (t )
λ(0)A (t )
for Cases 1 and 3; and
λ(1)C R (t ;θ)
λ(0)C R (t ;θ)
=HRR and λ
(1)
C A (t ;θ)
λ(0)C A (t ;θ)
=HRA for Cases 2 and 4 (we refer to the the original publication (Gómez and
Lagakos, 2013)27 for further details).
Under the above assumptions, expression (1.3) for Cases 1 and 3 becomes
ARE(Z∗, ZR )=
(∫ 1
0 log
{
λ(1)∗ (t )/λ
(0)
∗ (t )
}
f (0)∗ (t )d t
)2
(
log
{
HRR
})2 (∫ 10 f (0)∗ (t )d t )(∫ 10 f (0)R (t )d t ) ,
and for Cases 2 and 4
ARE(Z∗, ZR )=
(∫ 1
0 log
{HRRλ(0)C R (t )+HRAλ(0)C A (t )
λ(0)C R (t )+λ(0)C A (t )
}
f (0)∗ (t )d t
)2
(log{HRR})2(
∫ 1
0 f
(0)
∗ (t )d t )V
,
being
V =
∫ 1
0
e−HRA
∫ t
0 λ
(0)
C A (u)duS(0)∗ (t )λ
(0)
C R (t )
e−
∫ t
0 λ
(0)
C A (u)dupi+e−HRA
∫ t
0 λ
(0)
C A (u)du(1−pi)
d t ,
where f (0)R (t ) and f
(0)
∗ (t ) are the density functions of T
(0)
R and T
(0)
∗ , respectively; S
(0)
∗ (t ) stands for the
survival of T (0)∗ ; and pi stands for the probability, under the null hypothesis, of being in group 1.
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1.5.2 The ARE expression as a function of anticipatable parameter values
Gómez and Lagakos express the ARE function in terms of a list of parameter values that trialists might
anticipate at the design stage of the trial. These parameter values are:
1. The probabilities pR , p A of observing the ER and the EA , respectively, in the control group,
2. the relative treatment effects given by the hazard ratios HRR and HRA ,
3. the Spearman correlation coefficient ρ between ER and EA ,
4. decreasing, constant or increasing hazard rates given by the shape parameters βR and βA for the
Weibull marginal distribution for TR and TA , respectively, and
5. the probability pi, under the null hypothesis, of being in group 1 (only needed for Cases 2 and 4).
The above parameters are all easily interpretable for physicians and investigators. Interpretability
is important because researchers will have to decide, a priori, which are the most plausible anticipated
values in a study design of a clinical trial; then, based on those chosen values, the decision to adopt or
not a composite endpoint will have to be made on the ARE results. In cases where investigators cannot
specify the exact value of some parameter, they can consider a range of values to evaluate whether the
ARE affects their decision. The rule for deciding whether or not the composite is recommended will
be based on the following:
• When ARE(Z∗, ZR )> 1⇒ the composite endpoint should be used instead of the relevant.
• When ARE(Z∗, ZR )≤ 1⇒ the relevant endpoint alone should be used.
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1.6 Goals and thesis structure
The proper choice of the primary endpoint is crucial to achieve the main objectives in a randomized
clinical trial. The asymptotic relative efficiency provides a method on which base the decision on the
primary endpoint. Practical guidelines from the methodology can be of great help for trialists in their
field of research. Furthermore, computational tools that facilitate the use of methodological develop-
ments for a specific study might significantly help clinicials in the design of the study.
The present work is organized as follows:
In chapter 2, we carry out a a systematic search for the use of composite endpoints in the cardiovas-
cular field. Based on randomized clinical trials published in 2008, the ARE method is applied in order
to set general recommendations. This research gave rise to a publication in the journal Circulation:
Cardiovascular Quality and Outcomes (Gómez, Gómez-Mateu and Dafni, 2014).26
In chapter 3 we prove that the usual interpretation of the Asymptotic Relative Efficiency holds when
two different sets of hypotheses are set. This result implies that the ARE can be interpreted as the
ratio of the required sample sizes when using the relevant or the composite endpoint as the primary
endpoint. A publication in SORT (Gómez and Gómez-Mateu, 2014)24 presents these developments as
well as a simulation for empirically analyzing how close we are to the limiting relationship between the
ARE and the required sample sizes for a finite number of patients.
In chapter 4 we describe CompARE,28 a web-based platform that we have developed as a tool for
making the methodology widely applicable within the scientific community. It is of great help when
planning a clinical trial, since it quantifies how efficient a relevant subset of outcomes is with respect
to a larger subset of outcomes. CompARE is a user-friendly, free tool and, although it is programmed
internally in R, users need no knowledge of R, nor do they need to install it on their computers. Com-
pARE is currently accessible at the following website: https://cinna.upc.edu/compare.
Chapter 5 provides practical solutions for assigning anticipated probabilities and hazard ratios
when the relevant or the additional endpoints consist of several components. This is an important
issue in practice, since investigators may know the anticipated probabilities and hazard ratios of each
one of the components rather than the combined probabilities and hazard ratios. A letter to the editor
in Statistics in Medicine (Gómez, Gómez-Mateu, 2016)23 is published based on the evaluation of the
ARE depending on the choice of different combined parameter values.
In chapter 6, we present preliminary extensions of CompARE. Specifically, some settings assumed
by default in Chapter 4 are extended: i) we allow to assume Weibull distributions with decreasing or
increasing hazard rates, different correlations and copulas other than Frank’s, ii) possible values for
the combined probabilities and hazard ratios are also included in the platform when the relevant or
the additional endpoints consist of several components, iii) computations where both the relevant and
additional endpoint include death, and iv) sample size computations for achieving a specific power at
a fixed significance level when using the relevant or the composite endpoint.
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Finally, in the closing chapter 7 we describe new lines of research.
The complete list of references used in the literature search in chapter 2, the R code to perform the
computations of the ARE , some methodological details of chapter 5 and the publications derived from
this thesis are included in the Appendix.
C
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THE COMPOSITE ENDPOINT IN THE CARDIOVASCULAR
AREA
Composite endpoints are commonly used in randomized clinical cardiovascular trials to assess the
efficacy of a new treatment. In this field, the often rare event of the relevant primary endpoint (indi-
vidual or composite), such as cardiovascular death, myocardial infarction, or both, is combined with
a more common secondary endpoint, such as target lesion revascularization, with the aim to increase
the statistical power of the study. This increase, in the case of time-to-event endpoints, is expected to
be achieved by the inclusion of component endpoints that occur with higher frequency or earlier than
the main events of interest.19 However, in some scenarios, adding specific components might in fact
lead to loss of power to detect the true treatment differences.
The objective of the present study is to examine systematically the use of composite endpoints (CE)
in cardiovascular randomized clinical trials (RCT), to illustrate the ARE method by means of case stud-
ies, and to use it to provide guidelines for the informed choice of the primary endpoint in the context
of cardiovascular clinical trials.
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The contents of this chapter have been published in26 (See Appendix):
Gómez G, Gómez-Mateu M, Dafni U. Informed Choice of Composite End Points in Cardiovascular
Trials (2014). Circulation. Cardiovascular Quality and Outcomes, 7, 170–178.
This chapter is based on the above paper after excluding the introduction because its content has
been detailed in the previous chapter. The notation used here is coherent with the rest of this thesis,
and differs slightly from the one used in the paper.
In this chapter we have updated the computations of the ARE values for case study 2 in section 2.3.2
and figure 2.5, as well as part of the writing from the published one. After the publication of the paper,
we were aware of a misspecification in the R code when calculating the survival of the composite end-
point in control group for Case 2, which has been corrected. Luckily, the specific recommendation for
the case study have not changed and also the general recommendations with the computed scenarios
remains similar except that correlation is not affecting with the same strength.
Guadalupe Gómez, Moisés Gómez-Mateu and Urania Dafni
Informed Choice of Composite End Points in Cardiovascular Trials
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2.1 Background
2.1.1 Composite endpoints in cardiovascular research
In the past 15 years, many authors have addressed the issue of using and interpreting CEs in the cardio-
vascular research area. In what follows we present a brief summary of relevant readings. Freemantle
et al19, 20 examine the use of CE in major clinical trials, by means of a selection of 167 RCT (with a total
of 300,276 patients), that include a primary CE incorporating all-cause mortality, assess the arguments
for and against CE, and provide guidance on their applications and reporting. He acknowledges the in-
adequate reporting of CEs used as primary outcome measures in randomized trials, concluding that,
often, the reported results apply to the individual components of the CE rather than to the overall CE.
Ferreira-González et al14–16 use MEDLINE to conduct 2 systematic reviews to investigate the ra-
tionale, potential problems and solutions of using CEs. They point out that the CE, by capturing the
net benefit of the intervention, could give a more appropriate reflection of the clinical spectrum of im-
portant outcomes associated with the disease being treated than would any component alone. In the
conclusions, it is stated that the use of CE is often complicated by the magnitude of the effect of treat-
ment across component endpoints and by the relative importance of the different components for the
patients. The reader is referred to Huque et al35 for an excellent introduction together with some key
considerations for using a CE. They present as well some solutions through applications of multiple
testing strategies.
2.2 Survey of use of composite endpoints in the cardiovascular literature
2.2.1 Identification of published clinical trials that used composite endpoints
We explore the use of CE in recent literature through a systematic Medline search covering the 2008
publication of RCTs in 6 high impact medical journals (Table 2.1). Medline search was restricted to
randomized controlled trial and human subjects publications, including the terms coronary artery
disease, valvular heart disease, arrhythmia, cardiomyopathy, congestive, heart failure, cardiovascu-
lar, or cardiovascular disease in the abstract, title, or keywords. The systematic search resulted in 216
publications. The ones that mentioned in the abstract, title, or keywords, a composite or combined
endpoint, or the specific endpoints of MACE, or Net Adverse Clinical Events (NACE) were selected (87
of 216). Studies that dealt with other diseases, or looked at subgroup, or nonrandomized comparisons,
or did not use time-to-event endpoints were excluded (26 of 87). A total of 61 clinical trials were con-
sidered for exploring the use of a CE (Figure 2.1). The breakdown by journal is presented in Table 2.1.
The complete reference list is available in the Appendix.
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Abstracts screened (n=216)
Not including CE 
(n=129)
Trials including CE (n=87)
Did not deal with CV diseases, did not preserve randomized
allocation, reported on a subgroup analysis or did not use
time to event endpoints (n=26)
Cardiovascular RCT including CE 
(n=61)
CE as primary endpoint (n=47)
Not including Death (n=1)
Including Death in the CE (n=46)
With relative frequency higher than 
20%  (n=3)
CE as primary including Death
(high probabilities excluded) (n=43)
CE as secondary endpoint (n=14)
Not including Death 
(n=10)
Including Death 
(n=4)
Figure 2.1: Flow chart for systematic review of cardiovascular (CV) randomized clinical trials (RCTs). CE indicates
composite endpoint.
Journal (Papers and RCT) Total Articles % CE RCT %
NEJM 46 21% 17 28%
The Lancet 36 17% 13 21%
European Heart Journal 54 25% 12 20%
Circulation 53 25% 10 16%
JAMA 24 11% 9 15%
Annals of Internal Medicine 3 1% 0 0%
Total RCT 216 100% 61 100%
Table 2.1: Summary of Medline search, for cardiovascular terms, for 2008 Publication of RCTs.
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2.2.2 Information abstracted from each RCT
The following information was abstracted from each of the published articles: time to follow-up, sam-
ple size, components of each primary and secondary endpoint, frequency of occurrence of each end-
point (CE and components of interest), the corresponding HRs and p-values between groups com-
pared in the trial.
2.2.3 Method to set the recommendations
From the information abstracted for each trial together with previously examined scenarios in Gómez
and Lagakos,27 we establish all the possible parameter combinations. However, because not all the
combinations of frequencies (control group) and relative treatment effects (pR , HRR ) or (p A , HRA)
were found in the studied RCTs, we did restrict our computations to published pairs of values (p, HR).
The ARE is computed for each of a total of 320 combinations to provide recommendations for the
cardiovascular area trials. In all cases, computations have been done assuming that death is part of
the RE, modeling the marginal laws of the times to RE and AE as Weibull, representing decreasing,
constant and increasing hazard functions, combining each scenario with different degrees of depen-
dence between times to RE and to AE and using HR = 0.99 to represent relative treatment effects of no
interest.
Values of ARE > 1 are in favor of using the CE instead of the RE. However, because the advantage of
one endpoint over the other is small in the vicinity of 1, we follow, as Gómez and Lagakos did, a general
rule to use the CE instead of the RE if ARE > 1.1 and to retain the RE if ARE ≤ 1.1.
2.3 Case studies
Interesting cases of trials leading to a significant result for the RE whereas nonsignificant for the CE,
significant for the CE driven by the effect on the RE and nonsignificant for the RE whereas significant
for the CE are described next, the first two with greater detail.
2.3.1 Case study 1: treating patients after an acute coronary syndrome with
Succinobucol
An RCT to assess the effects of the antioxidant succinobucol (AGI-1067)70 on cardiovascular outcomes
in patients with recent acute coronary syndrome already managed with conventional treatments, uses
as PE, denoted by CE, the composite of RE (time to first occurrence of cardiovascular death, resusci-
tated cardiac arrest, MI, stroke), and AE (unstable angina or coronary revascularization; Figure 2.2).
A total of 6144 patients having experienced an acute coronary syndrome ≤ 1 year before recruitment
were randomized to receive succinobucol (n=3078) or placebo (n=3066), in addition to standard of
care. A beneficial effect of succinobucol on RE was found (207 events: succinobucol versus 252 events:
placebo; HR = 0.81; p-value=0.029). The less important but frequent outcomes (ie, hospitalization
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for unstable angina and coronary revascularization) were included in the primary CE. The expecta-
tion would be that by the inclusion of these outcomes, the resulting increase in the number of CE
events observed would lead to an increase in study power. On the contrary, these endpoints did not
differ significantly between the 2 treatment groups, and their contribution of a high relative number
of events in the primary CE led to the disappearance of the statistically significant benefit of the ac-
tive treatment on the important outcomes RE. Thus, the primary CE was not found to be significantly
different between treatment groups (530 events: succinobucol versus 529 events: placebo). We have
that the probability of observing the RE in control group is pR =8.2% with observed HRR =0.81, whereas
the probability of observing the AE in control group is p A=10.4% with HRA=1.05 (it corresponds to
coronary revascularization, whereas observed HR for unstable angina is 1.10).
RELEVANT
ENDPOINT
CV death
Myocardial infarction
Stroke
Res. cardiac arrest
ADDITIONAL 
ENDPOINT
Unstable angina
Coronary revascularization
COMPOSITE  ENDPOINT
Figure 2.2: Pictorial representation of the construction of a composite endpoint as the union of the relevant end-
point and the additional endpoint based on Tardif ’s randomized clinical trial. CV stands for cardiovascular and
Res. stands for resuscitated.
The ARE is explored for these parameter values. For all different shapes of the time-to-event distri-
butions (9 combinations including increasing, constant, and decreasing hazard functions) and corre-
lation values ranging from 0.15 to 0.75 (63 scenarios), it is found that the ARE is always <1.1. Following
the rule of Gómez and Lagakos, the benefits of using the CE over the RE are marginal and probably too
small to justify adding the AE.
The use of CE would be justified in the case that HRA ≤ 0.85, for all other parameters fixed (ie,
pR =8.2%; HRR =0.81; p A=10.4%; Figure 2.3). However, if HRA ≥ 0.95 not even an expected frequency
of 20% for the AE would justify the use of CE. If HRA=0.9, CE would only be justified if p A ≥ 20%, and
the association between RE and AE is weak (not shown). Thus, under these circumstances, the addi-
tional components of coronary revascularization or hospitalization for unstable angina on the primary
endpoint (PE) would had only been recommended if the expected beneficial effect of succinobucol on
these components would have been approximately as strong as the expected effect on cardiovascular
death, resuscitated cardiac arrest, MI, or stroke (Figure 2.4).
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 HRA = 0.99
 HRA = 1.05
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USE THE RE
Spearman 
correlation
Figure 2.3: Asymptotic relative efficiency (ARE) of composite versus relevant endpoint (CE and RE, respectively)
for a range of Spearman correlation coefficients and different values of the hazard ratio of the additional endpoint
HRA for the parameters of case study 1 (pR =0.082; HRR =0.81; p A=0.104) and marginal increasing hazards. HRR
stands for the hazard ratio of the RE; and pR and p A indicates the probability of RE and additional endpoint in
control group, respectively.
Recommendations from case study 1: 
 
• Use Composite Endpoint when having high treatment effect on AE (HRA ≤ 0.85). 
 
• Use Relevant Endpoint when having very low treatment effect on AE (HRA ≥ 0.95), or low 
treatment effect (HRA = 0.9) except for high frequency of AE (pA ≥ 20%) and very weak 
correlation between endpoints. 
Figure 2.4: Summary of recommendations for case study 1 as a guide to decide between using composite endpoint
(CE) or relevant endpoint (RE) as primary endpoint (PE). Values of treatment effect on RE and relative frequency
of RE and AE in control group (HRR =0.81; pR =8.2% and p A=10.4%) are fixed in advance and correspond to Tardif
randomized clinical trial.
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2.3.2 Case study 2: treating hemorrhagic complications during primary percutaneous
coronary intervention in acute MI
The Harmonizing Outcomes with Revascularization and Stents in the Acute MI (HORIZONS-AMI)69
study is a prospective, open-label, randomized, multicenter trial in patients with ST-segment–elevation
MI presented within 12 hours after the onset of symptoms. In this study, 3602 patients were assigned to
treatment with heparin plus a glycoprotein IB/ IIa inhibitor (n=1802) or the alternative treatment of bi-
valirudin alone (n=1800). The interest lies on whether hemorrhagic complications are reduced, when
using bivalirudin alone. Two primary 30-day endpoints were prespecified: (1) major bleeding, denoted
by RE and (2) NACE, denoted by CE, a composite of major bleeding and MACE. MACE, denoted by AE,
is composed, in this trial, of death, reinfarction, target vessel revascularization for ischemia and stroke.
In this case, while major bleeding is the relevant event of interest, the composite CE takes into account
all other additional adverse clinical events, including death. According to the results, MACE is almost
identical in the 2 groups (98 versus 99 events; p-value=0.95), whereas major bleeding is statistically
significantly lower in the bivalirudin-alone group (89 versus 149 events; p < 0.001). The comparison
of NACE (166 versus 218 events; p-value=0.005) between treatment groups is found statistically signif-
icant, and as mentioned by the authors, this is entirely driven by the effect on major bleeding. The risk
taken by the researchers of combining the endpoint of interest with an endpoint on which treatments
have no differential effect is demonstrated using this study.
The probability of observing a major bleeding event (RE) in control group, is pR =8.3% with HRR =0.6,
whereas the probability of observing a MACE event, AE, is p A=5.5% with HRA=1. MACE is occurring
with smaller frequency than the RE and in addition the treatment does not have an effect on it. Under
these parameter values the ARE is examined, as above, for 21 scenarios, corresponding to different
shapes of time-to-event distributions (including decreasing, constant, and increasing hazards) and
correlation values ranging from 0.15 to 0.75. In all those cases, the ARE between a major bleeding
event and a MACE event is <1.1, meaning that the use of the CE (NACE) is not recommended.
Other scenarios were also explored under all above combinations of distributional shapes and cor-
relation values. First, for higher values of the probability of observing a MACE event (5.5%≤ p A ≤ 80%),
the same situation occurs, that is, NACE is neither recommended for any of the cases. Second, the ARE
was also explored for larger beneficial effects on MACE (0.3 ≤ HRA ≤ 0.9), and the ARE value is >1.1
whenever the treatment effect on the additional endpoint is high (HRA ≤ 0.7). Figure 2.5 illustrates
the ARE s for the values of the parameters of this clinical trial (pR =8.3%; HRR =0.6; p A=5.5%) and for
marginal increasing hazards. We find that the ARE is always <1.1 for HRA ≥ 0.8, indicating that low to
weak effects on MACE are not enough to prefer NACE (irrespective of the correlation). However, high
or strong beneficial effects on MACE (HRA ≤ 0.7) would advocate for the use of the CE, NACE.
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Figure 2.5: Asymptotic relative efficiency (ARE) of composite versus relevant endpoint (CE and RE, respectively)
for a range of Spearman correlation coefficients and different values of the hazard ratio of the additional endpoint
HRA for the parameters of case study 2 (pR =0.083; HRR =0.6; p A=0.055) and marginal increasing hazards. HRR
stands for the hazard ratio of the RE; and pR and p A indicates the probability of RE and additional endpoint in
control group, respectively.
It is clear that the chosen PE, NACE, for the efficacy of bivalirudin alone in this study gave unex-
pected good results and that it was a matter of luck not to have a diluted effect in NACE because the
ARE can be as low as 0.51, meaning that major bleeding as a PE can be twice as efficient as NACE.
One could wonder under which circumstances the composite NACE would have been a better,
more efficient choice, and by running all the ARE computations for different values of the frequency
of observing an AE, we find that for the composite NACE to be justified, at least high treatment effect
on MACE (HRA ≤ 0.7) with low probability (p A = 0.055) or a treatment effect HRA ≤ 0.8 with high
frequency (p A ≥ 0.4) is needed.
2.3.3 Case Study 3: testing Fondaparinux in patients with ST-segment–elevation MI
In the clinical trial testing fondaparinux in patients with ST-segment–elevation MI,50 the RE of death
and the AE of myocardial reinfarction at 30 days occurred in 12.5% (pR =0.125) and 3.7% (p A=0.037) of
control patients, respectively. The CE occurred in 15.1% of control patients, indicating a weak corre-
lation between RE and AE. The corresponding HRs (HRR =0.83 and HRA=0.66) were both not signifi-
cantly different than 1. The increased number of events for the CE and the same direction of benefit
for both components led to a statistically significant HR with respect to CE of 0.80. In this trial, the use
of the CE is clearly indicated by the ARE in 100% of the scenarios.
2.3.4 Case study 4: prevention studies
A prevention study assessed the benefit on the risk of cardiovascular disease of low-dose aspirin in
the prevention of atherosclerotic events in patients with type 2 diabetes mellitus.49 Composite PE
was defined as fatal and nonfatal ischemic heart disease, fatal or nonfatal stroke, and peripheral arte-
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rial disease. This trial could be considered an outlier because of the combination of a low frequency
of fatal cardiovascular events (pR =0.008), yet significantly different between groups (HRR =0.10; p-
value=0.0037). The CE occurred in 6.7% of control patients, indicating a weak correlation between
RE and AE, leading to a hazard ratio for the CE (HR*) of 0.80 but not statistically significant.
Under these extreme conditions, the use of the RE would have been justified based on the low HRR ,
whereas the use of the CE would have been justified based on the low frequency of events. The ARE
points to the clear choice of the CE for anticipated strong effects of the aspirin on the nonfatal events
(HRA ≤ 0.2) and the clear choice of the RE for moderate effects (HRA ≥ 0.8), whereas for HRA values
between 0.2 and 0.8, the CE is recommended as HRA increases for progressively higher values of the
frequency of nonfatal events. In this particular situation, the choice of the CE based on an assumption
of a treatment effect at such an extreme value would be difficult to justify at the design stage although
it could be taken under consideration for the next trial designed on this question.
2.4 Results and recommendations
A CE was used as PE for 47 of the clinical trials and as secondary for the remainder of 14 clinical trials.
The frequency of use of different CEs, as well as of each individual component, for the 47 cases that
CE is the PE, is presented in Table 2.2. MI and stroke were encountered as components of the CE in
over half of these clinical trials (66% and 55%, respectively), Hospitalization and target vessel revascu-
larization are AE in 30% and 13%, respectively, whereas death is encountered in all of them but 1 (46 of
47). In addition, among the 14 trials with an individual PE, in 13 of them death is either the RE (in 4) or
used as an AE (in 9).
Endpoint Death MI Stroke Hospitalization TVR N with additional N Total (%)
combinations endpoints
1 X X X ... ... 8 14 (30%)
2 X X X X ... 5 8 (17%)
3 X ... ... X ... 1 6 (13%)
4 X X ... ... ... 2 5 (11%)
5 X ... ... ... ... 5 5 (11%)
6 X X ... ... X 2 4 (9%)
7 X ... X ... ... 2 2 (4%)
8 X ... ... ... X 1 1 (2%)
9 X ... X ... X 1 1 (2%)
10 ... ... X ... ... 1 1 (2%)
98% 66% 55% 30% 13% 28 47
Table 2.2: Frequencies for different combinations of endpoints for 47 RCTs with composite endpoint as primary
endpoint. MI indicates myocardial infarction; and TVR, target vessel revascularization. RCT stands for random-
ized clinical trial.
For all the trials, including death (46 out of 47), the frequency of death was relatively low (median
4%), with the exception of 3 trials where death was frequent (>20%). The observed relative frequencies
of death among the 43 low-frequency studied trials were between 0.002 and 0.15 (Table 2.3). The ob-
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served relative frequencies of the AEs (MI, stroke, hospitalization, and target vessel revascularization)
were between 0.002 and 0.31. Concerning the relative treatment effects, it was found that some of the
component endpoints had an observed HR >1 (17 of 43). Among the clinical trials with HR<1, we have
found relative treatment effects for death as small as 0.1 and as large as 0.98 and between 0.35 and 0.94
for the AEs (Table 2.3).
In the reviewed studies, specific combinations of the control group frequencies for the RE (pR ) and
AE (p A) with corresponding HR values emerged. The ARE of a CE with death as a RE adding MI, stroke,
or hospitalization as AE is computed for different shapes of time-to-event distributions and a range of
correlations between times to RE and AE and is described next to serve as a guide for the design of
future trials.
Death plus MI
For the relatively low frequency of MI (AE; ≤ 12%) for all HR combinations found in the trials, the CE
of death and MI is almost always justified based on the ARE except for the case where death and MI
present with the same frequency and the beneficial effect on death is higher than on MI (HRA>HRR ).
Death plus Stroke
For particularly low frequency of stroke found in the trials (0.5%), the CE of death and stroke is always
justified in the cases that the beneficial effect on stroke is higher than on death (HRA<HRR ). The same
is true for the higher frequency of stroke (12%), whereas the CE is also justified when the beneficial
effect on stroke is slightly less than on death, but death presents with lower frequency.
Death plus Hospitalization
The CE is justified in the cases that the HR for death is >0.8, or equal to 0.70 coupled with low frequency
of death (pR =3%), whereas the HR for hospitalization is <0.9. For a substantial benefit on death cou-
pled with low frequency (HRR =0.5; pR =6%), when the frequency of hospitalization is high (p A=39%)
even for a smaller benefit for hospitalization (HRA=0.70), the CE is justified.
The CE is not justified when, even for a substantial benefit on death (HRR ≈ 0.5), low frequency of
death (pR ≈ 6%), and high frequency of hospitalization (p A ≈ 39%), the benefit for hospitalization is
small (HRA>0.90). The CE is neither justified when HRA>HRR provided that the frequency of death is
higher (pR =12%).
2.4.1 Death from cardiovascular or death from any cause as the individual primary or
co-PE
In only 4 trials, death from cardiovascular or death from any cause was used as the individual primary
or co-PE.7, 30, 34, 60 The frequency of cardiovascular death or any death in 2 of the trials7, 34 on patients
with New York Heart Association class II–IV Chronic Heart Failure, or Atrial Fibrillation and New York
Heart Association class II or IV heart failure, was 25% and 29%, respectively. In such cases of high
death frequency, the use of the CE is justified only when the anticipated treatment benefit for the AE
is similar or higher than the one for survival. Such is the case in the trial exploring the effect of n-3
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polyunsaturated fatty acids in patients with chronic heart failure,7 where the use of the CE of death
and admission to hospital for cardiovascular reasons as co-PE would be fully supported by the ARE .
2.4.2 Recommendations for cardiovascular clinical trials
We present recommendations for future design choice between RE and CE for cardiovascular clinical
trials that use CEs as an option for the PE, include death as the RE, and add other nonfatal endpoints,
such as MI, hospitalization. We discuss the recommendations in terms of the values of the anticipated
hazard ratios HRR and HRA , and, when needed, in terms of the anticipated probabilities of occurrence
pR and p A . These guidelines have been based on the scenarios explored by Gómez and Lagakos and
on the 43 clinical trials of the 47 (Table 2.2) having death (observed control group frequency ≤ 15%)
as RE and stroke, MI, hospitalization, and target vessel revascularization as AE. Table 2.3 shows the
observed relative frequencies and relative treatment effects of death and the AEs , and Table 2.4 the
possible pairs (p, HR) for RE and AE, after excluding pairs with HR ≥ 1 (17 of 43).
Keeping in mind that the specific decision for a given trial has to be based on a thorough study as
has been shown in the case studies and the Results section of this chapter, a set of recommendations
on whether to use the RE or the CE is outlined below (Figures 2.6 and 2.7):
• HRA<HRR : the relative treatment effect is greater on the AE than on the RE⇒ CE should always
be used.
• HRA=HRR : RE and AE have approximately the same relative treatment effect ⇒ CE should al-
most always be used. Only in those cases where the anticipated probability for AE has a low
frequency (p A ≤ 0.06) and the frequency for RE is between 2 and 5 times the frequency of the
other endpoints (2< pR /p A < 5), RE could be a better choice.
• HRA=HRR +0.1: AE has a slightly smaller effect on treatment than RE ⇒ RE should always be
used if pR /p A ≥ 3 and CE should always be used if pR /p A ≤ 0.25. Whenever 0.25 < pR /p A < 3
the decision will depend on the anticipated values of the relative treatment effect, the frequency
of observation of either endpoint along with its correlation and to a lesser extent on the shape of
the marginal density.
• HRA=HRR +0.2: AE has a smaller effect on treatment than RE ⇒ RE should almost always be
used except when the relative frequency of the AE is extremely higher than that of the RE (pR /p A
≤ 0.06).
• HRA ≥ HRR +0.3: AE has a much smaller effect on treatment than RE ⇒ RE should always be
used.
• HRA close to 1 and p A ≤ 0.005⇒ RE should always be used.
2.4 RESULTS AND RECOMMENDATIONS 29
One has also to keep in mind that the association between time to RE and time to AE could play
an important role (ARE decreases when the correlation between the 2 endpoints increases) and that
decisions based on hazard plots as the ones in Figures 2.3 and 2.5 are recommended (ARE decreases
when the relative effect of treatment on the AE is smaller). Furthermore, the recommendations are to
be taken cautiously because infrequent events (p in the order of 0.005), frequencies of death with order
of magnitude larger than the frequency of AE (pR /p A > 12), and unlikely frequent endpoints (p > 0.35)
could reverse the direction of the recommendation.
Relative frequency Hazard Ratio
Endpoint Min. Median Max. Min. Median Max.
Death 0.2% 3.8% 15% 0.1 0.83 0.98
Myocardial Infarction 0.2% 3.7% 11.3% 0.35 0.78 0.92
Stroke 0.4% 2.2% 4.7% 0.52 0.83 0.89
Hospitalizations 0.3% 3.6% 31% 0.59 0.75 0.94
TVR 0.7% 7.3% 16.2% 0.79 0.79 0.83
Table 2.3: Summary of observed relative frequencies and relative treatment effect among clinical trials with ob-
served frequency of death < 20%. Hazard ratios restricted to clinical trials with HR<1. TVR indicates target vessel
revascularization.
Probability in control group
HR 0.005 0.03 0.06 0.09 0.12 0.15 0.18 0.27 0.39 0.48
0.3 AE ... ... ... ... ... ... ... ... ...
0.4 RE ... ... ... ... ... ... ... ... ...
0.5 AE ... RE ... ... ... ... ... ... ...
0.6 AE AE ... ... ... ... ... ... ... ...
0.7 ... RE RE RE ... ... ... ... AE ...
AE
0.8 AE RE RE ... RE RE ... ... ... ...
AE AE AE
0.9 ... AE RE RE RE ... AE AE ... AE
AE AE
0.99 RE RE RE ... RE ... ... ... ... ...
AE AE AE AE
Table 2.4: Chosen pairs of values (p, HR) for RE (Death), and AE (Stroke, Myocardial infarction, Hospitalization,
and Target Vessel Revascularization) used for the recommendations. p stands for the anticipated probability of ob-
serving the event in control group, and HR the corresponding hazard ratio. Clinical trials with HR>1 are excluded.
AE indicates additional endpoint; and RE, relevant endpoint.
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HRR HRR - 0.1 HRR - 0.3 HRR + 0.2 HRR + 0.3 
RE RE* RE if pR / pA ≥ 3 
CE if pR / pA ≤ 0.25 
CE* CE CE 
HRA HRA 
Higher beneficial effect on the 
additional endpoint 
Lower beneficial effect on the 
additional endpoint 
HRR + 0.1 HRR - 0.2 
CE 
Figure 2.6: The horizontal axis represents the values of the hazard ratio HRA of additional endpoint (AE) as a
function of the HRR of relevant endpoint (RE). Each tick summarizes several scenarios, corresponding to different
shapes of the marginal hazards and different degree dependences between RE and AE. For each tick, we indicate
whether it is advisable to adopt composite endpoint (CE) in preference to RE. See explanation in text for scenarios
with CE* and RE*.
Use Composite Endpoint when: 
• Treatment effect on AE is higher than on RE. 
• Same treatment effect between endpoints except for low frequency of AE (pA ≤ 0.06) and 
ratios between frequencies (pR /pA) between 2 and 5. 
• Slightly smaller treatment effect on AE and small ratio of frequencies (pR /pA ≤ 0.25). 
 
Use Relevant Endpoint when: 
• Slightly small treatment effect on AE and high ratio of frequencies (pR /pA ≥ 3). 
• Smaller treatment effect on AE (HRA = HRR + 0.2) except for small ratios between 
frequencies  (pR /pA ≤ 0.06). 
• Much smaller treatment effect on AE (HRA ≥ HRR + 0.3). 
• Very small treatment effect on AE and low frequency on treatment (HRA ≈ 1 and pA ≤ 
0.005). 
Figure 2.7: Summary of recommendations as a general guide for using composite or relevant endpoints (RE) as
primary endpoint in cardiovascular clinical trials. AE indicates additional endpoint; and HR, hazard ratio.
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2.5 Discussion
The use of composite PE in cardiovascular randomized trials has been addressed by many authors who
have discussed, among other issues, the suitability of components that are clinically less important
and the difficulties in interpreting results. Our study helps the trialist, in the design of a future trial,
to choose in an objective manner between candidates of PE, by computing the ARE based on the
anticipated values of the control group frequency and HR of each candidate endpoint.
It is clear that in the cardiovascular context, the CEs under consideration overwhelmingly include
a terminal event either as a RE or as an AE. This chapter explores under which circumstances adding
other endpoints to a RE of death would result in a more efficient choice. It is clear from our results
that, contrary to a common belief, adding a frequent event to a RE of death does not always help
and, indeed, may even prove harmful. The fact that the CE increases the number of events, does not
mean, even in the case of a common event rate and similar magnitude of the treatment effects, that
the required sample size of a trial is reduced because, depending on the strength of the association
between RE and AE, the ARE is not necessarily >1.
It is important to point out that the ARE method is intended for the planning phase of the RCT. The
reader should be aware of the presence of competing risks and how the analysis should appropriately
take care of this issue. Chi6 describes how to properly analyze a RCT based on CE. They recommend to
use all-cause mortality instead of cause-specific mortality to prevent from informative censoring, and
although not strictly necessary if the CE is valid, to analyze separately the individual components, and
to gain a more accurate assessment and interpretation of the clinical benefits and risks involved. They
propose 2 basic formats for the presentation of trial data and the results of the analysis.
Finally, although the ARE method has been developed with a RCT in mind, well-planned obser-
vational studies, viewed as conditionally randomized experiments could take advantage of an appro-
priately adjusted version of the ARE method. Recommendations about reporting completely and ac-
curately an observational study have been developed by the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) initiative.78 The explanation of how the study size was
arrived at is among the requirements included in the STROBE Statement Checklist.77 Admittedly, the
importance of sample size determination in observational studies depends on the context. When plan-
ning a new study, formal, a priori calculation of sample size is useful, especially for studies that will
gather new data and will be planned for the purpose to overcome potential problems with previous
reports. There is even a call for registration of observational studies on a World Health Organization-
compliant registry before they begin to lend greater credibility to the study findings.12 In the case of
large, hypothesis-driven cohort studies, there is no doubt that a solid protocol, including sample size
and power justification, is required, and in that context, the ARE method is as useful for the informed
choice of the endpoint as for any well-designed RCT.
As a conclusion, if a well-defined experiment is conducted and if the censoring patterns of both
groups can be considered similar, the ARE method could be a valid option to discriminate between a
RE and a CE.
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RELATIONSHIP BETWEEN THE ARE AND SAMPLE SIZES
The purpose of this chapter is to prove that the usual interpretation of the asymptotic relative efficiency
(ARE), as the ratio of sample sizes, n and n∗, needed to attain the same power for a given significance
level, still holds even though two different sets of hypotheses (H0 versus Ha and H∗0 versus H
∗
a ) are
compared, where H0, H∗0 and Ha , H
∗
a are the null and the alternative hypothesis of no treatment effect
evaluated on ER and on E∗, respectively.
To clarify the purpose of our investigation consider the following. If we were to test H0 versus Ha
with two different test statistics Sn and Tm , Pitman’s relative efficiency would be defined as the ratio
m/n, where n and m are the required sample sizes for Sn and Tm , respectively, to attain the same
power for a given significance level. Furthermore, if both Sn and Tm are asymptotically normal with
unit variance and means µS and µT , it can be proved that Pitman’s ARE corresponds to the squared
of the ratio of the noncentrality parameters, that is (µS/µT )2. Gómez and Lagakos’ method compares
the logrank statistics Z and Z∗, derived for two different set of hypotheses H0 versus Ha and H∗0 versus
H∗a and do so using, as definition of the ARE, the ratio (µ∗/µ)2 where µ and µ∗ are, respectively, the
asymptotic means of Z and Z∗, under alternative contiguous hypotheses to H0 and H∗0 .
We carry out a simulation to study under which conditions and for finite sample sizes, the relation-
ship ARE(Z∗, Z ) = (µ∗/µ)2 = n/n∗ holds where n and n∗ are the needed sample sizes for Z and Z∗,
respectively, to attain the same power for a given significance level.
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The contents of this chapter have been published in24 (see Appendix):
Gómez G, Gómez-Mateu M. The Asymptotic Relative Efficiency and the ratio of sample sizes when
testing two different null hypotheses (2014). SORT, 38, 73–88.
This chapter reproduces the paper after excluding the introduction because its content has been
detailed in previous chapters. The notation used here is coherent with the rest of this thesis, and differs
slightly from the one used in the paper.
Statistics & Operations Research Transactions
SORT 38 (1) January-June 2014, 73-88
Statistics &
Operations Research
Transactionsc© Institut d’Estadstica de Catalunya
sort@idescat.catISSN: 1696-2281
eISSN: 2013-8830
www.idescat.cat/sort/
The asymptotic relative efficiency and the ratio of
sample sizes when testing two different null
hypotheses
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Abstract
Composite endpoints, consisting of the union of two or more outcomes, are often used as the
primary endpoint in time-to-event randomized clinical trials. Previously, Go´mez and Lagakos
provided a method to guide the decision between using a composite endpoint instead of one
of its components when testing the effect of a treatment in a randomized clinical trial. Consider
the problem of testing the null hypotheses of no treatment effect by means of either the single
component or the composite endpoint. In this paper we prove that the usual interpretation of
the asymptotic relative efficiency as the reciprocal ratio of the sample sizes required for two test
procedures, for the same null and alternative hypothesis, and attaining the same power at the
same significance level, can be extended to the test procedures considered here for two different
null and alternative hypotheses. A simulation to study the relationship between asymptotic relative
efficiency and finite sample sizes is carried out.
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1. Introduction
In clinical trials research, one of the most important issues that investigators have
to solve at the design stage of the study is the appropriate choice of the primary
endpoint. Composite endpoints (CE) consisting of the union of two or more outcomes
are commonly used as primary endpoints. For example, in the cardiovascular area the
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3.1 Notation, the logrank test and the asymptotic relative efficiency
3.1.1 The logrank tests for the relevant and for the composite endpoints
Assume that we have a two-arm study involving random assignment to an active (X = 1) or control
treatment (X = 0) aiming to prove the efficacy of the new active treatment. The effect of treatment is
to be evaluated on the time T ( j )R to a relevant event ER , where the superscript j indicates the treatment
group ( j = 0 for the control group and j = 1 for the treatment group). Let λ( j )R (t ) denote the hazard
function of T ( j )R ( j = 0,1). The null hypothesis of no effect is given by H0 : HRR (t ) = λ(1)R (t )/λ(0)R (t ) = 1
and the alternative that the new treatment improves survival by Ha : HRR (t )< 1. The logrank test Z is
used to test that the new treatment improves survival.
Assume now that an additional endpoint EA is considered as component of the primary end-
point and the composite endpoint E∗ = ER ∪ EA is to be used, instead, to prove the efficacy of the
new treatment. The effect of treatment would then be evaluated on the time T ( j )∗ to E∗ where T
( j )
∗ =
min{T ( j )R ,T
( j )
A } and T
( j )
A stands for the time to EA ( j = 0,1). Let λ
( j )
A (t ) and λ
( j )
∗ (t ) denote, respectively,
the hazard functions of T ( j )A and T
( j )
∗ ( j = 0,1). The treatment effect on E∗ would then be tested with
the logrank test Z∗ to compare H∗0 : HR∗(t )=λ(1)∗ (t )/λ(0)∗ (t )= 1 versus H∗a : HR∗(t )< 1.
We assume that the additional endpoint does not include a terminating event, which corresponds
to Case 1 when neither the relevant nor the additional endpoint includes a terminating event, and Case
3, when the relevant endpoint includes a terminating event.
Schoenfeld (1981)65 studies the asymptotic behaviour of the logrank statistic and proves that un-
der the null hypothesis of no treatment difference, the logrank is asymptotically N (0,1) and, under a
sequence of alternatives contiguous to the null, the logrank is asymptotically normal with unit vari-
ance and finite mean. Gómez and Lagakos apply Schoenfeld’s results and proceed as follows. They
consider λ(0)R (t ) as fixed and define a sequence of alternatives Ha,n consisting of instantaneous haz-
ard functions close enough to λ(0)R (t ), for instance taking λ
(1)
R,n(t ) = λ(0)R (t )eg (t )/
p
n for some g (t ) func-
tion. These sequence of alternatives, formulated equivalently as HRR,n(t ) = eg (t )/
p
n , include propor-
tional hazard alternatives, i.e, taking g (t ) = β for a fixed real value β. Logrank Z is asymptotically
N (0,1) under the null hypothesis of no treatment difference (H0 : HRR (t ) = 1) and asymptotically
normal with unit variance and mean µ given in equation (3.1) under the sequence of alternatives
Ha,n : HRR,n(t ) = eg (t )/
p
n < 1. Analogously, fix λ(0)∗ (t ) and define H∗0 : HR∗(t ) = 1 and the sequence
of alternatives H∗a,n : HR∗,n(t )= eg∗(t )/
p
n < 1 for a given function g∗(t ). It follows that Z∗ is asymptot-
ically N (0,1) under H∗0 , and asymptotically normal with unit variance and mean µ∗ given in equation
(3.2) under the sequence H∗a,n . The asymptotic means of Z and Z∗ are given by
µ =
∫∞
0 g (t )p(t )[1−p(t )]PrH0 {U ≥ t }λ(0)R (t )d t√∫∞
0 p(t )[1−p(t )]PrH0 {U ≥ t }λ(0)R (t )d t
, (3.1)
µ∗ =
∫∞
0 g∗(t ))p∗(t )[1−p∗(t )]PrH∗0 {U∗ ≥ t }λ
(0)
∗ (t )d t√∫∞
0 p∗(t )[1−p∗(t )]PrH∗0 {U∗ ≥ t }λ
(0)
∗ (t )d t
, (3.2)
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where U =min{TR ,τ} (in Cases 1 and 3) and U∗ =min{T∗,τ} denote the observed outcome; τ denotes
the censoring time; p(t ) = PrH0 {X = 1|U ≥ t } and p∗(t ) = PrH∗0 {X = 1|U∗ ≥ t } are the null probabilities
that someone at risk at time t is in treatment group 1; PrH0 {U ≥ t } and PrH∗0 {U∗ ≥ t } are the null proba-
bilities that someone is still at risk at time t and PrH0 {U ≥ t }λ(0)R (t ) and PrH∗0 {U∗ ≥ t }λ
(0)
∗ (t ) correspond
to the probabilities, under the null hypothesis, of observing events ER and E∗, respectively, by time t .
3.1.2 Asymptotic Relative Efficiency
Efficiency calculations throughout this chapter will assume that end-of-study censoring at time τ (τ= 1
without loss of generality) is the only non-informative censoring cause for both groups; this assump-
tion indirectly implies that the censoring mechanism is the same for both groups. It is as well as-
sumed that the hazard functions λ( j )R (t ) and λ
( j )
A (t ) ( j = 0,1) are proportional, that is, HRR(t ) = HRR
and HRA(t ) = HRA, for all t , where HRR(t ) = λ(1)R (t )/λ(0)R (t ) and HRA(t ) = λ(1)A (t )/λ(0)A (t ) are the hazard
ratios between T (0)R and T
(1)
R and between T
(0)
A and T
(1)
A , respectively. Note that although we are as-
suming that the hazard functions λ( j )R (t ) and λ
( j )
A (t ) ( j = 0,1) are proportional, this does not imply the
proportionality of hazards λ(0)∗ (t ) and λ
(1)
∗ (t ) for the composite endpoint T∗ (see Figure 3.1).
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Figure 3.1: Survival and hazard ratio for the relevant endpoint (RE), TR , for the additional endpoint (AE), TA and
for the composite endpoint (CE), T∗ =min{TR ,TA}. TR ∼Weibull with shape parameterβR = 2 (increasing hazard)
for treatment groups 0 and 1 and TA ∼ Weibull with shape parameter βA = 1 (constant hazard) for treatment
groups 0 and 1. Scale parameters for TR and TA have been calculated such that Pr{TR observed in group 0}=0.1,
Pr{TA observed in group 0}=0.25, HRR = 0.5, HRA = 0.9 and Spearman’s ρ(TR ,TA)= 0.45 assuming Frank’s copula
between TR and TA . Considering the RE as a terminating event (case 3), in this setting ARE(Z∗, Z )= 0.21.
To assess the difference in efficiency between using logrank test Z , based on the relevant endpoint
ER , and logrank test Z∗, based on the composite endpoint E∗, Gómez and Lagakos27 base their strategy
on the behaviour of the asymptotic relative efficiency (ARE) of Z∗ versus Z . The ARE is a measure of
the relative power of two tests that can be interpreted, when the two tests are for the same null and
alternative hypothesis, as the ratio of the required sample sizes to detect a specific treatment effect
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to attain the same power for a given significance level (Lehmann and Romano, 2005).41 In this case,
a value of ARE = 0.6 would mean that we only need 60% as many cases to reach a given power if
we use ER as we would need if we used E∗. Whenever the tests under consideration, Z and Z∗, are
asymptotically N(0,1) under H0 and H∗0 , respectively, and asymptotically normal with variance 1 under
a sequence of contiguous alternatives to the null hypothesis, a different definition for Pitman’s relative
efficiency as the square of the ratio of the non-centrality parameters µ and µ∗ is appropriate
ARE(Z∗, Z )=
(
µ∗
µ
)2
, (3.3)
where µ and µ∗ are to be replaced by expressions (3.1) and (3.2).
Before providing the expression that is being used to evaluate the ARE , and for the sake of clarity,
we enumerate the assumptions that have been taken into account:
• End-of-study censoring at time τ is the only non-informative censoring cause for both groups.
• The additional endpoint does not include a terminating event.
• The hazard ratios between T (0)R and T
(1)
R and between T
(0)
A and T
(1)
A are proportional, that is,
HRR(t )=λ(1)R (t )/λ(0)R (t )=HRR and
HRA(t )=λ(1)A (t )/λ(0)A (t )=HRA for all t .
• Effect of treatment on ER is tested establishing H0 : HRR = 1 versus a sequence of alternatives
Ha,n :λ
(1)
R,n(t )=λ(0)R (t )eg (t )/
p
n for some g (t ) function. Note that g (t )/
p
n = log{λ(1)R,n(t )/λ(0)R (t )}.
• Effect of treatment on E∗ is tested establishing H∗0 : HR∗(t )= 1 versus a sequence of alternatives
H∗a,n : HR∗,n(t )= eg∗(t )/
p
n < 1 for a given function g∗(t ). Note that g∗(t )/
p
n = log{HR∗,n(t )}.
Under the above assumptions, expression (3.3) becomes
ARE(Z∗, Z )=
(∫ 1
0 log
{
λ(1)∗ (t )/λ
(0)
∗ (t )
}
f (0)∗ (t )d t
)2
(
log
{
HRR
})2 (∫ 10 f (0)∗ (t )d t )(∫ 10 f (0)R (t )d t ) , (3.4)
where f (0)R (t ) and f
(0)
∗ (t ) are the density functions of T
(0)
R and T
(0)
∗ , respectively.
Remark: The density function f (0)∗ (t ) is the density of the T
(0)
∗ = min{T (0)R ,T (0)A }, computed from the
joint density between T (0)R and T
(0)
A , which itself is built from the marginals of T
(0)
R and T
(0)
A by means
of a bivariate copula.
38 CHAPTER 3 RELATIONSHIP BETWEEN THE ARE AND SAMPLE SIZES
3.2 Relationship between ARE and sample sizes
We start establishing that if the hazard ratios for T ( j )R ( j = 0,1) and for T
( j )
A ( j = 0,1) approach the unity
as n gets large, so does the hazard ratio of the minimum T ( j )∗ between T
( j )
R and T
( j )
A ( j = 0,1).
Lemma 1 Given two sequences of hazard ratios {HRR,n(t )=λ(1)R,n(t )/λ(0)R (t )} and {HRA,n(t )=λ(1)A,n(t )/λ(0)A (t )},
both converging uniformly to 1 as n → ∞, the sequence corresponding to the hazard ratio of T ( j )∗ =
min{T ( j )R ,T
( j )
A }, namely {HR∗,n(t )=λ(1)∗,n(t )/λ(0)∗ (t )}, tends to 1 as n →∞. In particular, this lemma holds
whenever log(λ(1)k,n(t )/λ
(0)
k (t )}) =O(n−1/2), which in turn, is true if log(λ(1)k,n(t )/λ(0)k (t )}) = gk (t )/
p
n, for
any bounded real function gk (t ) (k =R, A).
Proof 1 It follows immediately that for fixed t , limn→∞λ(1)R,n(t ) = λ(0)R (t ) and limn→∞λ(1)A,n(t ) = λ(0)A (t ).
Furthermore, it follows that the corresponding densities and survival functions f (1)R,n(t ), f
(1)
A,n(t ), S
(1)
R,n(t )
and S(1)A,n(t ), converge to f
(0)
R (t ), f
(0)
A (t ), S
(0)
R (t ) and S
(0)
A (t ), respectively. Taking into account that the sur-
vival function of the minimum, S(1)∗,n(t ) is expressed in terms of the marginal survival functions S
(1)
R,n(t )
and S(1)A,n(t ) of T
(1)
R and T
(1)
A via a copula C , that is,
S(1)∗,n(t )=C (S(1)R,n(t ),S(1)A,n(t )), it remains to prove that limn→∞S(1)∗,n(t )= S(0)∗ (t ). This result will imply that
limn→∞ f (1)∗,n(t )= f (0)∗ (t ), limn→∞λ(1)∗,n(t )=λ(0)∗ (t ) and hence the sequence HR∗,n(t )→ 1 as n →∞, as
we wanted to prove.
The convergence of S(1)∗,n(t ) to S
(0)
∗ (t ) is guaranteed by the convergence of S
(1)
R,n(t ) and S
(1)
A,n(t ) to S
(0)
R (t ) and
S(0)A (t ), respectively, together with the fact that bivariate copulas C are bivariate distribution functions
with uniform marginals. The reader is addressed to Lindner and Szimayer (2005)42 for the corresponding
technical proofs.
Proposition 1 Consider two test proceduresφn andφ∗n to test H0 : HRR (t )= 1 against Ha,n : HRR,n(t )< 1
and H∗0 : HR∗(t ) = 1 against H∗a,n : HR∗,n(t ) < 1, respectively. Let n and n∗ be the sample sizes required
for φn and φ∗n , respectively, to have power at least Π at level α. Assume the sequences φ = {φn} and
φ∗ = {φ∗n} are based on the logrank statistics Z and Z∗, respectively, converging, to Normal (µ,1) and
Normal (µ∗,1) with µ and µ∗ given in (3.1) and (3.2), under sequences of local alternatives HRk,n(t )
(k =R, A) converging uniformly to 1 as n →∞. Given 0<α<Π< 1,
lim
HRR,n (t )→1
HRA,n (t )→1
n
n∗
= ARE(Z∗, Z ).
The usual interpretation of the ARE as the reciprocal ratio of the sample sizes holds even when two
different sets of hypotheses (H0 versus Ha,n and H∗0 versus H
∗
a,n) are tested. As a consequence of this
proposition, the interpretation of the ARE is the following. If ARE(Z∗, Z )= 0.7, then, asymptotically, we
only need 70% as many cases to attain a given power if we use Z as we would need if we used Z∗.
Proof 2 By Lemma 1, uniform convergence to 1 of {HRR,n(t )} and {HRA,n(t )} imply that limHR∗,n(t )→
1. Under the sequence of contiguous alternatives to the null, Ha,n : {HRR,n(t ) = λ(1)R,n(t )/λ(0)R (t )} → 1
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and H∗a,n : {HR∗,n(t ) = λ(1)∗,n(t )/λ(0)∗ (t )} → 1, both Z and Z∗ are asymptotically N (µ,1) and N (µ∗,1),
respectively. The power function for a one-sided test with size α is therefore given, respectively, by
ΠR = lim
n→∞Prob{Z < z1−α|Ha,n}= 1−Φ(−z1−α+µ)
Π∗ = lim
n→∞Prob{Z∗ < z1−α|H
∗
a,n}= 1−Φ(−z1−α+µ∗) (3.5)
where Φ is the distribution function of the standard normal and z1−α is the standard normal quantile
corresponding to the left tail probability α. It immediately follows that ΠR =Π∗ is equivalent to µ= µ∗,
given by (3.1) and (3.2). Equivalently
(
µ∗
µ
)2
= 1 ⇐⇒

∫∞
0 g (t )p(t )[1−p(t )]PrH0 {U≥t }λ(0)R (t )d t√∫∞
0 p(t )[1−p(t )]PrH0 {U≥t }λ(0)R (t )d t∫∞
0 g∗(t )p∗(t )[1−p∗(t )]PrH∗0 {U∗≥t }λ
(0)
∗ (t )d t√∫∞
0 p∗(t )[1−p∗(t )]PrH∗0 {U∗≥t }λ
(0)
∗ (t )d t

2
= 1. (3.6)
Since
p(t )= PrH0 {U ≥ t |X = 1}pi
PrH0 {U ≥ t }
= PrH0 {U
( j ) ≥ t }pi
PrH0 {U ≥ t }
where pi= PrH0 {X = 1}, we have
p(t )(1−p(t ))PrH0 {U ≥ t }=
PrH0 {U
(1) ≥ t }piPrH0 {U (0) ≥ t }(1−pi)
PrH0 {U
(0) ≥ t }(1−pi)+PrH0 {U (1) ≥ t }pi
.
Based in the stated assumptions, because T ( j )R is right-censored by the end-of-study at time τ, and under
the null hypothesis of no effect (S(0)R (t ) = S(1)R (t )), we have PrH0 {U ( j ) ≥ t } = S(0)R (t )1{[0,1]}(t ), for j = 0,1.
Replacing in (3.1), the noncentrality parameter µ becomes
µ=
p
pi(1−pi)∫ 10 g (t )S(0)R (t )λ(0)R (t )d t√∫ 1
0 S
(0)
R (t )λ
(0)
R (t )d t
=
p
pi(1−pi)∫ 10 g (t ) f (0)R (t )d t√∫ 1
0 f
(0)
R (t )d t
where f (0)R (t ) is the marginal density function for T
(0)
R . Analogously, it can be seen that
µ∗ =
p
pi(1−pi)∫ 10 g∗(t ) f (0)∗ (t )d t√∫ 1
0 f
(0)
∗ (t )d t
where f (0)∗ (t ) is the density function for T
(0)
∗ . The reader is addressed to the online supporting material
of Gómez and Lagakos paper for other technical details.
If we would replace g (t ) and g∗(t ) by
p
n log
(
λ(1)R,n (t )
λ(0)R (t )
)
= pn log(HRR) and
p
n∗ log
(
λ(1)∗,n (t )
λ(0)∗ (t )
)
, respec-
tively, equality (3.6), after cancelling pi(1−pi), becomes equal to
lim
HRR,n (t )→1
HRA,n (t )→1
p
n∗p
n
∫ 1
0 log
{
λ(1)∗ (t )/λ
(0)
∗ (t )
}
f (0)∗ (t )d t√∫ 1
0 f
(0)
∗ (t )d t
log(HRR)
√∫ 1
0 f
(0)
R (t )d t
= 1
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which in turn is equivalent to
lim
HRR,n (t )→1
HRA,n (t )→1
n
n∗
=
(∫ 1
0 log
{
λ(1)∗ (t )/λ
(0)
∗ (t )
}
f (0)∗ (t )d t
)2
(
log(HRR)
)2 (∫ 10 f (0)∗ (t )d t )(∫ 10 f (0)R (t )d t ) (3.7)
and it follows that ARE(Z∗, Z )= lim
HRR,n (t )→1
HRA,n (t )→1
n
n∗
, as we wanted to prove.
Note that (3.7) implies(∫ 1
0 log
{
λ(1)∗ (t )/λ
(0)
∗ (t )
}
f (0)∗ (t )d t
)2
(
log(HRR )
)2 (∫ 1
0 f
(0)
∗ (t )d t
)2 = limHRR,n (t )→1
HRA,n (t )→1
n(
∫ 1
0 f
(0)
R (t )d t )
n∗(
∫ 1
0 f
(0)
∗ (t )d t )
≈ expected number ER
expected number E∗
and whenever λ(1)∗ (t )/λ
(0)
∗ (t ) is approximately constant and equal to HR∗, we would have(
1
log(HRR )
)2
(
1
log(HR∗)
)2 = limHRR,n (t )→1
HRA,n (t )→1
n(
∫ 1
0 f
(0)
R (t )d t )
n∗(
∫ 1
0 f
(0)
∗ (t )d t )
≈ expected number ER
expected number E∗
.
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3.3 Simulation
3.3.1 Simulation
Our next aim is to simulate data to empirically check how close we are to the limiting relationship
n/n∗ = ARE(Z∗, Z ) when ΠR = Π∗ for different finite sample sizes. To conduct the simulations we
will assume, as Gómez and Lagakos did, that T ( j )R and T
( j )
A follow Weibull distributions. Weibull dis-
tributions are chosen for their wide use in the field of survival analysis due to its flexibility, allowing
decreasing, constant and increasing hazard rates. The corresponding shape and scale parameters are
denoted byβk and b
( j )
k ( j = 0,1, k =R, A) (shape parameters for both groups are taken equal so that the
assumption of the proportionality of the hazard ratios holds). To establish the bivariate distribution of
(T ( j )R ,T
( j )
A ), we consider Frank’s Archimedean survival copula, again as Gómez and Lagakos did. Other
choices of copulas would be possible, although main conclusions and recommendations will not differ
(Plana-Ripoll and Gómez, 2015).51 Frank’s copula depends on the association parameter θ( j ) between
T ( j )R and T
( j )
A . We assume equal association parameter θ = θ(0) = θ(1) for both groups 0 and 1, which is
biunivocally related to Spearman’s rank correlation ρ. Different scenarios will be simulated according
to several choices of (βR ,βA , p
(0)
R , p
(0)
A ,HRR ,HRA ,ρ), where p
(0)
R and p
(0)
A are the probability of observing
events ER and EA , respectively, for treatment group 0, and HRR , HRA are the relative treatment hazard
ratios of T (1)k versus T
(0)
k (k =R, A, respectively).
Given a set of values for (βR ,βA , p
(0)
R , p
(0)
A ,HRR ,HRA ,ρ), for a given powerΠ and a significance level
α, the simulation steps are the following:
1. Computations for the relevant endpoint ER . The scale parameters b
(0)
R and b
(1)
R and the proba-
bility p(1)R of observing the relevant endpoint in group 1 are derived as:
b(0)R =
1
(− log(1−p(0)R ))1/βR
b(1)R =
b(0)R
HR(1/βR )R
p(1)R = 1−e−(1/b
(1)
R )
βR
2. Computations for the additional endpoint EA. The scale parameter b
(0)
A is derived as:
b(0)A =

1
(− log(1−p (0)A ))1/βA
for Case 1
∗ for Case 3
∗ For Case 3, b(0)A is found as the solution of equation p(0)A =
∫ 1
0
∫∞
v f
(0)
(1,2)(u, v ;ρ)dud v , where
f (0)(1,2)(·, ·;ρ) is the joint density between T (0)R and T (0)A .
42 CHAPTER 3 RELATIONSHIP BETWEEN THE ARE AND SAMPLE SIZES
3. Computation of sample sizes n and n∗
a) Compute n (per group) following Freedman (1982)18 formulas as follows
n = E
p(0)R +p(1)R
, (3.8)
where
E = (HRR +1)
2(z1−α+ zΠ)2
(HRR −1)2
. (3.9)
b) Compute ARE(Z∗, Z ) based on (βR ,βA , p(0)R , p
(0)
A ,HRR ,HRA ,ρ).
c) Compute n∗ = n/ARE(Z∗, Z ).
d) Compute N =max{n,n∗}.
4. Simulation of T (0)R ,T
(1)
R ,T
(0)
A ,T
(1)
A ,T
(0)
∗ ,T
(1)
∗
Simulate 1000 samples of size N for the 4 endpoints T ( j )k from Weibull (b
( j )
k ,βk ) ( j = 0,1, k =R, A).
Compute T ( j )∗ =mi n{T ( j )R ,T
( j )
A }.
5. Computation of empirical powers ΠˆR and Πˆ∗
For each sample of size n (n∗), compute the logrank statistic Z (Z∗) to compare the treatment
effect between T (0)R and T
(1)
R ( T
(0)
∗ and T
(1)
∗ ). For a given significance level α, the rejection region
comprises all observed Z (Z∗) such that Z < z1−α (Z∗ < z1−α) where z1−α is the standard normal
quantile corresponding to the left tail probability α. The empirical powers, denoted by ΠˆR (Πˆ∗),
are calculated as the proportion of samples for which Z < z1−α (Z∗ < z1−α).
We note here that whenever n∗ < n, we only use, for each sample, the first n∗ simulated values
to compute Πˆ∗, while when n < n∗, we only use the first n simulated values to compute ΠˆR .
6. Comparison between ΠˆR and Πˆ∗
For each scenario (βR ,βA , p
(0)
R , p
(0)
A ,HRR ,HRA ,ρ), we compare the differences between the two
empirical powers ΠˆR and Πˆ∗ obtained from the 1000 simulations.
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3.3.2 Results
We setΠ= 0.9 andα= 0.05 (other values would not provide additional information). We choose mean-
ingful values for (βR ,βA , p
(0)
R , p
(0)
A ,HRR ,HRA ,ρ), based on those arising in cardiovascular clinical trials
(Gómez, Gómez-Mateu, Dafni, 2014)26 (see Table 3.1). We restrict our simulation study to 624 scenar-
ios corresponding to ARE(Z∗, Z ) ≤ 10 and sample sizes smaller than 1100 patients per group. These
scenarios yield ARE(Z∗, Z ) values between 0.20 and 9.93; sample sizes, n, for the relevant endpoint
between 142 and 1081; and, n∗, for the composite endpoint between 53 and 1077 (see Table 3.2).
Parameters
βR =βA 0.5 1 2
(p(0)R , p
(0)
A ) (0.05, 0.01) (0.05, 0.15) (0.05,0.35) (0.1, 0.01) (0.1, 0.15) (0.1,0.35)
(0.15, 0.01) (0.15, 0.15) (0.15,0.35) (0.35, 0.01) (0.35, 0.15) (0.35,0.35)
ρ 0.15 0.45 0.75
(HRR ,HRA) (0.5, 0.3) (0.5, 0.7) (0.5, 0.9) (0.6, 0.3) (0.6, 0.7) (0.6, 0.9)
(0.7, 0.3) (0.7, 0.7) (0.7, 0.9) (0.8, 0.3) (0.8, 0.7)
Total number
of cases 624
Table 3.1: Values of parameters βR , βA , p
(0)
R , p
(0)
A , HRR , HRA and ρ used for the simulations. There are 624
different configurations, excluding those yielding sample sizes larger than 1100 and ARE(Z∗, Z )> 10.
min median max
n 142 509 1081
n∗ 53 398 1077
ARE(Z∗, Z ) 0.2 1.04 9.93
Table 3.2: Computed values of n, n∗ and ARE(Z∗, Z ) in step 3 of the simulation based on the parameter values
given in Table 3.1.
The empirical powers ΠˆR in our simulation study resulted in powers between 0.87 and 0.94, with a
median of 0.91. A slightly higher median was found for scenarios with low hazard ratios. This finding
is acknowledged as well by Freedman (1982)18 .
Table 3.3 provides the percentiles for the absolute value differences between Πˆ∗ and ΠˆR . We ob-
serve that in 75% of the cases the difference is smaller than 2.3%, and among cases with ARE as large
as 3 the difference shrinks to 1.9%. There are, however, few instances, where this difference can be as
large as 6%, and they deserve a closer look.
Figure 3.2 plots the differences Πˆ∗−ΠˆR as a function of the ARE(Z∗, Z ) values. The behaviour is re-
markably different when ARE(Z∗, Z )≤ 3 or ARE(Z∗, Z )> 3. Whenever ARE(Z∗, Z )≤ 3, Πˆ∗ fluctuates
around ΠˆR , within a range of 4%. However, when ARE(Z∗, Z ) > 3, corresponding mostly to scenar-
ios where treatment has an stronger effect on the additional endpoint than on the relevant endpoint
(HRA ≤HRR−0.2) and the anticipated number of events in the control group is larger for the additional
endpoint than for the relevant (p(0)A ≥ p(0)R ), the empirical power Πˆ∗ of the logrank test based on the CE
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min w0.1 w0.25 w0.5 w0.75 w0.9 max
For all ARE 0 0.002 0.004 0.010 0.023 0.036 0.062
ARE(Z∗, Z )≤ 3 0 0.002 0.004 0.008 0.019 0.033 0.062
ARE(Z∗, Z )> 3 0.001 0.009 0.016 0.026 0.038 0.046 0.062
Table 3.3: Percentiles of |Πˆ∗− ΠˆR | as a function of ARE values, where wi indicates the corresponding percentile.
never achieves the same power as the logrank test for the relevant endpoint would get. In these cases
the interpretation of the ARE(Z∗, Z ) as the ratio of the sample sizes, n/n∗, is not as straightforward.
Nevertheless, this does not mean that the recommendation of using the CE does not have to be fol-
lowed since larger values for n∗ needed to attain the same power as n does, would reduce the ARE
value but not as much as to cross the “1” border that would imply to use the relevant endpoint instead
of the CE.
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Figure 3.2: Differences between empirical powers Πˆ∗− ΠˆR as function of ARE(Z∗, Z ) and in terms of HRA−HRR .
If we analyze the differences between Πˆ∗ and ΠˆR as a function of the differences between the two
hazard ratios (HRA−HRR ), we observe that when the two hazard ratios are very close, the two empirical
powers are as well very close. Whenever HRA−HRR ≤ 0.2, not only ARE(Z∗, Z ) values tend to be higher,
but also Πˆ∗ < ΠˆR . (see Figure 3.2).
Taking into account that absolute differences between powers smaller than 5% could be considered
irrelevant, we conclude that the asymptotic relationship ARE(Z∗, Z )= n/n∗ is valid in the majority of
scenarios.
All computations in this chapter have been implemented in R and are available under request to
either author.
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3.4 Discussion
Pitman’s relative efficiency is defined as the limiting ratio of sample sizes to give the same asymptotic
power under sequences of local alternatives. Given two asymptotically standard normal tests Sn and
Tm under the same null and alternative hypotheses, the alternative definition ARE = (µS/µT )2 can be
used because the equality of the powers holds if mn = (
µS
µT
)2.
Gómez and Lagakos’ method uses the alternative definition of ARE to develop all the computations
for the two corresponding logrank tests. Our goal has been to check that the relationship between
(µS/µT )2 and the ratio of sample sizes still held when the two hypotheses under test were not the same
(H0 versus Ha and H∗0 versus H
∗
a ).
It is important to keep in mind that these two hypotheses tests are by no means equivalent. For
instance, to check whether treatment has a beneficial effect, we might use ER or we might add endpoint
EA and use E∗. As it is shown in Gómez (2011),21 even if we assume that the times to ER and to EA are
independent, a beneficial effect on E∗ can occur simultaneously with a beneficial effect on ER and a
harmful effect on EA and not finding a beneficial effect on the composite event E∗ is no guarantee of
not having some effect on the individual events ER or EA .
The main result of this paper proves that ARE(Z∗, Z ) coincides with n/n∗, being n and n∗ the
sample sizes needed to detect specific alternatives HRR and HR∗ to attain power Π and for the same
significance level α. Therefore, we can use and interpret ARE in its usual way.
The simulation study has been conducted in such a way that for fixed values n and ARE(Z∗, Z ),
the sample size n∗ is calculated as n∗ = n/ARE(Z∗, Z ). Hence, an approximate equality of the empir-
ical powers ΠˆR , of logrank test Z for H0 versus Ha,n , and of Πˆ∗ of logrank test Z∗ for H∗0 versus H
∗
a,n ,
indicates that the relationship ARE(Z∗, Z )= n/n∗ holds. Main results from our simulations show that
the absolute differences between ΠˆR and Πˆ∗ are most of the times less than 2.5%, hence the usual
interpretation between (n,n∗) and ARE(Z∗, Z ) holds for finite sample sizes.
For those scenarios under which ARE(Z∗, Z ) > 3, we observe that the empirical power of the test
based on E∗ never achieves the empirical power that the logrank test based on ER would get. Conse-
quently, larger values of n∗ would be needed to attain the same power as n does. In these instances,
even though the relationship ARE(Z∗, Z ) = n/n∗ is not necessarily true, the recommendation to use
the composite endpoint E∗ instead of the relevant endpoint ER will still be valid because very rarely a
value of ARE(Z∗, Z )> 3 would go down to less than 1. However, caution will be needed if one wants to
use the relationship ARE(Z∗, Z )= n/n∗ to compute the required sample size n∗ if ARE(Z∗, Z )> 3. In
these cases, a different formulation should be seek.

C
H
A
P
T
E
R 4
CompARE. AN ON-LINE PLATFORM AS A DECISION
TOOL FOR INVESTIGATORS
CompARE is an online web-based platform that provides efficient measures for discerning between
possible time-to-event endpoints when evaluating the efficacy of a treatment. In the design phase of
a clinical trial, clinicians, biostatisticians, and other members of the team can use CompARE to study
the performance of different endpoints in a variety of scenarios. CompARE has an intuitive interface
and it is a convenient tool for a better informed decision on the primary endpoint.
Users introduce the information needed in CompARE by means of intuitive web-page forms, such
as the list of candidate endpoints, together with the anticipated parameter values. The information,
which is saved in trackers, is used to run the code written in R, statistical software that is widely used in
the field of statistics (see the schematic in Figure 4.1). It is not necessary to install R to run CompARE,
nor is knowledge of R required. Furthermore, all the itnputs and outputs are presented in HTML format
and are compatible with any web browser.
In this chapter we detail the software we used to build CompARE and the basic features of this
platform, describing step by step how to access, register, run it and get the results. We illustrate one
of the capabilities of CompARE using the ARE method to quantify how efficient is a relevant subset of
outcomes with respect to a larger subset. Results from different scenarios, depending on the parameter
values, are shown immediately by means of tables and plots such as survival and hazard ratio curves.
Moreover, conclusions and recommendations are provided in written form as an aid. A complete on-
line user’s guide is also available. CompARE is currently accessible as a beta version at the following
website: https://cinna.upc.edu/compare.
47
48 CHAPTER 4 CompARE. AN ON-LINE PLATFORM AS A DECISION TOOL FOR INVESTIGATORS
Input information
(HTML forms)
Information processed
on the server
Execution of R code
(plugin R)
Results shown on
the Web
USER
Web interface
Internal results
saved in trackers
https://cinna.upc.edu/compare
Figure 4.1
In Chapter 6, we extend CompARE to develop different advanced options. Among other features,
we detail how to specify different marginal distribution laws, copulas and correlations between times.
Sample size calculations based on these parameters are calculated as well. CompARE is also extended
to accommodate the computation of combined probabilities and combined hazard ratios, based on
the marginal components. For non-proportional hazards, CompARE visualizes how the hazard ratios
of the components depart from constancy by depicting the corresponding values during the follow-up
period for different scenarios.
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4.1 Software used to build CompARE
The web-based platform CompARE was built using the free software Tightly Integrated Knowledge In-
frastructure (Tiki Wiki CMS/Goupware).79 Free software is widely used and is commonly developed
with volunteer computer programmers, guaranteeing that every user has equal rights of access. It
allows any programmer to study the source code, modify it, and share it (FSF).17 Moreover, online
graphic interfaces based on free software leads to collaboration synergies between partners from dif-
ferent areas such as informatics, biology or statistics.
We chose Tiki because the majority of other interface web programs that include the use of R rou-
tines present problems in the short or medium term (de Pedro and Sánchez, 2010).11 Some of the
reasons might be because either they do not work with free software, they are not updated or they
are too complex to be used by most professionals who are not involved in web computing. Moreover,
Tiki is safe and updated periodically by their community members, who add new features, fix bugs
and patch security holes. It is constantly maintained under the license LGPL (Lesser General Public
License). Repositories are used for the version control system.
Other remarkable features of Tiki are the use of standard codes and its flexibility. Web standard
codes such as HTML, PHP and javascript are used. It allows to design entry forms on the web through
the use of trackers that save the data collected in items. Due to its flexibility, these parameter values can
be used to execute other applications through the use of plugins (see Sapir (2010) for more details63).
By means of the pluginR,71 developed by de Pedro and Sánchez,11 it is possible to execute the ARE
method in R in CompARE.
The Tiki software is installed in a virtual machine at the Universitat Politècnica de Catalunya. It
runs under a Linux server Ubuntu 12.04 LTS with a total of 32GB of RAM, 2 Quad Core Processor and
2x1TB of disk space.
Initially, before designing Comp ARE , the code to execute the ARE method was written in MAPLE
by Gómez G. The code was programmed to run scenarios where both the relevant endpoint (RE) and
the additional endpoint (AE) does not include a terminating event (Case 1) or either the relevant or
additional endpoint includes a terminating event (Cases 2 and 3). We adapted the code in R because it
is free software and because of its the great capabilities and flexibility. Moreover, it is compatible with
the software used in Comp ARE . We also extended the R code to Case 4, where both the RE and the AE
includes a terminating event, and it is described in Chapter 6.
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4.2 CompARE step by step
Access and registration
CompARE is a completely free tool. You can access CompARE by means of any standard web
browser such as Mozilla Firefox, Internet Explorer or Google Chrome by clicking on the following link:
https://cinna.upc.edu/compare.
Figure 4.2
Only a quick registration is needed from the main web page. The system asks you for a username
and a password, which will be used to enter the application under your own session (see Figure 4.3).
For security reasons, an e-mail is required. You will have to accept the registration from your own e-
mail. In order to avoid spam registrations, you need to correctly introduce a captcha code (Completely
Automated Public Turing test to tell Computers and Humans Apart). The web administrator accepts
the registration as a final step.
Figure 4.3
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Running CompARE. Information about all the candidate endpoints
Once you are logged in to CompARE, you can get to the input grid of information by clicking on
the "Start" button from the main web page (see Figure 4.4). Then, enter the information about the
endpoints you might plan to use as the primary endpoint in your randomized clinical trial. Place the
cursor over each header as an aid for getting a quick definition of each concept:
1. In the first column, write the name of each endpoint. Indicate whether each endpoint is ter-
minating (i.e., when the occurrence of it precludes the observation of other endpoints, as for
example Death).
2. Specify the expected probabilities of observing the event in the control group during the follow-
up period. By default, when the relevant or the additional endpoints consist of several compo-
nents, CompARE will use their maximum probability to calculate the ARE values. In Chapter 5,
we discuss how to assign the specific value or range of plausible values for this combined prob-
ability by means of the marginal information of each component.
3. Indicate the anticipated treatment effect in terms of the hazard ratios between groups (constant
hazard ratios are assumed). By default, when the relevant or the additional endpoints consist of
several components, CompARE will use the average hazard ratio to calculate the ARE values. As
for the combined probability, in Chapter 5 we discuss how to assign the specific value or range
of plausible values of this combined hazard ratio by means of the marginal information of each
component.
4. Select whether the endpoint is a component of the relevant or the additional endpoint.
5. In the last column, select those candidates that form the composite endpoint. Note: unselected
endpoints will be excluded from the current analysis.
6. At the bottom, click on "Remove executions history" to delete previous analyses you may have
done before.
7. When ready, click on the "Run" button to execute the process.
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Figure 4.4
By default, exponential distributions and the Frank copula relationship between marginal times
with moderate correlations is assumed. In Chapter 6, among other developments, we extend CompARE
in order to allow users to modify these assumptions.
As an example, in Figure (4.4) we consider the union of Cardiovascular Death + Myocardial Infarc-
tion as the relevant endpoint (RE), and the union of Stroke + Hospitalization as the additional endpoint
(AE). The union of the RE and the AE forms the composite endpoint (CE).
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Results
Once the program executes the computations, an output screen that is divided into four tags appears
at the top:
• Results (see Figure 4.5): In this tag, a table specifies the parameter information set by the user
together with the exact value of ARE. When ARE > 1, the composite endpoint should be used.
That is, a smaller sample size would be required, using the composite endpoint as primary rather
than the relevant endpoint (Gómez and Gómez-Mateu, 2014)24 . Otherwise, the relevant end-
point will be advisable to use as primary endpoint. A paragraph below the table shows a detailed
recommendation written in text.
Figure 4.5
54 CHAPTER 4 CompARE. AN ON-LINE PLATFORM AS A DECISION TOOL FOR INVESTIGATORS
• Other scenarios (see Figure 4.6): Several scenarios depending on different correlations and haz-
ard ratios for the additional endpoint are detailed in a table.
Figure 4.6
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• Graphical outputs (see Figure 4.7): The results from the previous tag are shown graphically here.
Also, a plot with survival distributions and hazard ratios is shown at the bottom. The "end of
study" time point corresponds to the follow-up period of your clinical trial.
Figure 4.7
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• Recorded results (see Figure 4.8): In this tag, the user can see the history of results performed in
previous analyses.
Figure 4.8
In our example, the use of the composite endpoint is clearly advisable, since the ARE is higher than
1 (ARE = 2.1). That is, by considering moderate correlations between endpoint times, we would need
less than half of the sample size when using the CE as primary instead of the RE. As we see in Figure (4.7,
top), the decision remains the same irrespective of the correlation. However, note that if the expected
hazard ratio for the additional endpoint was 0.8 instead of 0.7 (i.e., a smaller expected effect of the AE),
the use of the relevant endpoint would be recommended when having a strong correlation between
marginal times.
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4.3 Summary
CompARE provides investigators a free online tool that can be used at the design stage of randomized
clinical trials. One of the capabilities of CompARE is to help in deciding whether the primary endpoint
should consist of a composite of several components, or of a smaller subset that forms the relevant
endpoint. In this chapter we have shown some illustrations and the basic functionality of the platform.
CompARE is permanently extended with new functionalities and features, and we are constantly
improving it thanks to the feedback of colleagues from different national and international universities,
institutions and companies. In Chapter 6 we detail several improvements, such as the possibility of
assuming other distribution laws, copulas or correlations. Sample size calculations will also be tackled.
An important issue to address is the assignment of the combined probability and hazard ratio when
having several components in the relevant or the additional endpoint, as seen in the example in Figure
4.4. By default, CompARE assigns the maximum value of the marginal probabilities and the average of
the marginal hazard ratios. The assignment of these combined outcomes is of paramount importance,
because it might affect the decision regarding the primary endpoint and also regarding sample size
calculations. In the next chapter, we develop practical solutions for calculating a specific value or
assigning a plausible range of values for the combined probability and combined hazard ratio. We
apply this development in CompARE and describe it in Chapter 6.
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PRACTICAL ISSUES TO ASSIGN COMBINED
PROBABILITIES AND HAZARD RATIOS
When the relevant and/or the additional endpoint consist of a composite of several components, in-
vestigators may anticipate the probabilities and hazard ratios of each one of the components instead
of the combined probabilities and hazard ratios. For example, consider the relevant endpoint as a
composite of stroke and myocardial infarction. While the marginal parameter values for stroke and
myocardial infarction might be anticipated by trialists (ex. the LIFE trial10), the specific parameter
values for the union of stroke+myocardial infarction could be more difficult to specify (see Figure 5.1).
Since the computation of the ARE needs specific values for the probability (in the control group)
and hazard ratio of both the relevant and additional endpoints, we will discuss in this chapter how
to derive these quantities based on the marginal values. We propose solutions to assign combined
probabilities and combined hazard ratios from any pair of endpoints E1 and E2. These two endpoints
might refer either to the marginal components of the relevant endpoint or the additional endpoint.
In this chapter, we will use the term combined endpoint instead of composite endpoint in order
to avoid confusion with the definition used by Gómez and Lagakos of E∗ as the union of the rele-
vant endpoint ER and the additional endpoint EA . We restrict to combined endpoints with only two
components although some of the results of this chapter could be extended to more than two compo-
nents. The development of the practical implementation has been incorporated in CompARE and is
described in chapter 6.
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A letter to the editor in Statistics in Medicine is published based on the evaluation of the ARE de-
pending on the choice of different combined parameter values23 (See Appendix) :
Gómez G, Gómez-Mateu M. Comments on "Use of composite endpoints in clinical trials" by Abdul J.
Sankoh, Haihong Li and Ralph B. D’Agostino, Sr (2016). Statistics in Medicine, 35, 317–318.
Letter to the Editor
(wileyonlinelibrary.com) DOI: 10.1002/sim.6483 Published online in Wiley Online Library
Comments on ‘Use of composite endpoints
in clinical trials’ by Abdul J. Sankoh,
Haihong Li and Ralph B. D’Agostino, Sr
From: Guadalupe Gómez
Moisés Gómez-Mateu
Department of Statistics and Operations Research,
Universitat Politècnica de Catalunya,
Barcelona, Spain
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5.1 Combined probability
In this section we study how to assign the combined probability p∗ of observing the combined end-
point E∗ = E1∪E2 when having two marginal components E1 and E2 . The value of p∗ depends on the
marginal probabilities p1 and p2 together with the correlation between E1 and E2 (Bahadur, 1961).4
Hence, whenever the correlation is anticipated, the value of p∗ is univocally determined by p1 and p2.
Otherwise, a range of plausible values can be proposed.
COMPOSITE ENDPOINT
RELEVANT ENDPOINT
p1
p2
Stroke
Myocardial Infarction
pR
ADDITIONAL ENDPOINT
pA HRAHospitalizations
Combined 
probability
Combined 
hazard ratio
HRR(t)
HR1
HR2
Figure 5.1: Combined probability pR and hazard ratio HRR (t ) of a combined endpoint consisting of the union
of Stroke and Myocardial infarction that forms the relevant endpoint. p1, p2 and HR1, HR2 corresponds to the
probability and hazard ratio of each component. p A and HRA stands for the probability and hazard ratio of the
additional endpoint.
5.1.1 Boundaries for the combined probability
Consider that we have two endpoint components E1 and E2 belonging to the combined endpoint E∗ =
E1∪E2. Let p1, p2 and p∗ be the probability of observing E1, E2 and E∗, respectively.
Proposition: The probability p∗ is bounded by:
max(p1, p2)≤ p∗ ≤ p1+p2. (5.1)
Proof:
p∗ = P (E1∪E2)= P (E1)+P (E2)−P (E1∩E2)= p1+p2−P (E1∩E2). Since 0≤ P (E1∩E2)≤mi n(p1, p2),
we have
p1+p2−mi n(p1, p2)≤ p∗ ≤ p1+p2, which implies
max(p1, p2)≤ p∗ ≤ p1+p2, because p1+p2−mi n(p1, p2)=max(p1, p2).
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In case of independence between E1 and E2, that is if P (E1 ∩ E2) = P (E1) ·P (E2), we have p∗ =
p1+p2−p1p2.
Corollary: Let p1, ..., pm be the probabilities of observing each component E1, ...,Em , respectively, and
define p∗m = P (E1∪ ...∪Em). Bounds from (5.1) are straightforwardly generalized as:
max(p1, p2, ..., pm)≤ p∗m ≤ p1+p2+ ...+pm .
5.1.2 Expression of the combined probability p∗ as a function of the correlation
coefficient
Given two Bernoulli random variables X1 and X2 with pk = P (Xk = 1) > 0 (k = 1,2), it is possible to
calculate the specific combined probability from the marginal probabilities and a correlation coeffi-
cient. Following Bahadur,4 the joint probability of two correlated Bernouilli variables is determined
by the marginal probabilities p1, p2 and the second order correlation coefficient δ (Pearson product-
moment correlation coefficient) given by
δ= E [Z1 ·Z2],
where Zk = (Xk −pk )/
√
pk (1−pk ), (k = 1,2).
The joint probability function can be expressed as
P (X1 = x1, X2 = x2)=
2∏
k=1
pxkk ·q
(1−xk )
k (1+δ · z1 · z2) ,
where zk = xk−pkppk qk and qk = 1−pk , (k = 1,2).
Hence, the combined probability p∗ of observing at least one response is given by:
p∗ = 1−P (X1 = 0, X2 = 0)= 1−q1q2−δpp1q1p2q2.
Unlike in the continuous data case, the correlation δ is not free to range over (-1,1) (see Bahadur(1961)
and Sozu(2010) for more details).4, 68 The correlation coefficient δ is bounded by:
max
{
−
√
p1p2
q1q2
,−
√
q1q2
p1p2
}
≤ δ≤mi n
{√
p1q2
q1p2
,
√
q1p2
p1q2
}
.
Note that given p1 and p2, the higher (positive) correlation, the lower the combined probability p∗
is. In Table 5.1 we indicate the possible range of values of the combined probability and correlation
depending on the marginals p1 and p2. For example, if we assume the two relevant marginal proba-
bilities p1 = 0.1 and p2 = 0.2, the possible values of the combined probability p∗ will range over the
interval (0.2, 0.3) whose probability boundaries will correspond to the correlation coefficients δ equal
to 0.67 and -0.17, respectively. In case of independence between X1 and X2, then p∗ = 0.28. When
p1 = p2 = 0.5, it leads to the widest correlation’s interval (−1,1) and the widest probability interval
(0.5,1).
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Table 5.1: Range of combined probability values (grey shadow) and the corresponding correlation coefficient
(below, in italics) depending on the marginal probabilities p1 and p2.
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5.1.3 Expression of the combined probability p∗ as a function of several parameters.
Time-to-event data
We follow analogous steps that Gómez and Lagakos did to develop the ARE method, to calculate the
combined probability. Considering time-to-event data, we can express the p∗ in terms of several pa-
rameters depending on joint and marginal distribution assumptions.
Some notation
Define T1 and T2 as the marginal times to E1 and E2, respectively. The time to the combined end-
point E∗ is given by T∗ =mi n(T1,T2). Assuming that τ is the only non-informative censoring time, the
combined probability p∗ of observing the combined endpoint during the follow-up period is given by:
p∗ = P ((T1 < τ)∪ (T2 < τ))= P (T∗ < τ)= 1−S∗(τ),
where S∗(τ) is the survival function of the combined endpoint at time τ.
We can approach the bivariate distribution (T1,T2) decoupling the joint survival of (T1,T2) into
univariate components using a copula model given by.
S∗(t )=C (S1(t ),S2(t );θ),
where S1(t ) and S2(t ) are the marginal survival functions for E1 and E2, respectively; and θ is the asso-
ciation parameter between T1 and T2, which is biunivocally related to Spearman’s rank correlation ρ
(−1< ρ < 1) (1). Therefore, the probability p∗ for a follow-up period τ is in terms of the marginal laws
of T1 and T2, the chosen copula for the joint distribution of (T1,T2), and θ:
p∗ = 1−S∗(τ)= 1−C (S1(τ),S2(τ);θ). (5.2)
Expression of p∗ depending on whether E1 or E2 includes terminating events
The values of S1(τ) and S2(τ) depend on whether the relevant components include a terminating
event since the observation of one component might preclude the observation of the other component
(Cases 1,2,3 and 4 in Gómez and Lagakos27). We next derive the expression of S1(τ) and S2(τ) for each
Case separately.
• Neither E1 nor E2 includes a terminating event (Case 1)
The expression of the marginal survival functions at time τ is given by:
S1(τ) = 1-p1,
S2(τ) = 1-p2.
Hence, from (5.2) the expression of p∗ in Case 1 is given by:
p∗ = 1−C (1−p1,1−p2;θ). (5.3)
1See more details in the Appendix. Other copulas could also be considered (Plana-Ripoll O. and Gómez G., 2015).51
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• Either E1 or E2 includes a terminating event (Cases 2 and 3)
In these cases, the occurrence of one endpoint might preclude the observation of the other. Consid-
ering E2 as the terminating event (Case 2), the occurrence of E2 precludes the observation of E1 when
T1 > T2 (see Figure 5.2). Hence, S1(τ) has to be derived in terms of the probability p1 plus another
unobservable probability U1:
S1(τ)= 1− [p1+P (T1 > T2,T1 < τ)]= 1− [p1+U1]
S2(τ)= 1−p2,
where U1 =
∫ τ
0
∫ u
0 f(1,2)(u, v)d vdu, and f(1,2)(u, v) is the joint density of (T1,T2).
Thus, from the expression 5.2, p∗ in Case 2 is given by:
p∗ = 1−C (1−p1−U1,1−p2;θ). (5.4)
In Case 3, the occurrence of the terminating event E1 precludes the observation of E2 when T1 < T2
(see Figure 5.2). Thus, S2(τ) is function of the probability p2 plus another unobservable probability U2:
S1(τ)= 1−p1
S2(τ)= 1− [p2+P (T2 > T1,T2 < τ)]= 1− [p2+U2],
where U2 =
∫ τ
0
∫ v
0 f(1,2)(u, v)dud v . Hence, p∗ in Case 3 is given by:
p∗ = 1−C (1−p1,1−p2−U2;θ). (5.5)
If we assume a Frank’s Archimedean survival copula, the joint density of (T1,T2) is given by
f(1,2)(t1, t2;θ)= θe
−θ(S1(t1)+S2(t2))
e−2θS(1,2)(t1,t2;θ)(e−θ−1) [ f1(t1)][ f2(t2)]. (5.6)
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• Both E1 and E2 include a terminating event (Case 4)
In Case 4, both marginal survival functions are in terms of the unobservable probabilities U1 and U2
(defined previously for Cases 2 and 3):
S1(τ)= 1− [p1+U1],
S2(τ)= 1− [p2+U2].
Therefore, from (5.2), p∗ in Case 4 is given by:
p∗ = 1−C (1−p1−U1,1−p2−U2;θ). (5.7)
Note that the expression of p∗ can be simplified as p∗ = p1+p2.
Proof:
We have that p∗ = P (mi n(T1,T2) < τ). In Case 4, the observation of E1 precludes the observation
of E2, and vice versa. Thus, p∗ = P (T1 < τ,T1 < T2)+P (T2 < τ,T1 > T2)= P (T1 <mi n(T2,τ))+
P (T2 <mi n(T1,τ))= p1+p2.
It is important to take into account whether each endpoint includes a terminating event. As com-
mented in Rauch56 and Gooley,31 the calculation of the probabilities via 1− S(τ) ignoring that one
event is censoring the other might lead to inflated values above the true event probability. That is,
ignoring the probabilities U1 and U2 might inflate the values of S1(τ) and S2(τ) for Cases 2, 3 and 4.
Summarizing, for Case 4 the combined probability p∗ can be calculated as the sum of the marginal
observed probabilities p1 and p2 (see Table 5.2). For Case 1, p∗ can be calculated straightforwardly
from expression (5.3) given p1, p2 and the association parameter θ for any copula, regardless of the
marginal distribution laws of T1 and T2. For Cases 2 and 3, we also need to set the laws for T1 and T2 in
order to calculate the joint density f(1,2)(t1, t2) for a chosen copula (expressions for Weibull distribution
are detailed in the Appendix).
p∗
Case 4 p1+p2
Case 3 1−C (1−p1,1−p2−U2;θ)
Case 2 1−C (1−p1−U1,1−p2;θ)
Case 1 1−C (1−p1,1−p2;θ)
Table 5.2: Expression of the combined probability p∗ for each Case. p1 and p2 stands for the probability of observ-
ing E1 and E2, respectively; θ is the association parameter between the time T1 and T2 to E1 and E2, respectively.
U1 and U2 are the unobservable probabilities. C indicates the copula.
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τ
T2
T1
Case 1
S1 (τ) = 1 – p1 S2 (τ) = 1 – p2
τ
T2
T1
Case 2
S1 (τ) = 1 – (p1 + U1) S2 (τ) = 1 – p2
τ
T2
T1
Case 3
S1 (τ) = 1 – p1 S2 (τ) = 1 – (p2 + U2)
U1
(T2 < T1)
T1
T2τ
T1
T2τ
T1
T2
U2
(T1 < T2)
τ
T2
T1
S1 (τ) = 1 – (p1 + U1)
U1
(T2 < T1)
S2 (τ) = 1 – (p2 + U2)
T1
T2
U2
(T1 < T2)
τ
τ
Case 4
Figure 5.2: Calculation of the marginal survival functions S1 and S2 of the endpoints E1 and E2 at the end-of-
study time τ for each Case in terms of the observable probabilities p1 and p2 and the unobservable probabilities U1
and U2. The green/red shadows represent the observable/unobservable combinations of times T1 and T2. In Case
1, T1 and T2 will be always observable until τ. In Case 2, the observation of T2 precludes the observation T1 when
(T1 > T2). In Case 3, the observation of T1 precludes the observation T2 when (T1 < T2). In Case 4, the observation
of T1 and T2 precludes the observation of T2 and T1 when T1 < T2 and T1 > T2, respectively.
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5.2 Combined hazard ratio
The combined hazard ratio HR∗(t ) is defined as the ratio of the hazard functions λ(1)∗ (t ) and λ
(0)
∗ (t ). In
this section we propose a practical solution to assign HR∗(t ) values in terms of the marginal hazard
ratios. The specific expression for the combined HR∗(t ) can be derived in terms of several parameter
values. In cases where the HR∗(t ) is constant over time, we can calculate the specific HR∗(t ) in terms
of these parameter values. Otherwise, since some of these parameters are difficult to anticipate by
trialists, and since the HR∗(t ) is not always constant over time, we propose to use a range of plausible
values.
5.2.1 Notation and assumptions
We denote by T ( j )1 and T
( j )
2 the marginal times to the endpoint components E1 and E2, respectively, for
both groups j ( j = 0,1). Define the time to the combined endpoint E∗ = E1∪E2 as T ( j )∗ for each group
j . We assume for the remainder of this section:
• Censoring: The end-of-study censoring at time τ is the only non-informative censoring cause
for both groups.
• Proportional hazards: The hazard ratios between T (0)1 and T
(1)
1 and between T
(0)
2 and T
(1)
2 are
constant. That is, HR1(t )=λ(1)1 (t )/λ(0)1 (t )=HR1 and HR2(t )=λ(1)2 (t )/λ(0)2 (t )=HR2 for all t . Note
that although we are assuming that the hazard functions λ( j )1 (t ) and λ
( j )
2 (t ) ( j = 0,1) are propor-
tional, this does not imply the proportionality of the combined hazards λ(0)∗ (t ) and λ
(1)
∗ (t ) for the
combined endpoint E∗ (see Figure 5.3, right).
• Copula assumptions: We consider a Frank’s Archimedean copula relationship between T (0)1 and
T (0)2 , which is in terms of an association parameter θ
(0), and between T (1)1 and T
(1)
2 , which is in
terms of an association parameter θ(1). We assume equal association parameter θ = θ(0) = θ(1) for
both groups 0 and 1, which is biunivocally related to Spearman’s rank correlation ρ (−1< ρ < 1)
(see Appendix for more details). Other copulas can also be used (Plana-Ripoll O. and Gómez G.,
2015).51
• Marginal laws: We assume Weibull distributions for T ( j )1 and T
( j )
2 ( j = 0,1) with scale and shape
parameters b( j )1 , b
( j )
2 and β
( j )
1 , β
( j )
2 , respectively. The shape parameters are chosen equal for both
groups, that isβ(0)k =β(1)k =βk (k = 1,2), so that the assumption of proportionality of the marginal
hazards holds.
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Figure 5.3: Values of the combined hazard ratio HR∗(t ) over time assuming constant hazard ratios HR1 = 0.7 and
HR2 = 0.95, with a probability p1 = 0.15 and p2 = 0.15 of observing the marginal component E1 (terminating)
and E2(non terminating), respectively. We assume Weibull distributions with constant hazard rates for E1 and
increasing hazard rates for E2 with correlation ρ = 0.95 (right); and constant hazards with null correlation (left).
5.2.2 Expression of HR∗(t ) as a function of several parameters
The expression of the combined hazard ratio is given by:
HR∗(t )= λ
(1)
∗ (t )
λ(0)∗ (t )
=
f (1)∗ (t )
S(1)∗ (t )
f (0)∗ (t )
S(0)∗ (t )
, (5.8)
where f ( j )∗ (t ) and S
( j )
∗ (t )( j = 0,1) are the density and survival functions of T ( j )∗ , respectively.
In the same way that Gómez and Lagakos did to derive the hazard ratio for the composite endpoint
of the relevant and the additional endpoint, we can derive the combined HR∗(t ) from the following
parameters:
• The marginal hazard ratios HR1 and HR2,
• the probabilities p1 and p2 of observing each component E1 and E2 in control group,
• the shape parameters β1 and β2 for E1 and E2, respectively,
• and the correlation ρ between the two components.
The expression of HR∗(t ) also depends on whether the E1 or E2 has a terminating event or not (Cases
1,2,3 and 4).
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5.2.3 Scenarios with constant HR∗(t )
We next describe how to calculate the combined hazard ratio HR∗(t ) when it is constant over time (see
Figure 5.3, left). In section (5.3) we will describe some practical solutions in order to supply a value for
HR∗(t ) when the proportionality of the hazards for the combined endpoint does not hold (see Figure
5.3, right). A brief summary of the results is shown in Table 5.8.
a) Null treatment effect on E1 and E2 (HR1 =HR2 = 1) implies HR∗(t )= 1.
If there is no treatment effect on the marginal components (HR1 =HR2 = 1), then there is no treatment
effect on the combined endpoint (HR∗(t )= 1). That is, if the null hypotheses of no treatment effect of
E1 and E2 are true (H0 : HR1 = 1 and H0 : HR2 = 1, respectively) , it implies that the null hypothesis of
no treatment effect of E∗ (H0∗ : HR∗(t )= 1) is also true.
Proof:
The expression of S( j )∗ for each group j is given by:
S( j )∗ (t )=C (S( j )1 (t ),S
( j )
2 (t )), (5.9)
where C indicates the copula model between the marginal times.
If HR1(t )=λ(1)1 (t )/λ(0)1 (t )= 1, then λ(0)1 (t )=λ(1)1 (t ). Since the hazard function characterizes the law
of the random variables, we have that S(0)1 (t ) = S(1)1 (t ). Analogously, if HR2(t ) = 1, we have S(0)2 (t ) =
S(1)2 (t ). Therefore, from (5.9), S
(0)
∗ (t )= S(1)∗ (t ) and hence f (0)∗ (t )= f (1)∗ (t ) . Thus,
HR∗(t )=
f (1)∗ (t )
S(1)∗ (t )
f (0)∗ (t )
S(0)∗ (t )
= 1.
Note that it also applies to any marginal distribution, copula model, and correlation between marginal
times.
b) Null correlation between marginal times when λ(0)2 (t )/λ
(0)
1 (t ) is contant implies constant HR∗(t ).
When assuming null correlation, the combined HR∗(t ) is constant when the ratio of the baseline haz-
ard functions λ(0)1 (t ) and λ
(0)
2 (t ) is as well constant (Gómez G., 2011).
21 The expression of this ratio is
given by:
λ(0)2 (t )
λ(0)1 (t )
= HR1−HR∗(t )
HR∗(t )−HR2
. (5.10)
Proof:
The expression of the survival function S( j )∗ (t ) for each group j = 0,1 is given by:
S( j )∗ (t )= P (T1 > t ∩ T2 > t ).
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Assuming independence between times (and hence ρ = 0 for Spearman’s correlation), S( j )∗ (t ) is given
by
S( j )∗ (t )= P (T ( j )1 > t ) ·P (T
( j )
2 > t )= S
( j )
1 (t ) ·S
( j )
2 (t ).
The expression of the density function f ( j )∗ (t ) for each group j is given by:
f ( j )∗ (t )=
−∂S( j )∗ (t )
∂t
= −∂(S
( j )
1 (t ) ·S
( j )
2 (t ))
∂t
= f ( j )1 (t ) ·S
( j )
2 (t )+S
( j )
1 (t ) · f
( j )
2 (t ).
Hence, from (5.8) we have:
HR∗(t )= f
(1)
∗ (t )/S
(1)
∗ (t )
f (0)∗ (t )/S
(0)
∗ (t )
=
[
f (1)1 (t ) ·S(1)2 (t )+S(1)1 (t ) · f (1)2 (t )
]
/S(1)1 (t ) ·S(1)2 (t )[
f (0)1 (t ) ·S(0)2 (t )+S(0)1 (t ) · f (0)2 (t )
]
/S(0)1 (t ) ·S(0)2 (t )
.
We express f ( j )1 (t )=λ
( j )
1 (t ) ·S
( j )
1 (t ), and f
( j )
2 (t )=λ
( j )
2 (t ) ·S
( j )
2 (t ):
HR∗(t )=
[
λ(1)1 (t ) ·S(1)1 (t ) ·S(1)2 (t )+S(1)1 (t ) ·λ(1)2 (t ) ·S(1)2 (t )
]
·S(0)1 (t ) ·S(0)2 (t )[
λ(0)1 (t ) ·S(0)1 (t ) ·S(0)2 (t )+S(0)1 (t ) ·λ(0)2 (t ) ·S(0)2 (t )
]
·S(1)1 (t ) ·S(1)2 (t )
=
=
S(1)1 (t ) ·S(1)2 (t ) ·
[
λ(1)1 (t )+λ(1)2 (t )
]
·S(0)1 (t ) ·S(0)2 (t )
S(0)1 (t ) ·S(0)2 (t ) ·
[
λ(0)1 (t )+λ(0)2 (t )
]
·S(1)1 (t ) ·S(1)2 (t )
.
After canceling the survival functions, we have:
HR∗(t )=
λ(1)1 (t )+λ(1)2 (t )
λ(0)1 (t )+λ(0)2 (t )
.
Therefore, since λ(1)1 (t )=HR1 ·λ(0)1 (t ) and λ(1)2 (t )=HR2 ·λ(0)2 (t ):
HR∗(t )=
HR1 ·λ(0)1 (t )+HR2 ·λ(0)2 (t )
λ(0)1 (t )+λ(0)2 (t )
. (5.11)
The previous equality can be expressed as:
λ(0)2 (t )
λ(0)1 (t )
= HR1−HR∗(t )
HR∗(t )−HR2
.
If λ(0)2 (t )/λ
(0)
1 (t )= c (c constant), then
c · (HR∗(t )−HR2)=HR1−HR∗(t ).
Hence, we have:
HR∗(t )= HR1+ c ·HR2
c+1 .
Since HR1 and HR2 are constant, it implies that HR∗(t ) is constant.
This result applies to any marginal distribution and copula model.
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c) Null correlation when HR1 =HR2 = k implies HR∗(t )= k.
Proof:
Assuming ρ = 0, from (5.11), if HR1 =HR2 = k, we have:
HR∗(t )=
k ·λ(0)1 (t )+k ·λ(0)2 (t )
λ(0)1 (t )+λ(0)2 (t )
= k.
This result applies to any marginal distribution and copula model.
d) Null correlation and Weibull distributions with (β1 =β2 =β) implies constant HR∗(t ).
When the marginal laws of T1 and T2 are Weibull with equal shape parameters (β1 = β2 = β) for both
components E1 and E2, the combined HR∗(t ) is constant and given by:
HR∗(t )=
HR1+HR2
(
b(0)1
b(0)2
)β
1+
(
b(0)1
b(0)2
)β . (5.12)
Proof:
The ratio of the baseline hazard functions λ(0)1 (t ) and λ
(0)
2 (t ) is given by:
λ(0)2 (t )
λ(0)1 (t )
=
f (0)2 (t )
S(0)2 (t )
f (0)1 (t )
S(0)1 (t )
.
Since we assume Weibull distributions with equal shape parameters (β1 = β2 = β), from expressions
(B.6) and (B.7) (Appendix), we have:
λ(0)2 (t )
λ(0)1 (t )
=
β
(b(0)2 )
β
· t (β−1)
β
(b(0)1 )
β
· t (β−1)
=
(
b(0)1
b(0)2
)β
. (5.13)
From expressions (5.10) and (5.13), we can express the following equality:
(
b(0)1
b(0)2
)β
= HR1−HR∗(t )
HR∗(t )−HR2
.
Solving the equation for HR∗(t ), we have:
HR∗(t )=
HR1+HR2
(
b(0)1
b(0)2
)β
1+
(
b(0)1
b(0)2
)β .
This result applies to any copula model.
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e) Null correlation, Weibull distributions with (β1 = β2 = β) and p1 = p2 for Case 1 implies HR∗(t )=
(HR1+HR2)/2.
If the probability of observing both endpoints is the same (p1 = p2) with no competing events (Case 1)
and equal shape parameters (β1 =β2 =β), then the combined HR∗(t ) is equal to the mean of HR1 and
HR2.
Proof:
The equality of the marginal probabilities p1 and p2 of observing E1 and E2 in group 0 at censoring
time τ, respectively, for Case 1, implies that:
S(0)1 (τ)= S(0)2 (τ).
Since we assume Weibull distributions, we have:
e−(τ/b
(0)
1 )
β = e−(τ/b(0)2 )β ,
which implies that
b(0)1 = b(0)2 = b(0).
Hence from (5.12),
HR∗(t )=
HR1+HR2
(
b(0)
b(0)
)β
1+
(
b(0)
b(0)
)β = HR1+HR22 .
This result applies to any copula model.
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5.3 Practical solutions to assign combined hazard ratios
5.3.1 General behavior of the HR∗(t ) over time
In the previous section 5.2 we have seen that it is possible to calculate the specific value of the com-
bined HR∗(t ) when investigators can anticipate all the required parameters. The main objective of
this section is to assign a specific value HR∗(t ) among all the values that the HR∗(t ) can take over time
when it is not constant or when investigators cannot anticipate all the needed parameters. To do so,
a range of values for the combined hazard ratio will be calculated over the follow-up period from ex-
pression 5.8 and the assumptions detailed in subsection 5.2.1. For example, in Figure 5.4 (top left), we
represent a specific scenario where the combined hazard ratio HR∗(t ) ranges from 0.75 to 0.89.
We analyze how the combined HR∗(t ) behaves taking the marginal HR1 and HR2 as fixed refer-
ences. That is, the HR∗(t ) interval, consisting of the minimum and maximum HR∗(t ) over time, might
have both boundaries inside the marginal hazard ratios, both outside or either one outside (see Figure
5.4). We consider multiple scenarios consisting of different parameter value combinations. Aggregated
results will give us a general idea of how the HR∗(t ) behaves depending on different parameter values.
Thus, when investigators cannot anticipate all the needed parameter values (such as the correlation),
they will be able to calculate a range of plausible values of HR∗(t ) and act accordingly.
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Figure 5.4: Behaviour of HR∗(t ) over time with respect to the marginal hazard ratios HR1 and HR2. That is,
HR∗(t ) can remain inside, outside or cross the marginal hazard ratios. Parameter values used to depict these plots
belong to the parameter value setting used for the executions except for the plot "Both below", with which negative
correlation is used only for illustration purpose.
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Parameter setting
We choose a wide range of values for each parameter in order to cover a wide range of scenarios (see
Table 5.3). These chosen parametric values lead to 117,855 different scenarios and can be somehow
understood as if we took a huge representative sample from the universe we want to study. We set a
study duration from time t = 0 to t = 1 divided into intervals of width 0.1.
Only positive correlations and equal shape parameters β1 = β2 = β were included because they
represent more realistic situations in clinical trials. Hazard ratios higher than 1 were excluded since in-
vestigators are not likely to include components with harmful effects at the design stage. Moreover, the
ARE methodology is applied considering an alternative hypothesis of no treatment effect with hazard
ratios lower than 1. We excluded probabilities larger than 0.5 and extremely low or high correlations
in Cases 2,3 and 4. These excluded scenarios led to very low survival values (in the order of 10−16) for
some parameter value combinations at some time t < τ= 1, indicating that the support of T∗ was not
[0,1].
Note that since we are not including scenarios with neither HR1 = HR2 = 1 nor ρ = 0 (although
they are very near 1 and 0, respectively), all the computed HR∗(t ) lead to non-proportional hazards, as
shown in section (5.2.3).
Parameters
Case 1
p1, p2 0.01 0.05 0.1 0.5 0.9 0.95 0.99
ρ 0.01 0.1 0.5 0.9 0.99
Cases 2,3,4
p1, p2 0.01 0.05 0.1 0.5
ρ 0.1 0.25 0.5 0.75 0.9
HR1,HR2 0.01 0.05 0.1 0.25 0.5 0.75 0.9 0.95 0.99
β1 =β2 =β 0.5 1 2
Time points 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Number Total Case 1 Case 2 Case 3 Case 4
of scenarios 117,855 59,535 19,440 19,440 19,440
Table 5.3: Parameter settings to compute the combined hazard ratios HR∗(t ) for each parameter value combi-
nation. HR1, p1 and HR2, p2 stands for the marginal constant hazard ratio and probability in control group of
each endpoint E1 and E2, respectively. ρ stands for the Spearman rank correlation between endpoint times. β1
and β2 are the shape parameters. For computational reasons, we use the values 0.01 and 0.99 instead of 0 and 1,
respectively, for the hazard ratios and probabilities; 0.49 instead of 0.5 in Case 4 for the probabilities; and 0.0001
instead of 0 as the first time point.
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Results
Behaviour of HR∗(t ) with respect to HR1 and HR2
For every pair of marginal hazard ratios we study when the different values of the HR∗(t ) fall inside
the area delimited by HR1 and HR2. Whenever the HR∗(t ) is outside this area for some t , we study the
nature of the distinct departures (see Figure 5.4). Since Case 1 consists of a different parameter setting
than Cases 2,3,4, we split the results by Cases. Due to their symmetry, we merge Cases 2 and 3 because
they lead to the same aggregated results of HR∗(t ).
In 73% of scenarios, the combined HR∗(t ) always remains between the marginal hazard ratios
(see "Inside" in Table 5.4). For the rest of cases, we observe 5% of scenarios where the HR∗(t ) crosses
both the upper and lower marginal hazard ratios (which we call "Across"); 18% of scenarios where the
HR∗(t ) crosses or remains above the upper marginal HR ("Above"+"Both above"), and 5% of scenarios
where the HR∗(t ) crosses the lower marginal HR ("Below"). Note that the situation where the HR∗(t )
remains below the lower marginal HR for all t never occurs in our setting. We executed some scenarios
with negative correlations, and some cases led to this latter behaviour in the HR∗(t ) (see bottom right
in Figure 5.4).
Global Case 1 Cases 2&3 Case 4 HR1 6=HR2 HR1 =HR2
Inside 73% 67% 79% 80% 82% 0%
Across 5% 8% 1% 2% 0% 41%
Both above 7% 3% 10% 10% 0% 59%
Above 11% 14% 8% 7% 12% 0%
Below 5% 8% 2% 1% 5% 0%
Both below 0% 0% 0% 0% 0% 0%
Table 5.4: Table representing the range of possible values of HR∗(t ) over the follow-up time in relation to the
marginal hazard ratios HR1 and HR2. Whenever HR1 ≤ HR2, we distinguish situations according to whether
maxt {HR∗(t )}≤HR1 (both below), mi nt {HR∗(t )}≥HR2 (both above), HR1 ≤HR∗(t )≤HR2 ∀t (inside), as well
as three other combinations. Analogously, the same is applied whenever (HR1 ≥HR2).
Whenever HR1 = HR2, since we are excluding scenarios with ρ = 0 (and hence non-constant
HR∗(t )), none of the scenarios will fall between the marginal hazard ratios for all t . In those cases,
HR∗(t ) either always remains above the marginals (59%) or crosses the marginal hazard ratio (41%)
(see the last column in Table 5.4). Whenever HR1 6= HR2, the HR∗(t ) either is inside the marginals for
all t (82%), or crosses one marginal hazard ratio (17%).
The correlation ρ between endpoint times plays an important role. The lower correlation, the
higher percentage of scenarios where the combined HR∗(t ) remains between the marginal hazard
ratios for all t (see Table 5.5). Indeed, as stated in Gómez G.,21 when having null correlation (ρ = 0),
the constant combined HR∗(t ) lies always between HR1 and HR2. That is, the treatment effect on
the combined E∗ lies between the treatment effect on E1 and E2. Whenever HR1 6= HR2, the HR∗(t )
remains always inside HR1 and HR2 for low correlations (ρ ≤ 0.25), and remains inside in the vast
majority of cases whenever the correlation is moderate or high (0.5≤ ρ ≤ 0.75).
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ρ Global Case 1 Cases 2&3 Case 4 HR1 6=HR2
0.01 89% 89% - - 100%
0.1 89% 89% 89% 89% 100%
0.25 89% - 89% 89% 100%
0.5 86% 84% 87% 87% 96%
0.75 72% - 71% 74% 81%
0.9 51% 42% 60% 62% 58%
0.99 30% 30% - - 34%
Global 73% 75% 89% 90% 82%
Table 5.5: Scenarios with HR∗(t ) inside the marginal hazard ratios HR1 and HR2.
Summarizing, we observe that although HR∗(t ) is not constant, their range of values lies between
the marginal hazard ratios in 73% of cases, with this proportion reaching to almost 90% if the two
components are close to be independent, and almost 100% whenever HR1 6= HR2 with moderate or
low correlations. This behaviour informs the investigators about the plausible values for HR∗(t ), and
hence to know that the assigned HR∗(t ) might be between the marginal hazard ratios in the majority
of scenarios, specially when having medium or low correlations.
Departure of HR∗(t ) with respect to HR1 and HR2
We now study the behaviour of HR∗(t ) whenever it is outside the interval [HR1, HR2](27% of sce-
narios). In particular, we analyze the departure of HR∗(t ) from HR1 and HR2 for t such that HR∗(t ) ∉
[HR1, HR2]. In Figure 5.5, the distribution of the maximum distances between the marginal bound-
aries and the combined HR∗(t ) is shown by means of a table with the percentiles in cases where the
combined hazard ratio falls above or below the maximum and minimum marginal hazard ratios, re-
spectively. We observe that these distances are very small in the majority of scenarios. Only 1% of
scenarios reach distances above 0.05 and 0.07 in the upper and lower boundary. Therefore, given
HR1 ≤ HR2, the general combined HR∗(t ) interval given by [HR1 − 0.07, HR2 + 0.05] would cover all
the plausible HR∗(t ) values over time in the 99% of the scenarios. Whenever HR1 6= HR2, this inter-
val shrinks to [HR1−0.01, HR2+0.03]. The interval is also shrunk when having low correlations (not
shown). Scenarios reaching the widest interval consist of scenarios with HR1 =HR2 and high correla-
tion.
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Percentiles Global Case 1 Cases 2&3 Case 4 HR1 6=HR2 HR1 =HR2
Minimum 0 0 0 0 0 0
P50 (Median) 0.002 0.001 0.003 0.004 0.002 0.002
P90 0.02 0.01 0.02 0.02 0.01 0.02
P99 0.05 0.05 0.05 0.06 0.03 0.06
Maximum 0.09 0.09 0.07 0.08 0.05 0.09
Percentiles Global Case 1 Cases 2&3 Case 4 HR1 6=HR2 HR1 =HR2
Minimum 0 0 0 0 0 0
P50 (Median) 0.001 0 0.001 0.002 0.001 0
P90 0.01 0.01 0.01 0.02 0.01 0.02
P99 0.07 0.07 0.02 0.09 0.01 0.08
Maximum 0.15 0.15 0.02 0.11 0.04 0.15
Figure 5.5: Illustrative examples, histograms and percentiles of the maximum distances between the HR∗(t ) and
the marginal hazard ratios HR1 and HR2 when HR∗(t ) falls outside the marginal hazard ratios at some t. All
the numbers are > 0 althought we do not specify all the decimals in order to make the table easier to read. Values
in upper plot: (HR1, HR2) = (0.1,0.95), (p1, p2) = (0.05,0.1). Values in bottom plot: (HR1, HR2) = (0.9,0.75), p1 =
p2 = 0.99. In both plots: Case 1 with β1 =β2 = 1 and ρ = 0.99.
Departure from constancy of HR∗(t )
Finally, we analyze r = maxt {HR∗(t )}−mi nt {HR∗(t )} (see Figure 5.6) to assess how the HR∗(t )
departs from being constant. In Figure 5.6 we depict the distribution of this measure by means of
a histogram and we split in tables the median and maximum values by correlation and by absolute
difference between the marginal hazard ratios (|HR1−HR2|). We observe that the larger the correlation
and larger differences between marginal HR, the larger the distance r we get, and hence the larger
departure from constancy of HR∗(t ). We remark that although these departures are close to zero in
median, we have to take into consideration that small changes in hazard ratios might have a great
impact in sample size calculations, as it is commented in Chapter 7 as future research.
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0.25 - - 0.005 0.11 0.006 0.09
0.5 0.011 0.21 0.012 0.22 0.015 0.19
0.75 - - 0.023 0.33 0.03 0.31
0.9 0.017 0.42 0.035 0.41 0.05 0.4
0.99 0.017 0.47 - - - -
Global 0.004 0.47 0.01 0.41 0.012 0.4
Global
Med. Max.
HR1 =HR2 0.002 0.22
|HR1−HR2| ≤ 0.1 0.002 0.07
0.1< |HR1−HR2| ≤ 0.25 0.007 0.26
0.25< |HR1−HR2| ≤ 0.5 0.011 0.37
0.5< |HR1−HR2| ≤ 0.75 0.015 0.39
|HR1−HR2| > 0.75 0.017 0.47
Global 0.007 0.47
Figure 5.6: Illustration of the range of HR∗(t ) (top left) and histogram (top right). Descriptive results are split
in tables according to the values of the correlation ρ and differences between the marginal hazard ratios (|HR1−
HR2|). Med. and Max. stand for median and maximum values, respectively. All the numbers are > 0 althought
we do not specify all the decimals in order to make the tables easier to read. Values used in the top-left plot:
(HR1, HR2)= (0.5,0.95), p1 = p2 = 0.1,β1 =β2 = 2,ρ = 0.9 (Case 3).
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5.4 Example from the cardiovascular area
The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) trial (Dahlöf et al.,
2002)10 was performed to test the efficacy of Losartan-based antihypertensive treatment in patients
with hypertension. The primary composite endpoint was composed by cardiovascular death, my-
ocardial infarction and stroke. Cardiovascular death + myocardial infarction are considered the most
clinically important components (Sankoh et al., 2014),62 and hence we refer to them as the relevant
endpoint ER , and stroke as the additional endpoint EA (see Table 5.6).
Endpoint Type Control treatment Hazard ratio
Probability (n) (CI, 95%)
Cardiovasc. mortality E1 0.05 (234) 0.89 (0.73 – 1.07)
Myocardial infarction E2 0.04 (188) 1.07 (0.88 – 1.31)
Stroke EA 0.07 (309) 0.75 (0.63 – 0.89)
E1∪E1∪EA Composite 0.13 (588) 0.87 (0.77 – 0.98)
Table 5.6: Probabilities in control group and hazard ratios of each endpoint from the LIFE trial. E1 and E2 stand
for relevant endpoint component 1 and 2 respectively; EA stands for additional endpoint; and CI stands for the
confidence interval.
The probability of observing the two components of the relevant endpoint E1 and E2 in control
group is p1 = 0.05 and p2 = 0.04, respectively. We assume exponential distributions for each compo-
nent and a hazard ratio of Cardiovascular death and Myocardial infarction of HR1 = 0.75 and HR2 =
0.9, respectively.
Following the calculations described in this chapter for the LIFE study, we observe that the plau-
sible values for the combined probability, in terms of the correlation, would range between 0.05 and
0.09 (see Figure 5.7, left), and the possible values of the combined HRR (t ) would range from 0.82 to
0.88 (see Figure 5.7, right).
Whenever the investigator cannot anticipate the correlation, we can consider to use either the low-
est, the average or the highest plausible values of pR and HRR (t ). We illustrate the results combining
these possibilities in Table 5.7 which includes the Asymptotic Relative Efficiency (ARE) values for each
scenario. Based on the ARE method, we observe that the decision of using the composite endpoint is
always recommended since the ARE is always greater than 1. However, note that the required sample
size can triple if we compare the smallest value of ARE (2.12) versus the highest (6.28).
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[0.82]
[0.82 , 0.84]
[0.82      ,    0.88]
 0.4 ≤ ρR < 0.7
HRR(t)
pR
0.05
δR = 0.89
0.09
δR = -0.05
HR1 = 0.75 HR2 = 0.9max(p1, p2) (p1 + p2)
 ρR ≥ 0.7
 0 ≤ ρR < 0.4
Figure 5.7: Boundaries for the combined probability pR and hazard ratio HRR (t ) in terms of Pearson’s correlation
δR and Spearman’s correlation ρR , respectively. p1 and p2 stand for the marginal probability of observing the
relevant component E1 and E2 in control group, respectively. HR1 and HR2 stand for the marginal hazard ratio of
each component. We assume constant hazard rates (exponential distributions) for each component. Component
parameter values are taken from the LIFE study.
pR HRR (t ) ARE
0.05 0.82 3.34
0.05 0.85 4.42
0.05 0.88 6.28
0.07 0.82 2.55
0.07 0.85 3.26
0.07 0.88 4.48
0.09 0.82 2.12
0.09 0.85 2.64
0.09 0.88 3.52
Table 5.7: Asymptotic Relative Efficiency (ARE) by different values of the probability pR in control group and
hazard ratio HRR (t ) of the relevant endpoint. Exponential distribution and moderate correlation (ρR A = 0.5) is
assumed between the relevant endpoint and additional endpoint (do not confuse with ρR , which corresponds to
the correlation between the components of the relevant endpoint). With respect to the additional endpoint, we fix
the probability in control group p A = 0.07 and the hazard ratio HRA = 0.75.
A letter to the editor in response of Sankoh’s paper is published. We discuss other scenarios which
would have led to different results of ARE depending on different parameter combinations (Gómez
and Gómez-Mateu, 2016).23
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5.5 Conclusion
The ARE method is based on the assumption that, even when the relevant endpoint consist of several
components, the combined probability in control group and the combined hazard ratio can be antici-
pated by researchers. Analogously, the same is assumed with respect to the additional endpoint. Since
investigators may know the anticipated probabilities and hazard ratios of each one of the components
rather than the combined probabilities and hazard ratios, we have discussed in this chapter how to
derive these quantities based on the marginal components.
Based on binary data, the combined probability p∗ can be calculated in terms of the probability p1
and p2 of observing the components E1 and E2, respectively, given the Pearson’s correlation δ between
endpoints. It is also possible to calculate the combined probability values based on time-to-event vari-
ables. However, the calculation of the combined probability is based on several assumptions and on
some parameter values that trialists might not known. It is for that reason that we would recommend
to assign the combined p∗ in terms of the Pearson correlation, except for Case 4, since p∗ is straight-
forwardly calculated as p∗ = p1 + p2. Whenever investigators cannot anticipate the correlation, we
propose to assign a value among the plausible range of values that the combined probability can take
as it is developed in 5.1.
Under some assumptions, the combined HR∗(t ) can be derived in terms of the marginal hazard
ratios HR1 and HR2, the probabilities of observing E1 and E2 in control group, and the correlation
ρ between endpoint times. Whenever the combined HR∗(t ) is constant over time and investigators
can anticipate all the required parameter values, a HR∗(t ) can be specifically calculated. In particular,
when having null correlation (ρ = 0), the combined hazard ratio is constant and lies between HR1 and
HR2. In some specific scenarios, the combined HR∗(t ) corresponds to the mean of HR1 and HR2.
In cases where the HR∗(t ) is not constant over time or trialist cannot anticipate all the parameter
values, we propose to calculate the range of plausible values that the HR∗(t ) can take as it has been
described in this chapter. Among these range of values, trialists might have to assign a specific HR∗(t )
that they consider appropriate based on their experience. We have seen that the interval range of
values of HR∗(t ) given by the general interval [HR1−0.07, HR2+0.05] (HR1 ≤HR2) would cover almost
all of the scenarios considered in our work. Whenever HR1 6=HR2 or for low correlations, this interval
is narrower.
The more information that investigators can anticipate (such as the correlation), the more precise
the assignment of the combined hazard ratio will be. We briefly summarize in table 5.8 the values and
range of values of HR∗(t ) depending on several parameters.
Special attention must be taken for scenarios with high correlation because they might lead to large
departure from constancy of HR∗(t ) and consequently they will have an important impact in sample
size assessment. As a matter of fact, even small departures from constancy might have a considerable
impact on sample size. We are working on that issue and it is detailed in the future research of this
thesis.
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We have implemented in CompARE, as advanced options, the practical solutions developed in this
chapter. When possible, CompARE will calculate the specific values p∗ and HR∗(t ) when having sev-
eral components in the relevant endpoint or in the additional endpoint. Whenever a parameter value,
such as the correlation, is unknown, or whenever the HR∗(t ) is not constant over time, CompARE will
recommend a range of plausible values of p∗ and HR∗(t ). Hence, CompARE will help investigators to
choose a plausible value of p∗ and HR∗(t ) to calculate the corresponding ARE values for the choice of
the primary endpoint of a clinical trial.
Whenever ρ = 0 HR∗(t )
λ(0)2 (t )
λ(0)1 (t )
= c HR∗(t )= HR1+c·HR2c+1
HR1 =HR2 = k k
Weibull with β1 =β2 =β HR∗(t )=
HR1+HR2
(
b(0)1
b(0)2
)β
1+
(
b(0)1
b(0)2
)β
Weibull with
β1 =β2 =β & p1 = p2 HR∗(t )= HR1+HR22
Whenever ρ > 0 Range of values of HR∗(t )*
Global [HR1 - 0.07, HR2 + 0.05]
HR1 =HR2 = k [k - 0.08, k + 0.06]
ρ ≤ 0.1 [HR1 - 0.02, HR2 + 0.01]
0.25≤ ρ ≤ 0.5 [HR1 - 0.07, HR2 + 0.04]
0.75≤ ρ ≤ 0.99 [HR1 - 0.08, HR2 + 0.06]
Table 5.8: Combined hazard ratio HR∗(t ) depending on the parameter values. HR1, HR2, p1, p2, β1,β2 and
b(0)1 ,b
(0)
2 stand for the hazard ratio, probability in control group, shape and scale (control group) parameters of
endpoints E1 and E2, respectively. ρ stands for the correlation between the two endpoints. * Corresponding inter-
vals in 99% of scenarios executed in section 5.3 (that is, until percentile 99 for each cut). We consider HR1 ≤ HR2
to determine the intervals; analogously, the same applies for HR1 ≥HR2.
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APPLIED EXTENSIONS IN COMPARE
Throughout the previous chapters, we have seen that the efficiency of a composite endpoint can be
evaluated in terms of several parameter values. In some cases, changing one of these parameters might
influence the choice of the primary endpoint and might also have influence in the required sample size
of the trial. Furthermore, some of the needed values to anticipate might be unknown by the investiga-
tors, specially when consisting of a union of several marginal components.
In the current chapter, we have extended Comp ARE to accommodate the comparison of distinct
scenarios that could represent other realistic situations in the design of a clinical trial. First, the user
can choose different marginal laws for the time to each endpoint, different degrees of correlation as
well as different copulas. Second, Comp ARE has been extended to compute ARE values in cases
where both the relevant endpoint (RE) and the additional endpoint (AE) include a terminating event.
Third, Comp ARE has been also extended to quantify specific values for the combined probabil-
ity and hazard ratios whenever it comes from a combination of several components. When the user
cannot anticipate some of the needed parameters, Comp ARE provides a range of plausible values.
Moreover, the departure from constancy of a combined hazard ratio, which might have a strong influ-
ence in treatment effect interpretation and in sample size assessment, can be explored by visualizing
its shape over time for different scenarios. Finally, sample size computations based on the chosen
scenarios are implemented as well in Comp ARE .
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6.1 Extended options to change parameter values
By default, Comp ARE assumes exponential distributions for the time to the occurrence of the relevant
endpoint (TR ) and for the time to the additional endpoint (TA), moderate correlation (ρ = 0.5) and
Frank’s copula relationship between times. We next detail how to modify these assumptions.
We have extended Comp ARE to allow different distributions, other than exponential, whenever
investigators assume increasing or decreasing hazards of endpoints over the follow-up period of the
trial (see Figure 6.1).
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Figure 6.1: Hazard rate functions from Weibull distributions W (β,b) with increasing (β = 2), constant (β = 1)
and decreasing shape parameter (β= 0.5) and scale paremeter b = 1.
From the drop-down menu in the advanced features box, the user can choose between the follow-
ing options (see Figure 6.2, top):
• Weibull distribution with decreasing hazard rate (β= 0.5),
• Weibull with constant hazard rate (β= 1) (Exponential distribution),
• Weibull distribution with increasing hazard rate (β= 2),
where β is the shape parameter and the scale parameter b is derived automatically. The density and
survival functions used in Comp ARE are parametrized as follows:
f (t ) = β
(b)β
tβ−1e(−(t/b)
β)
S(t ) = e(−(t/b)β).
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Figure 6.2
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As we have seen previously in this thesis, the correlation might play a crucial role. Trialist might
need to compare the efficiency of one endpoint over the other in terms of the strength of the associa-
tion between the relevant endpoint and the additional endpoint. Therefore, we have incorporated in
Comp ARE the possibility to change Spearman’s correlations as follows (see figure 6.2, middle):
• Very Strong (ρ = 0.9),
• Strong (ρ = 0.7),
• Moderate (ρ = 0.5),
• Weak (ρ = 0.3),
• Very Weak (ρ = 0.15),
• No correlation (ρ = 0),
where ρ indicates the Spearman correlation coefficient.
We have also implemented an extension of the methodology to allow to other copulas binding the
relevant and the additional endpoint. The methodology was extended by Plana-Ripoll O. and Gómez
G.51 That is, the joint distribution of (TR ,TA) can be derived in Comp ARE by means of the following
copulas (see Figure 6.2, bottom):
• Frank,
• Gumbel,
• Clayton,
• GM,
• Normal,
• T,
• Galambos,
• HuslerReiss,
• Tawn,
• Tev,
• Plackett.
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6.2 Computation of HR and probability for combined endpoints
CompARE is also extended to accommodate the computation of combined probabilities and com-
bined hazard ratios based on the marginal components.
When the RE or the AE consist of several components, the user can specify each marginal endpoint
in the input grid (see Figure 6.3, top). In this example, the union of cardiovascular death ER1 and my-
ocardial infarction ER2 forms the relevant endpoint. The marginal probabilities and hazard ratios of
each component ER1 and ER2 are (0.05, 0.75) and (0.04, 0.9), respectively. By default, Comp ARE uses
the maximum probability and the average hazard ratio to calculate the ARE values (see chapter 5 for
the rationale of this default choice). Alternatively, Comp ARE proposes a range of plausible values of
the corresponding combined probability and combined hazard ratio (for the latter case, only imple-
mented for two components so far). Based on this range of values, the user can introduce a specific
value for the combined parameters by means of the advanced features box (see Figure 6.3, bottom).
Figure 6.3
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In order to visually evaluate the departure from constancy that the combined hazard ratio might
have, Comp ARE depicts the shape of the hazard ratio over time (see Figure 6.4)
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Figure 6.4: Marginal constant hazard ratios (HR RE1) and (HR RE2) of the relevant endpoint, and combined
hazard ratio (HR RE) over time.
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6.3 Sample size
Comp ARE has also been designed to incorporate sample size computation. We start noticing that in
survival analysis the power of the test depends on the number of events rather than on the needed
sample size. The sample size, as we develop below, depends heavily on the allocation rate of patients
into the RCT and the patterns of censoring including the loss to follow-up.
Required number of events
We define α as the significance level, and Π = 1−β as the statistical power, where β is the type II
error. We assume proportional hazards for the marginal hazard ratio of the relevant endpoint RE, i.e.
HRR (t ) = HRR , and we consider the logrank test to compare treatment effects. We assume that the
end-of-study censoring at time τ is the only censoring cause in both groups.
Based on the asymptotic behaviour of the logrank statistic, Schoenfeld65 estimate the required
number of events eR,S given by:
eR,S =
4(zα+ zβ)2
(ln(HRR ))2
,
where zα and zβ are the standard normal quantiles corresponding to the left tail probability α and β,
respectively.
Another approach was developed by Freedman.18 The number of events eR,F is estimated by means
of the expected value and variance of the logrank statistic, and assuming that the ratio of the number
of patients at risk in each group just before the event is equal to 1. The expression of eR,F is given by:
eR,F =
(HRR +1)2
(HRR −1)2
(
(zα+ zβ
2
p
HRR
HRR +1
)2
.
Taking the coefficient 2
p
HRR
HRR+1 as approximately equal to 1 (it approaches 1 when HR → 1), the expres-
sion becomes
eR,F =
(HRR +1)2(zα+ zβ)2
(HRR −1)2
.
Required number of patients
If we assume that patients are randomized to receive one of the two treatments in the ratio (1 :
A), for example treatment group triples the control group (A = 3), the required number of patients is
derived as follows (Machin, 1997):43
NR =
(1+ A)eR
p(0)R + A(p(1)R )
,
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where eR is the required number of events; and p
(0)
R , p
(1)
R are the probability of observing the relevant
endpoint in control and treatment group, respectively. Thus, the required number of patients to be
recruited to the control and treatment group is N (0)R =NR /(1+ A) and N (1)R =NR A/(1+ A), respectively.
If we assume equal allocation between groups, that is A = 1, the total number of required patients NR
is given by:
NR =
2eR
p(0)R +p(1)R
.
Censoring due to loss to follow-up might affect the estimation of the required number of patients.
Given an anticipated withdrawal proportion W , the required number of patients must be increased to:
NR,W =
NR
(1−W ) .
Different accrual rates and the duration of the trial will also affect sample size estimation and will be
developed in future research.
In a recent article published by Abel et al. (2015),1 the authors compare Schoenfeld and Freedman
approaches. They state that, in terms of number of events, Schoenfeld’s formula would be preferable
because eR,S < eR,F . Indeed, the ratio r = eR,S /eR,F may be considerably lower than 1 for low and high
(above 1) values of HRR . Whenever HRR approaches 1 (low treatment effect), the ratio r approaches
1, and hence both formulas would lead to similar number of events. The simulations included in their
paper show that special attention must be taken whenever we have small sample sizes. In those cases,
Schoenfeld’s formula would lead to an overestimation of power, while the Freedman approach under-
rates the power by almost the same absolute amount. Furthermore, loss of power may occur in case of
deviations from the assumed distributions.
We remark that the formulas to calculate the number of events are based on the assumption that
the HRR (t ) is constant over time. Whenever we do not have proportional hazards, the previous formu-
las are not appropriate.
Sample size for the composite endpoint
Assume that the hazard ratio of the additional endpoint is constant, i.e. HRA(t ) = HRA . As co-
mented in Chapter 3, given the asymptotic relative efficiency ARE(Z∗, ZR ) of the logrank statistics Z∗
and ZR of the composite endpoint and the RE, respectively, the required number of patients N∗ for the
CE can be estimated as:
N∗ = NR
ARE(Z∗, ZR )
.
Based on the previous formulas, Comp ARE computes the sample size for each specific scenario and
shows the results written in text (see Figure 6.5). The user can modify the parameter values to eval-
uate how the sample size changes depending on the different value sets. By default, Comp ARE uses
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Schoenfeld’s approach, equal allocation and no withdrawals to make the computations. We are ex-
tending the platform to derive sample sizes whenever the user considers other choices, and it is de-
scribed in chapter 7 as future research.
Figure 6.5
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6.4 Computations when both the relevant and additional endpoints
include terminating events
As already mentioned in Chapter 4, before designing the platform Comp ARE , the code to execute the
ARE method was written in MAPLE by Gómez G. to run scenarios where both the RE and AE do not
include a terminating event (Case 1) or either RE or AE includes a terminating event (Cases 2 and 3).
As part of my thesis work, I have adapted the MAPLE code to R and I have programmed, from scratch,
the code for Case 4, where both the RE and the AE includes a terminating event.
The extension to Case 4 has not been straightforward because of the simultaneous solution of the
following double integrals to derive the scale parameters b(0)R and b
(0)
A in control group for the RE and
the AE, respectively:
pR =
∫ 1
U L
∫ V L(0)(x)
0
g (x, y)d yd x
p A =
∫ 1
V L
∫ U L(0)(y)
0
g (x, y)d xd y,

where
• pR and p A are the probabilities of observing the RE and the AE in control group, respectively,
• U L = exp{− ((b(0)R )−βR ) },
• V L(0)(x)= exp
{
− (b
(0)
R )
βA (−l og x)βA /βR
(b(0)A )
βA
}
,
• V L = exp{− ((b(0)A )−βA ) }, and
• U L(0)(y)= exp
{
− (b
(0)
A )
βR (−log y)βR /βA
(b(0)R )
βR
}
.
The function g (x, y) is given by:
g (x, y)= θ(1−e
−θ)exp{−θ(x+ y)}
(e−θ+e−θ(x+y)−e−θx −e−θy )2 ,
where θ the association parameter between TR and TA .
The code in R used to compute the ARE values is included in the Appendix.
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FUTURE RESEARCH
New lines of research are open after the development of this thesis. As a member of the research groups
GRBIO33 and GRASS,32 we are collaborating with other partners and researchers of other groups in
order to achieve new goals that might contribute in the improvement of trial designs.
7.1 Extension of the ARE method
The methodology of Gómez and Lagakos is based on several assumptions described in Chapter 1. We
aim to relax some of these assumptions and to study the robustness of the method when some of the
assumptions do not hold.
The lifetimes of the outcomes are assumed to be distributed as Weibull, because they are widely
used in survival analysis. However, other distributions with different features could be applied. For
example, the lognormal distribution has been applied successfully in cancer studies (like in chronic
leukemia40) due to its pronounced right asymmetry. Other distributions like the log-logistic are some-
times preferred since the survival function is mathematically more tractable than the lognormal.37
So far, the method has been developed under the assumption that the end-of-study time is the
only non-informative cause of censoring. Moreover, it is also assumed that the censoring is the same
in both groups. Other types of censoring, even different in each group, could be implemented, such as
that derived from loss to follow-up or withdrawals.
Equal Spearman’s rank correlation ρ is assumed between the marginal times of the relevant and the
additional endpoints for both groups. This assumption might sometimes lead to unlikely scenarios for
some parameter value combinations that might not be realistic for the design of the study. We want to
relax this assumption to analyze how the ARE values would change whenever the correlations are not
equal.
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The ARE methodology is also being extended to dichotomous variables (Gómez and Ayestaran,
2014;22 Gómez, Gómez-Mateu and Bofill, 201625). We want to extend the methodology to binary data
with more than two components, perform an exhaustive literature search in several fields, and carry
out simulations to confirm the interpretation of the ARE as the ratio of sample sizes for finite sample
sizes.
Observational studies are commonly conducted whenever the exposure of interest cannot be ran-
domized, such as smoking, or the goal of the trial is to detect a rare or late adverse treatment effect.78
The ARE method can be extended to observational cohort trials, as it has been discussed in a recent
paper (Gómez, Plana-Ripoll and Dafni, 2016).29 They apply the methodology to a cohort of adults with
coronary heart disease to study the effect of concurrent depression and stress. We plan to accommo-
date different censoring patterns and extend further the ARE method for observational studies.
7.2 Non-proportional hazards and alternative measures
As we showed in Chapter 5, most of the times the hazard ratio of a composite endpoint is not constant
over time. Based on the ARE method, from the sequence of contiguous alternatives to H0 when using
composite endpoints given by H1,n : λ
(1)
R,n(t ) = λ(0)R (t )eg (t )/
p
n , we have that g (t ) ≈ log
(
λ(1)R,n (t )
λ(0)R (t )
)p
n is
proportional to the log of the hazard ratio for sufficiently large n. Thus, g (t ) allows us to evaluate the
behaviour of the ARE when the hazard functions for the two groups are non-proportional.
The non-proportionality of the hazards may lead to difficulties in its interpretation as a measure of
treatment effect. It may also have a great influence in ARE computations and hence, in sample size.
Together with professors G. Gómez and K. Kim (University of Wisconsin-Madison), we are studying the
different patterns and shapes that the composite hazard ratio HR∗(t ) follows when it is not constant
over time for realistic clinical trial scenarios. A study on the changes in sample size depending on how
HR∗(t ) departs from constancy will be of great help for the design of clinical trials.
We will also analyze the impact of non-proportionality on sample size whenever the investigator
erroneously assumes constant hazard ratio. We will simulate scenarios where the HR∗(t ) is clearly non
constant and compare the required sample size using the commonly used formulas such as Shoenfeld’s
versus the corresponding sample size using the ARE method.
Alternative measures to assess treatment effects not relying on the proportionality of the hazards
have been proposed (Uno et al, 2015).75 The absolute and relative risk difference, derived from the
difference in event rates at some fixed time point, provides a clinically interpretable comparison be-
tween groups. It is an appropriate measure for quantifying relatively long-term survival benefits. The
difference and ratio of percentiles can also be considered as another plausible measure, since it has a
simple mathematical interpretation. However, except for the median, it may not be as much intuitively
interpretable to investigators or patients. Furthermore, whenever the event rate is relatively low, the
censoring is high, or the follow-up is short, this measure might not be estimable from the observed
data. Another alternative measure is the restricted mean survival time (RMST), which provides a clin-
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Figure 7.1: Estimated hazard ratio (low dose over high dose) over time (left) with the corresponding 0.95 point-
wise confidence band, and restricted mean survival time (right, blue area) with data from the Eastern Cooperative
Oncology Group E4A03 study81 up to 40 months for the low-dose group. Adapted from Figure 1 in Uno H, 2014.74
ically meaningful summary of treatment effect and gives more stable estimates than the differences
of percentiles. It is defined as the expected event-free survival time experienced during a specified
time, and it is estimated by the area under the survival curve up to that time point (see Figure 7.1,
right). The RMST of a random variable T is the mean of the survival time Y =min(T,τ) limited to the
time-to-follow up τ of the study (Royston, 2013).61 Its expression is given by:
RMST = E(Y )=
∫ τ
0
S(t )d t ,
where S(t ) is the survival function.
Alternatively, we could consider the restricted mean time lost (RMTL), corresponding to the area
above the survival curve up to τ. It can be interpreted as the life lost during the follow-up of the study.
The Restricted Average Log Hazard ratio (RALH) can also be considered as an alternative measure
of the effect. Its expression derives from the sample size n∗ required to achieve a given power for a
significance level α. For Cases 1 and 3 (the additional endpoint is not terminating), n∗ is given by:
n∗ = 1
pi(1−pi) ·
(zα+ zβ)2p(0)∗
R ALH 2
,
where pi is the percentage of patients allocated to the control group, p(0)∗ is the probability of observing
the CE in control group, zα and zβ are the standard normal quantiles corresponding to the left tail
probability α and type II error β, respectively, and RALH is given by
R ALH =
∫ 1
0 log(HR∗(t )) f
(0)
∗ (t )d t
p(0)∗
,
where f (0)∗ (t ) is the density function of the time T∗ to the CE in control group.
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We consider to use the logrank test specifying the null and alternative hypothesis in terms of the
RALH and derive the needed sample size based on that measure.
We plan to carry out a research based on the convenience of using the aforementioned measures,
specially when the proportionality of the hazards does not hold. We will study the impact of the non
proportionality of the HR versus the rest of measures for plausible scenarios with considerable depar-
ture from constancy.
The time to follow up τ is also crucial to assess treatment effect, and it does not affect equally on
the results for each measure. Results based on HR might show different effects depending on τ. As an
illustrative example, in Figure 7.1 (left) we see that the estimated HR remains below 1 during the first
22 months approximately, but it shows no treatment effect afterwards. If we use RMST, the effect on
each arm will always increase or keep constant over time, as it is shown in Figure 7.1 (right). That is, the
longer τ, the longer effect might exist on each group. By means of simulated scenarios, we are studying
how different prespecified τ’s might influence the treatment effect assessment for different measures,
including scenarios with hazard ratios fluctuating over 1.
7.3 Composite endpoints in other medical fields
In the last years, the use of progression-free survival (PFS), defined as the union of death and progres-
sion, has increased in non-small cell lung cancer studies (Booth and Eisenhauer, 2012).5 Progression,
usually considered as the additional endpoint, may have a strong weight in the calculation of the ARE
values, and hence in sample size calculations. However, information about progression in randomized
clinical trials is almost never reported.
Together with professors G. Gómez and U. Dafni (University of Athens), we are carrying out a liter-
ature search based on the lung cancer field, in a similar way that we did in our cardiovascular research
described in Chapter 2, to give general recommendations about the convenience of using PFS, taking
into consideration the plausible values that progression can have. We will also analyze the impact in
sample size and primary endpoint decision depending on variations of the parameter values from the
study, such as the correlation between endpoints. Some case studies will be discussed in depth as well.
Furthermore, we will study alternative methods involving terminating and non-terminating events.
As an example, Potthoff and Halabi53 develop a test based on the time to death if the patient has died
or the time to death based on a pre-specified model otherwise.
Other areas of interest involving the use of composite endpoints, such as HIV-AIDS and oncology
studies, will be considered to our research as well.
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7.4 Future extensions in CompARE
We are working to develop the following extensions in Comp ARE platform:
• We plan to extend computations of sample size. It will incorporate the choice of different accrual
rates, unequal allocation, the duration of the trial and loss to follow-up for different values of the
significance level α to achieve a specific power.
• Computations based on different approaches, such as Schoenfeld’s or Freedman’s, will be imple-
mented.
• We want as well to allow different distributional assumptions. On the one hand, we will allow the
user to specify any value for the shape parameter β of the marginal Weibull distributions, other
than the fixed by default (0.5, 1 and 2), to make the computations. On the other hand, other
choices of distributions will be implemented as well on the platform.
• Based on the methodology for binary data, we will also adapt Comp ARE to make the compu-
tations for clinical trials where the primary endpoint is dichotomous. The platform will also be
accommodated to deal with data from observational studies.
• We will create a new library in R from the code to compute the ARE values so as Comp ARE calls
and keep all the functions updated throughout the on-line repository.
• Other written outputs in text will be incorporated to guide the decision depending on the afore-
mentioned extensions. Moreover, graphical results will be improved by using other applications
such as Shiny,67 which allows to build interactive web applications straight from R, and includes
the use of dynamical plots and instantaneous interaction with the user.
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APPENDIX FOR CHAPTER 5
Weibull distribution laws of T1 and T2 for Cases 2 and 3.
If we assume that the time Tk (k = 1,2) to Ek follows a Weibull distribution, with shape and scale
parameters βk and bk , respectively, the density and survival functions are given by:
fk (t ) =
βk
(bk )βk
tβk−1e(−(t/bk )
βk )
Sk (t ) = e(−(t/bk )
βk ).
Fixing the shape parameters β1 and β2, the scale parameters are derived specifically for each one of
the two cases:
Case 2: The scale parameter b1 is a function of the joint density f(1,2)(t1, t2;θ) (see 5.6) and it is found
as the solution of equation p1 =
∫ τ
0
∫∞
u f(1,2)(u, v ;θ)d vdu, where p1 is the probability of observing E1
in control group. The scale parameter b2 is a function of p2 and β2 and given by b2 = 1(− log(1−p2))1/β2 ,
where p2 is the probability of observing E2 in control group.
Case 3: The scale parameter b1 is a function of p1 and β1 and given by b1 = 1(− log(1−p1))1/β1 . The scale
parameter b2 is a function of the joint density f(1,2)(t1, t2;θ) and it is found as the solution of equation
p2 =
∫ τ
0
∫∞
v f(1,2)(u, v ;θ)dud v .
117
118 CHAPTER B APPENDIX FOR CHAPTER 5
Copula assumptions
We consider a Frank’s Archimedean survival copula relationship between the marginal times T ( j )1
and T ( j )2 ( j = 0,1). The copula is given by:
C (t1, t2;θ)=−1
θ
log
{
1+ (e
−θt1 −1)(e−θt2 −1)
e−θ−1
}
, (B.1)
where the association parameter θ is biunivocally related to Spearman’s rank correlation ρ given by
ρ = ρ(θ)= 1− 12θ [ 1θ
∫ θ
0
t
e t−1 d t − 2θ2
∫ θ
0
t 2
e t−1 d t ].
Assuming equal association parameter θ = θ(0) = θ(1) for both groups 0 and 1, the joint survival and
joint density for (T ( j )1 , T
( j )
2 ) are given by:
S( j )(1,2)(t1, t2;θ)=−
1
θ
log
{
1+ (e
−θS( j )1 (t1)−1)(e−θS( j )2 (t2)−1)
e−θ−1
}
(B.2)
f ( j )(1,2)(t1, t2;θ)=
θe−θ(S
( j )
1 (t1)+S( j )2 (t2))
e−2θS
( j )
(1,2)(t1,t2;θ)(e−θ−1)
[ f ( j )1 (t1)][ f
( j )
2 (t2)], (B.3)
where S( j )1 (t1) and f
( j )
1 (t1), S
( j )
2 (t2) and f
( j )
2 (t2) are the marginal survival and marginal densities of T
( j )
1
and T ( j )2 , respectively.
The survival functions of T ( j )∗ =mi n{T ( j )1 ,T
( j )
2 } are given by:
S( j )∗ (t ;θ)= P (T ( j )∗ > t )= P (T ( j )1 > t ,T
( j )
2 > t )= S
( j )
(1,2)(t , t ;θ)=
=C (S( j )1 (t ),S
( j )
2 (t ))=−
1
θ
log
{
1+ (e
−θS( j )1 (t )−1)(e−θS( j )2 (t )−1)
e−θ−1
}
. (B.4)
The density function of T ( j )∗ can be calculated as f
( j )
∗ (t ;θ)=−∂S( j )∗ (t ;θ)/∂t :
f ( j )∗ (t ;θ)=
e−θS
( j )
1 (t )(e−θS
( j )
2 (t )−1) f ( j )1 (t )+e−θS
( j )
2 (t )(e−θS
( j )
1 (t )−1) f ( j )2 (t )
(e−θ−1)+ (e−θS( j )1 (t )−1)(e−θS( j )2 (t )−1)
 . (B.5)
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Marginal laws of T ( j )k
We assume that the time T ( j )k to observe each k component for each group j follows a Weibull
distribution, with scale parameter b( j )k and shape parameter β
(0)
k = β(1)k = βk (so that constant hazard
ratios’ assumption holds). The density and survivals functions are given by:
f ( j )k (t ) =
βk
(b( j )k )
βk
tβk−1e(−(t/b
( j )
k )
βk ) (B.6)
S( j )k (t ) = e(−(t/b
( j )
k )
βk ). (B.7)
Scale parameters for group 0
The scale parameters b(0)1 , b
(0)
2 , for group 0, have to be derived specifically for each one of the four
Cases taking into account whether endpoints E1 and E2 are terminating as it is shown in the equations
below:
Case 1: For k = 1,2, the scale parameter b(0)k is a function of pk andβk and given by b(0)k = 1(− log(1−pk ))1/βk .
Case 2: The scale parameter b(0)1 is a function of the joint density f
(0)
(1,2)(t1, t2;θ) and it is found as the
solution of equation p1 =
∫ τ
0
∫∞
u f
(0)
(1,2)(u, v ;θ)d vdu. The scale parameter b
(0)
2 is a function of p2 and β2
and given by b(0)2 = 1(− log(1−p2))1/β2 .
Case 3: The scale parameter b(0)1 is a function of p1 and β1 and given by b
(0)
1 = 1(− log(1−p1))1/β1 . The scale
parameter b(0)2 is a function of the joint density f
(0)
(1,2)(t1, t2;θ) and it is found as the solution of equation
p2 =
∫ τ
0
∫∞
v f
(0)
(1,2)(u, v ;θ)dud v .
Case 4: The scale parameters b(0)k (k = 1,2) are functions of the joint density f (0)(1,2)(t1, t2;θ) and are found
as the simultaneous solution of equations p1 =
∫ τ
0
∫∞
u f
(0)
(1,2)(u, v ;θ)d vdu and
p2 =
∫ τ
0
∫∞
v f
(0)
(1,2)(u, v ;θ)dud v .
Scale parameters for group 1
The scale parameters for group 1, b(1)1 and b
(1)
2 , are derived in such a way that the marginal hazard
ratio HRk (k = 1,2) is constant and given by
HRk =
λ(1)k (t )
λ(0)k (t )
=
(
b(0)k
b(1)k
)βk
, (B.8)
where λ(0)k (t ) and λ
(1)
k (t ) are the hazard functions of T
(0)
k and T
(1)
k , respectively.
Hence, the scale parameters for group 1, b(1)k , can be expressed as a function of b
(0)
k and HRk, that
is, b(1)k =
b(0)k
HRk
1
βk
.
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APPENDIX: R CODE TO COMPUTE THE ASYMPTOTIC
RELATIVE EFFICIENCY (ARE) VALUES
##################################################################################
# ARE_case1234 . R
##################################################################################
# Computation of the Asymptotic r e l a t i v e E f f i c i e n c y (ARE) values f o r censoring
# cases 1 ,2 ,3 and 4 , f o r s e v e r a l copulas and Weibull d i s t r i b u t i o n s .
#
##################################################################################
#
# CASE 1 : The composite endpoint does not include a f a t a l event ( i . e . Death )
# neither in the Relevant endpoint nor in the Additional endpoint .
#
# CASE 2 : The composite endpoint does not include a f a t a l event
# in the Relevant endpoint but i t does in the Additional endpoint .
#
# CASE 3 : The composite endpoint does include a f a t a l event
# in the Relevant endpoint but i t does not in the Additional endpoint .
#
# CASE 4 : The composite endpoint does include a f a t a l event
# both in the Relevant endpoint and in the Additional endpoint .
#
# Last update : 8 / 03 / 2016
#
# R version : R 3 . 2 . 3
#
# Authors : Moisés Gómez Mateu ( moises . gomez . mateu@upc . edu )
# Oleguer Plana Ripoll ( oleguerplana@gmail . com)
#
##################################################################################
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#
# References :
# − [ 1 ] Gómez G. and Lagakos S .W. ( 2 0 1 3 ) . S t a t i s t i c a l considerations when using a composite
# endpoint f o r comparing treatment groups . S t a t i s t i c s in Medicine , 32 , 719−38.
# − [ 2 ] Gómez G. and Lagakos S . ( 2 0 1 3 ) . Web−based Supporting Materials f o r " S t a t i s t i c a l
# Considerations when Using a Composite Endpoint f o r Comparing Treatment Groups "
# by G. Gómez and S .W. Lagakos .
# − [ 3 ] Gómez G. and Gómez−Mateu M ( 2 0 1 4 ) . The Asymptotic Rel at i ve E f f i c i e n c y and the r a t i o
# of sample s i z e s when t e s t i n g two d i f f e r e n t null hypotheses . SORT. 38 , 73−88.
#
##################################################################################
i f ( "copula" %in% rownames( i n s t a l l e d . packages ( ) ) == FALSE) { i n s t a l l . packages ( "copula" ) }
l ibrary ( copula )
i f ( "numDeriv" %in% rownames( i n s t a l l e d . packages ( ) ) == FALSE) { i n s t a l l . packages ( "numDeriv" ) }
l ibrary (numDeriv)
i f ( " rootSolve " %in% rownames( i n s t a l l e d . packages ( ) ) == FALSE) { i n s t a l l . packages ( " rootSolve " ) }
l ibrary ( ’ rootSolve ’ )
#######################################################################################
# Function : ARE
#
#######################################################################################
# Description : I t computes the ARE value f o r the given arguments
#
# rho0 Spearman ’ s c o e f f i c i e n t between T1 and T2 in control group
# rho1 Spearman ’ s c o e f f i c i e n t between T1 and T2 in treatment group
# beta1 Shape parameter f o r a Weibull law f o r the relevant event
# beta2 Shape parameter f o r a Weibull law f o r the additional event
# HR1 Hazard Ratio f o r a Weibull law f o r the relevant event
# HR2 Hazard Ratio f o r a Weibull law f o r the additional event
# p1 Proportion of Relevant events in control group
# p2 Proportion of Additional events in control group
# case Censoring case −− > 1 ( default ) , 2 , 3 or 4
# copula Copula used :
# Archimedean : " Frank " ( default ) , "Gumbel" or " Clayton "
# E l l i p t i c a l : "Normal" or "T"
# Extreme Value : "Galambos " , " HuslerReiss " , "Gumbel" , "Tawn" or " Tev "
# Others : "FGM" or " Plackett "
#######################################################################################
ARE<−function ( rho0 , rho1=rho0 , beta1 , beta2 , HR1, HR2, p1 , p2 , case = 1 , copula="Frank" )
{
############################################################
###### 0 . WARNINGS AND ERRORS
i f ( rho0>1 | rho0 <(−1)) {
stop ( " correlat ion rho must be a number between −1 and 1" , c a l l .=FALSE)
}
i f ( p1<0 | p2<0| p1>1 | p2>1) {
stop ( " p r o b a b i l i t i e s p1 and p2 must be between 0 and 1 . " , c a l l .=FALSE)
}
case_check<−0
i f ( case ==1| case ==2| case ==3| case ==4) { case_check=1}
i f ( case_check ==0){ stop ( " Please , introduce a v al id Case value : 1 ,2 ,3 or 4 . " , c a l l .=FALSE ) }
# Note : Warning f o r copula validation already implemented . See CopulaSelection function .
############################################################
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############################################################
###### 1 . SELECTION OF THE COPULA
copula0<−CopulaSelection ( copula , rho0 )
theta<−copula0 [ [ 2 ] ]
which . copula0<−copula0 [ [ 1 ] ]
which . copula1<−CopulaSelection ( copula , rho1 ) [ [ 1 ] ]
############################################################
############################################################
###### 2 . SELECTION OF THE MARGINAL DISTRIBUTIONS
MarginSelec<−MarginalsSelection ( beta1 , beta2 ,HR1,HR2, p1 , p2 , case , theta )
T1dist<−MarginSelec [ [ 1 ] ]
T2dist<−MarginSelec [ [ 2 ] ]
T1pdist<−MarginSelec [ [ 3 ] ]
T2pdist<−MarginSelec [ [ 4 ] ]
T10param<−MarginSelec [ [ 5 ] ]
T20param<−MarginSelec [ [ 6 ] ]
T11param<−MarginSelec [ [ 7 ] ]
T21param<−MarginSelec [ [ 8 ] ]
############################################################
############################################################
###### 3 . ARE EXPRESSION FOLLOWING GÓMEZ AND LAGAKOS ( See r e f e r e n c e [ 2 ] , pages 2 and 3 ) .
# Bivariate d i s t r i b u t i o n in control and treatment groups
distr ibut ion0 <− mvdc( copula = which . copula0 , margins = c ( T1dist , T2dist ) , paramMargins = l i s t (T10param , T20param ) )
distr ibut ion1 <− mvdc( copula = which . copula1 , margins = c ( T1dist , T2dist ) , paramMargins = l i s t (T11param , T21param ) )
i f ( case ==1| case ==3) {
# Inside the i n t e g r a l in the numerator ( See r e f e r e n c e [ 2 ] , page 2 ) .
inside _ i n t e g r a l <− function ( t ) {
Sstar0<−Sstar ( x=t , d is t1 =T1pdist , dist2 =T2pdist , param1=T10param , param2=T20param , d i s t _ biv= distr ibut ion0 )
Sstar1<−Sstar ( x=t , d is t1 =T1pdist , dist2 =T2pdist , param1=T11param , param2=T21param , d i s t _ biv= distr ibut ion1 )
f s t a r 0<−(−grad ( Sstar , x=t , d is t1 =T1pdist , dist2 =T2pdist , param1=T10param , param2=T20param , d i s t _ biv= distr ibut ion0 ) )
f s t a r 1<−(−grad ( Sstar , x=t , d is t1 =T1pdist , dist2 =T2pdist , param1=T11param , param2=T21param , d i s t _ biv= distr ibut ion1 ) )
Lstar0 <− ( f s t a r 0 / Sstar0 )
Lstar1 <− ( f s t a r 1 / Sstar1 )
HRstar <− ( Lstar1 / Lstar0 )
logHRstar <− log ( HRstar )
return ( logHRstar * f s t a r 0 )
}
# I n t e g r a l in the numerator
i n t e g r a l<−integrate ( inside _ integral , lower =0 ,upper=1 , subdivisions =1000 , stop . on . error = FALSE)
numerator<−( i n t e g r a l $value )^2
# Denominator
Sstar0 _1<−Sstar ( x =1 , dist1 =T1pdist , dist2 =T2pdist , param1=T10param , param2=T20param , d i s t _ biv= distr ibut ion0 )
ST10_1 <− 1−do . c a l l ( T1pdist , c (q=1 ,T10param ) )
denominator <− ( ( log (HR1) ) ^ 2 ) *(1−Sstar0 _ 1) *(1−ST10_ 1)
# ARE value
AREstarT <− ( numerator / denominator )
# I f the i n t e g r a l i s not computed , we assign a missing value
i f ( i n t e g r a l $message ! ="OK" ) { AREstarT <− NA}
} else
i f ( case ==2| case ==4) {
# Computation of the s c a l e parameter values b10 , b20
i f ( case ==2) {
# Compute b20
b20 <− 1 / (− log(1−p2 ) ) ^ ( 1 / beta2 )
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# Compute b10
Fb10<−function ( b10 , p1 ) {
i n t e g r a l<−integrate ( function (u) {
sapply (u , function (u) {
integrate ( function ( v ) ( ( theta *(1−exp(− theta ) ) *exp(− theta * (u+v ) ) ) / ( exp(− theta )+ exp(− theta * (u+v ) )
− exp(− theta *u)−exp(− theta *v ))^2 ) , lower =0 , upper= exp ( ( b10*(− log (u) ) ^ ( 1 / beta1 ) ) ^ beta2 * log(1−p2 ) ) ) $value
} )
} , lower= exp(−1 / b10^beta1 ) , upper=1)$value
return ( integral−p1 )
}
l i m i t s <− c (0.00001 ,10000) # The f i r s t and the l a s t values must be in opposite s igns f o r the function
b10 <− uniroot ( Fb10 , i n t e r v a l =l imits , p1=p1 ) $root # Find the root ( value which equals the function to zero )
}
i f ( case ==4) {
# We need to c r e a t e x [ 1 ] and x [ 2 ] to run ’ multiroot ’ function ( l i b r a r y : rootSolve ) (NA’ s i n i t i a l l y assigned )
x<−NA
y<−NA
x [ 1 ]<−x
x [ 2 ]<−y
# We need to change the name of variables as ( b10=x [ 1 ] , b20 = [ 2 ] ) to execute ’ multiroot ’
# Compute b10
Fb10<−function ( b10 , b20 , p1 ) {
b10−>x [ 1 ]
b20−>x [ 2 ]
i n t e g r a l<−integrate ( function (u) {
sapply (u , function (u) {
integrate ( function ( v ) ( ( theta *(1−exp(− theta ) ) *exp(− theta * (u+v ) ) )
/ ( exp(− theta )+ exp(− theta * (u+v ) ) − exp(− theta *u)−exp(− theta *v ))^2 ) , lower =0 ,
upper= exp ( ( x [ 1 ] *(− log (u) ) ^ ( 1 / beta1 ) ) ^ beta2 * ( −1/ ( x [2]^ beta2 ) ) ) ) $value
} )
} , lower= exp(−1 / x [1]^ beta1 ) , upper=1)$value
return ( integral−p1 )
}
# Compute b20
Fb20<−function ( b10 , b20 , p2 ) {
b10−>x [ 1 ]
b20−>x [ 2 ]
i n t e g r a l<−integrate ( function ( v ) {
sapply ( v , function ( v ) {
integrate ( function (u ) ( ( theta *(1−exp(− theta ) ) *exp(− theta * (u+v ) ) )
/ ( exp(− theta )+exp(− theta * (u+v))−exp(− theta *u)−exp(− theta *v ) ) ^ 2 ) , lower =0 ,
upper=exp(−((((− log ( v ) ) ^ ( 1 / beta2 ) ) * x [ 2 ] ) / x [ 1 ] ) ^ beta1 ) ) $value
} )
} ,
lower= exp(−(1 / x [ 2 ] ) ^ beta2 ) , upper=1)$value
return ( integral−p2 )
}
model <− function ( x ) {
c ( Fb10 ( x [ 1 ] , x [ 2 ] , p1 ) , Fb20 ( x [ 1 ] , x [ 2 ] , p2 ) )
}
( sol <− multiroot ( f = model , s t a r t = c ( 1 , 1 ) ) )
sol<−as . data . frame ( sol [ 1 ] )
b10<−sol [ 1 , ]
b20<−sol [ 2 , ]
}
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## Computation of the numerator
# Note : Only marginal Weibull d i s t r i b u t i o n s f o r fT10 , fT20 , ST10 , ST20 .
fT10 <− function ( t ) {
( beta1 / b10 ) * ( ( t / b10 ) ^ ( beta1−1) ) * ( exp(−( t / b10)^ beta1 ) )
}
ST10 <− function ( t ) {
exp(−( t / b10)^ beta1 )
}
fT20 <− function ( t ) {
( beta2 / b20 ) * ( ( t / b20 ) ^ ( beta2−1) ) * ( exp(−( t / b20)^ beta2 ) )
}
ST20 <− function ( t ) {
exp(−( t / b20)^ beta2 )
}
# Sstar0 and f s t a r 0 f o r any copula
Sstar0 <− function ( t ) {
Sstar0<−Sstar ( x=t , d is t1 =T1pdist , dist2 =T2pdist , param1=T10param , param2=T20param , d i s t _ biv= distr ibut ion0 )
}
f s t a r 0<− function ( t ) {
f s t a r 0<−(−grad ( Sstar , x=t , d is t1 =T1pdist , dist2 =T2pdist , param1=T10param , param2=T20param , d i s t _ biv= distr ibut ion0 ) )
}
aux21 <− function ( t , y ) {
theta *exp(− theta * ( ST10 ( t )+y ) ) *(1−exp(− theta ) ) / ( exp(− theta )−exp(− theta *ST10 ( t ))−exp(− theta *y)+exp(− theta * ( ST10 ( t )+y ) ) ) ^ 2
}
aux22<−function (u ) {
integrate ( aux21 , 0 , ST20 (u ) , t=u , subdivisions =10000)$value
}
lambdaC10<−function ( t ) {
aux22 ( t ) * fT10 ( t ) / Sstar0 ( t )
}
lambdaC11<−function ( t ) {
HR1*lambdaC10( t )
}
aux23<−function ( x , t ) {
theta *exp(− theta * ( x+ST20 ( t ) ) ) *(1−exp(− theta ) ) / ( exp(− theta )−exp(− theta * x)−exp(− theta *ST20 ( t ) ) + exp(− theta * ( x+ST20 ( t ) ) ) ) ^ 2
}
aux24<−function (u ) {
integrate ( aux23 , 0 , ST10 (u ) , t=u , subdivisions =10000)$value
}
lambdaC20<−function ( t ) {
aux24 ( t ) * fT20 ( t ) / Sstar0 ( t )
}
lambdaC21<−function ( t ) {
HR2*lambdaC20( t )
}
# EVALUATION OF LambdaC20 BEFORE COMPUTATION ( IT MAY FAIL IN CASES 2 / 4 FOR BETAS = 0.5 BECAUSE IT IS NOT ALWAYS
# EVALUABLE AT T=0)
LambdaC20_check<−tryCatch (
LambdaC20<−function ( t ) {
integrate ( lambdaC20 , lower =0 ,upper=t , subdivisions =10000)$value }
, error = function ( e ) e )
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# WHENEVER LambdaC20 FAILS , WE INCREASE THE LOWER LIMIT OF INTEGRATION
lower_LambdaC20<−0
while ( inherits (LambdaC20_check , " error " )== "TRUE" ) {
lower_LambdaC20=lower_LambdaC20+0.001
LambdaC20_check<−tryCatch (
LambdaC20<−function ( t ) {
integrate ( lambdaC20 , lower=0+lower_LambdaC20, upper=t , subdivisions =10000)$value }
, error = function ( e ) e )
}
LambdaC20<−function ( t ) {
integrate ( lambdaC20 , lower=0+lower_LambdaC20, upper=t , subdivisions =10000)$value
}
# Computation of the hazards f o r both groups
Lstar0<−function ( t ) {
lambdaC10( t )+lambdaC20( t )
}
Lstar1<−function ( t ) {
lambdaC11( t )+lambdaC21( t )
}
# Computation of HRstar
HRstar <− function ( t ) {
Lstar1 ( t ) / Lstar0 ( t )
}
logHRstar <− function ( t ) {
log ( Lstar1 ( t ) / Lstar0 ( t ) )
}
temp3<− function ( t ) {
logHRstar ( t ) * f s t a r 0 ( t )
}
# EVALUATION OF temp4 BEFORE COMPUTATION ( IT MAY FAIL IN CASES 2 / 4 FOR BETAS = 0.5 BECAUSE IT IS NOT
# ALWAYS EVALUABLE AT T=0)
temp4_check<−tryCatch (
temp4<−integrate (temp3 , 0 , 1 , subdivisions =10000)$value
, error = function ( e ) e )
# WHENEVER temp4 FAILS , WE INCREASE THE LOWER LIMIT OF INTEGRATION
lower_temp4<−0
while ( inherits (temp4_check , " error " )== "TRUE" ) {
lower_temp4=lower_temp4+0.001
temp4_check<−tryCatch (
temp4<−integrate (temp3 , lower_temp4 , 1 , subdivisions =10000)$value
, error = function ( e ) e )
}
temp4<−integrate (temp3,0+ lower_temp4 , 1 , subdivisions =10000)$value
numerator<−(temp4)^2
## Computation of PROBT1UNC
PROBT1UNC_temp_num <− function ( t ) {
exp(−HR2*LambdaC20( t ) ) * Sstar0 ( t ) *lambdaC10( t )
}
PROBT1UNC_temp_den <− function ( t ) {
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exp(−LambdaC20( t ) ) *1 / 2 + exp(−HR2*LambdaC20( t ) ) *1 / 2
}
PROBT1UNC_temp <− function ( t ) {
PROBT1UNC_temp_num( t ) / PROBT1UNC_temp_den( t )
}
PROBT1UNC_ i n t _check<− tryCatch ( integrate (PROBT1UNC_temp , lower =0 , upper=1 , subdivisions =10000)$value , error = function ( e ) e )
############################################
############################################
# WE EVALUATE THE FUNCTION PROBT1UNC_ int BECAUSE IT MAY FAIL IN CASES 2 / 4 FOR BETAS = 0.5 PROBABLY DUE
# TO THE LOWER LIMITS OF THE INTERGATES lambdaC20 AND temp4 .
# WHEN IT FAILS , WE SEARCH FOR THE MINIMUM EVALUABLE LIMIT OF INTEGARTION FOR lambdaC20 AND temp4 ;
# AND WE SET A LOWER LIMITS OF 0.001 FOR THE REST OF INTEGRATES TO ENSURE CONVERGENCE.
lower_PROBT1UNC_ i n t<−0
inc _lower<−0
while ( inherits (PROBT1UNC_ i n t _check , " error " )== "TRUE" ) {
lower_PROBT1UNC_ i n t<−0.001
inc _lower<−inc _lower +0.001
aux22<−function (u ) {
integrate ( aux21 , 0 . 0 0 1 , ST20 (u ) , t=u , subdivisions =10000)$value
}
lambdaC10<−function ( t ) {
aux22 ( t ) * fT10 ( t ) / Sstar0 ( t )
}
lambdaC11<−function ( t ) {
HR1*lambdaC10( t )
}
aux23<−function ( x , t ) {
theta *exp(− theta * ( x+ST20 ( t ) ) ) *(1−exp(− theta ) ) / ( exp(− theta )−exp(− theta * x)−exp(− theta *ST20 ( t ) ) + exp(− theta * ( x+ST20 ( t ) ) ) ) ^ 2
}
aux24<−function (u ) {
integrate ( aux23 , 0 . 0 0 1 , ST10 (u ) , t=u , subdivisions =10000)$value
}
lambdaC20<−function ( t ) {
aux24 ( t ) * fT20 ( t ) / Sstar0 ( t )
}
lambdaC21<−function ( t ) {
HR2*lambdaC20( t )
}
LambdaC20<−function ( t ) {
integrate ( lambdaC20 , lower=lower_LambdaC20 + inc _lower , upper=t , subdivisions =10000)$value
}
Lstar0<−function ( t ) {
lambdaC10( t )+lambdaC20( t )
}
Lstar1<−function ( t ) {
lambdaC11( t )+lambdaC21( t )
}
HRstar <− function ( t ) {
Lstar1 ( t ) / Lstar0 ( t )
}
logHRstar <− function ( t ) {
log ( Lstar1 ( t ) / Lstar0 ( t ) )
}
temp3<− function ( t ) {
logHRstar ( t ) * f s t a r 0 ( t )
}
temp4<−integrate (temp3 , lower_temp4 + inc _lower , 1 , subdivisions =10000)$value
numerator<−(temp4)^2
128
CHAPTER C APPENDIX: R CODE TO COMPUTE THE ASYMPTOTIC RELATIVE EFFICIENCY (ARE) VALUES
PROBT1UNC_temp_num <− function ( t ) {
exp(−HR2*LambdaC20( t ) ) * Sstar0 ( t ) *lambdaC10( t )
}
PROBT1UNC_temp_den <− function ( t ) {
exp(−LambdaC20( t ) ) *1 / 2 + exp(−HR2*LambdaC20( t ) ) *1 / 2
}
PROBT1UNC_temp <− function ( t ) {
PROBT1UNC_temp_num( t ) / PROBT1UNC_temp_den( t )
}
PROBT1UNC_ i n t _check<− tryCatch ( integrate (PROBT1UNC_temp , lower =0.001 , upper=1 , subdivisions =10000)$value , error = function ( e ) e )
}
PROBT1UNC_ i n t<−integrate (PROBT1UNC_temp , lower=lower_PROBT1UNC_ int , upper=1 , subdivisions =10000)$value
############################################
############################################
AREstarT <− numerator / ( ( log (HR1)^2) * PROBT1UNC_ i n t * (1−Sstar0 ( 1 ) ) )
AREstarT
}
return ( AREstarT )
}
#######################################################################################
# Function : CopulaSelection
#
#######################################################################################
# Description : Constructs a copula c l a s s o b j e c t from the family given and the
# the corresponding dependence parameter from the given c o r r e l a t i o n
#
# copula Copula given :
# Archimedean : " Frank " ( default ) , "Gumbel" or " Clayton "
# E l l i p t i c a l : "Normal" or "T"
# Extreme Value : "Galambos " , " HuslerReiss " , "Gumbel" , "Tawn" or " Tev "
# Other : "FGM" or " Plackett "
# rho Spearman ’ s c o e f f i c i e n t between the 2 marginal d i s t r i b u t i o n s
#######################################################################################
CopulaSelection <− function ( copula , rho ) {
i f ( copula=="Frank" ) {
theta<−iRho ( frankCopula ( 1 ) , rho )
which . copula <− archmCopula ( family = " frank " , dim = 2 , param = theta )
return ( c ( which . copula , theta ) )
} else
i f ( copula=="Gumbel" ) {
theta<−iRho ( gumbelCopula ( 2 ) , rho )
which . copula <− archmCopula ( family = "gumbel" , dim = 2 , param = theta )
return ( c ( which . copula , theta ) )
} else
i f ( copula==" Clayton " ) {
theta<−iRho ( claytonCopula ( 1 ) , rho )
which . copula <− archmCopula ( family = " clayton " , dim = 2 , param = theta )
return ( c ( which . copula , theta ) )
} else
i f ( copula=="FGM" ) {
theta<−iRho ( fgmCopula ( 1 ) , rho )
which . copula <− fgmCopula (dim = 2 , param = theta )
return ( c ( which . copula , theta ) )
} else
i f ( copula=="Normal" ) {
theta<−iRho ( normalCopula ( 0 . 5 ) , rho )
which . copula <− normalCopula (dim = 2 , param = theta )
return ( c ( which . copula , theta ) )
} else
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i f ( copula=="T" ) {
theta<−iRho ( tCopula ( 0 . 5 ) , rho )
which . copula <− tCopula (dim = 2 , param = theta )
return ( c ( which . copula , theta ) )
} else
i f ( copula=="Galambos" ) {
theta<−iRho ( galambosCopula ( 0 . 5 ) , rho )
which . copula <− galambosCopula (param = theta )
return ( c ( which . copula , theta ) )
} else
i f ( copula==" HuslerReiss " ) {
theta<−iRho ( huslerReissCopula ( 0 . 5 ) , rho )
which . copula <− huslerReissCopula (param = theta )
return ( c ( which . copula , theta ) )
} else
i f ( copula=="Tawn" ) {
theta<−iRho ( tawnCopula ( 0 . 5 ) , rho )
which . copula <− tawnCopula (param = theta )
return ( c ( which . copula , theta ) )
} else
i f ( copula=="Tev" ) {
theta<−iRho ( tevCopula ( 0 . 5 ) , rho )
which . copula <− tevCopula (param = theta )
return ( c ( which . copula , theta ) )
} else
i f ( copula==" Plackett " ) {
theta<−iRho ( plackettCopula ( 0 . 5 ) , rho )
which . copula <− plackettCopula (param = theta )
return ( c ( which . copula , theta ) )
} else { stop ( paste ( "Not implemented for " , copula , "copula . " ) ) }
return ( c ( which . copula , theta ) )
}
#######################################################################################
# Function : MarginalsSelection
#
#######################################################################################
# Description : Returns the family d i s t r i b u t i o n and parameters of the marginals
# (ONLY WEIBULL DISTRIBUTIONS SO FAR)
#
# beta1 Shape parameter f o r a Weibull law f o r the relevant event
# beta2 Shape parameter f o r a Weibull law f o r the additional event
# HR1 Hazard Ratio f o r a Weibull law f o r the relevant event
# HR2 Hazard Ratio f o r a Weibull law f o r the additional event
# p1 Proportion of the relevant event expected in group zero
# p2 Proportion of the additional event expected in group zero
# case Censoring case : 1 ( default ) , 2 , 3 or 4
# theta Dependence parameter f o r the b i v a r i a t e d i s t r i b u t i o n in control group
#######################################################################################
MarginalsSelection<−function ( beta1 , beta2 ,HR1,HR2, p1 , p2 , case , theta )
{
# Scale parameters f o r group 0 b10 , b20
i f ( case ==1) {
b10 <− 1 / ((− log(1−p1 ) ) ^ ( 1 / beta1 ) )
b20 <− 1 / ((− log(1−p2 ) ) ^ ( 1 / beta2 ) )
} else
i f ( case ==2) {
Fb10<−function ( b10 , p1 ) {
i n t e g r a l<−integrate ( function (u) {
sapply (u , function (u) {
integrate ( function ( v ) ( ( theta *(1−exp(− theta ) ) *exp(− theta * (u+v ) ) ) / ( exp(− theta )+ exp(− theta * (u+v ) ) −
exp(− theta *u)−exp(− theta *v ))^2 ) , lower =0 , upper= exp ( ( b10*(− log (u) ) ^ ( 1 / beta1 ) ) ^ beta2 * log(1−p2 ) ) ) $value
} )
} , lower= exp(−1 / b10^beta1 ) , upper=1)$value
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return ( integral−p1 )
}
l i m i t s <− c (0.00001 ,10000) # The f i r s t and the l a s t values must be in opposite s igns f o r the function
b10 <− uniroot ( Fb10 , i n t e r v a l =l imits , p1=p1 ) $root # Find the root ( value which equals the function zero )
b20 <− 1 / (− log(1−p2 ) ) ^ ( 1 / beta2 )
} else
i f ( case ==3) {
b10 <− 1 / ((− log(1−p1 ) ) ^ ( 1 / ( beta1 ) ) )
Fb20<−function ( b20 , p2 ) {
i n t e g r a l<−integrate ( function ( v ) {
sapply ( v , function ( v ) {
integrate ( function (u ) ( ( theta *(1−exp(− theta ) ) *exp(− theta * (u+v ) ) )
/ ( exp(− theta )+exp(− theta * (u+v))−exp(− theta *u)−exp(− theta *v ) ) ^ 2 ) , lower =0 ,
upper=exp(−((((− log ( v ) ) ^ ( 1 / beta2 ) ) *b20 ) / b10)^ beta1 ) ) $value
} )
} ,
lower= exp(−(1 / b20)^ beta2 ) , upper=1)$value
return ( integral−p2 )
}
l i m i t s <− c (0.00001 ,10000)
b20 <− uniroot ( Fb20 , i n t e r v a l =l imits , p2=p2 ) $root
} else
i f ( case ==4) {
# We need to c r e a t e x [ 1 ] and x [ 1 ] (we assign NA’ s )
x<−NA
y<−NA
x [ 1 ]<−x
x [ 2 ]<−y
# We need to change the name of variables as ( b10=x [ 1 ] , b20 = [ 2 ] ) to execute ’ multiroot ’
# Compute b10
Fb10<−function ( b10 , b20 , p1 ) {
b10−>x [ 1 ]
b20−>x [ 2 ]
i n t e g r a l<−integrate ( function (u) {
sapply (u , function (u) {
integrate ( function ( v ) ( ( theta *(1−exp(− theta ) ) *exp(− theta * (u+v ) ) )
/ ( exp(− theta )+ exp(− theta * (u+v ) ) − exp(− theta *u)−exp(− theta *v ))^2 ) , lower =0 ,
upper= exp ( ( x [ 1 ] *(− log (u) ) ^ ( 1 / beta1 ) ) ^ beta2 * ( −1/ ( x [2]^ beta2 ) ) ) ) $value
} )
} , lower= exp(−1 / x [1]^ beta1 ) , upper=1)$value
return ( integral−p1 )
}
# Compute b20
Fb20<−function ( b10 , b20 , p2 ) {
b10−>x [ 1 ]
b20−>x [ 2 ]
i n t e g r a l<−integrate ( function ( v ) {
sapply ( v , function ( v ) {
integrate ( function (u ) ( ( theta *(1−exp(− theta ) ) *exp(− theta * (u+v ) ) )
/ ( exp(− theta )+exp(− theta * (u+v))−exp(− theta *u)−exp(− theta *v ) ) ^ 2 ) , lower =0 ,
upper=exp(−((((− log ( v ) ) ^ ( 1 / beta2 ) ) * x [ 2 ] ) / x [ 1 ] ) ^ beta1 ) ) $value
} )
} ,
lower= exp(−(1 / x [ 2 ] ) ^ beta2 ) , upper=1)$value
return ( integral−p2 )
}
model <− function ( x ) {
c ( Fb10 ( x [ 1 ] , x [ 2 ] , p1 ) , Fb20 ( x [ 1 ] , x [ 2 ] , p2 ) )
}
( sol <− multiroot ( f = model , s t a r t = c ( 1 , 1 ) ) )
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sol<−as . data . frame ( sol [ 1 ] )
b10<−sol [ 1 , ]
b20<−sol [ 2 , ]
}
# Scale parameters f o r group 1 b11 , b21 ( Although we do not need to compute the s c a l e parameters f o r
# group 1 ( b11 , b21 ) to c a l c u l a t e the ARE)
b11 <− b10 /HR1^(1 / beta1 )
b21 <− b20 /HR2^(1 / beta2 )
T1dist<−" weibull "
T2dist<−" weibull "
T1pdist<−pweibull
T2pdist<−pweibull
T10param<− l i s t ( shape = beta1 , scale = b10 )
T20param<− l i s t ( shape = beta2 , scale = b20 )
T11param<− l i s t ( shape = beta1 , scale = b11 )
T21param<− l i s t ( shape = beta2 , scale = b21 )
return ( l i s t ( T1dist , T2dist , T1pdist , T2pdist , T10param , T20param , T11param , T21param ) )
}
#######################################################################################
# Function : Sstar
#
#######################################################################################
# Description : Returns the value of the survival function of S* at point x given the
# marginal d i s t r i b u t i o n s and the b i v a r i a t e d i s t r i b u t i o n s via copula
#
# x Point in which to be evaluated
# d i s t 1 Distribution function of the marginal T1 ( pweibull )
# d i s t 2 Distribution function of the marginal T2 ( pweibull )
# param1 Parameters of the marginal d i s t r i b u t i o n function T1 ( pweibull )
# param2 Parameters of the marginal d i s t r i b u t i o n function T2 ( pweibull )
# d i s t _ biv Distribution function of the b i v a r i a t e d i s t r i b u t i o n via copula
#######################################################################################
Sstar<−function ( x , dist1 , dist2 , param1 , param2 , d i s t _ biv ) {
y <− i f ( length ( x ) == 1) c ( x , x ) else cbind ( x , x )
return (
1
− do . c a l l ( dist1 , c ( l i s t (q=x ) , param1 ) )
− do . c a l l ( dist2 , c ( l i s t (q=x ) , param2 ) )
+ (pMvdc( y , d i s t _ biv ) )
)
}
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The asymptotic relative efficiency and the ratio of
sample sizes when testing two different null
hypotheses
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Abstract
Composite endpoints, consisting of the union of two or more outcomes, are often used as the
primary endpoint in time-to-event randomized clinical trials. Previously, Go´mez and Lagakos
provided a method to guide the decision between using a composite endpoint instead of one
of its components when testing the effect of a treatment in a randomized clinical trial. Consider
the problem of testing the null hypotheses of no treatment effect by means of either the single
component or the composite endpoint. In this paper we prove that the usual interpretation of
the asymptotic relative efficiency as the reciprocal ratio of the sample sizes required for two test
procedures, for the same null and alternative hypothesis, and attaining the same power at the
same significance level, can be extended to the test procedures considered here for two different
null and alternative hypotheses. A simulation to study the relationship between asymptotic relative
efficiency and finite sample sizes is carried out.
MSC: 62N03, 62P10
Keywords: Asymptotic relative efficiency, composite endpoint, logrank test, sample size, simula-
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1. Introduction
In clinical trials research, one of the most important issues that investigators have
to solve at the design stage of the study is the appropriate choice of the primary
endpoint. Composite endpoints (CE) consisting of the union of two or more outcomes
are commonly used as primary endpoints. For example, in the cardiovascular area the
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relevant endpoint of death is often combined with other additional endpoints such as
myocardial infarction, stroke or hospitalization. Pros and cons on the use of CE have
been extensively discussed (Freemantle et al., 2003; Ferreira-Gonza´lez et al., 2007,
among many others). One of the main advantages of using a CE relies in the fact that
by means of a CE the problem of multiplicity is adequately addressed and the bias
associated with competing risks (Wittkop et al., 2010) is avoided. Also, with a CE the
number of observed events will be higher and, hopefully, the power of the test will
increase. However, as it has been discussed (Montori et al., 2005) and shown in Go´mez
and Lagakos (2013), adding inappropriate components to the relevant endpoint might
actually lead to a decrease in the power of the test statistic, consequently having a larger
chance to fail in detecting a real effect of the treatment under study.
Go´mez and Lagakos (2013) developed a methodology to help to decide when it is
worthwhile to base the analysis on the composite endpoint E∗ = E1 ∪E2 where E1 and
E2 are two candidate relevant endpoints to evaluate the effect of a treatment instead of
sticking to one of them, E1, say. In order to do so, they compared how more efficient than
E1 would E∗ be to justify its use. Let H0 be the null hypothesis of no treatment effect
evaluated on E1 and denote by Ha an alternative hypothesis, for instance, claiming to
delay the event E1. Analogously, define H∗0 and H∗a the null and alternative hypotheses
if the treatment effect is to be evaluated on E∗. Since when comparing two treatment
groups based on time-to-event endpoints, the primary analysis would be based, very
commonly, on a logrank test, their method considers the logrank test Z to test H0 versus
Ha and the logrank test Z∗ to test H∗0 versus H∗a . The asymptotic relative efficiency
(ARE) of Z∗ versus Z is the measure proposed to choose between E1 and E∗, with
values larger than 1 in favour of E∗. This relative measure can be computed as (µ∗/µ)2
where µ and µ∗ are, respectively, the asymptotic means of Z and Z∗, under alternative
contiguous hypotheses to H0 and H∗0 . The purpose of this paper is to prove that the usual
interpretation of the ARE, as the ratio of sample sizes, n and n∗, needed to attain the
same power for a given significance level, still holds even though two different sets of
hypothesis (H0 versus Ha and H∗0 versus H∗a ) are compared.
To clarify the purpose of our investigation consider the following. If we were to test
H0 versus Ha with two different test statistics Sn and Tm, Pitman’s relative efficiency
would be defined as the ratio m/n, where n and m are the required sample sizes for Sn
and Tm, respectively, to attain the same power for a given significance level. Furthermore,
if both Sn and Tm are asymptotically normal with unit variance and means µS and
µT , it can be proved that Pitman’s ARE corresponds to the square of the ratio of the
noncentrality parameters, that is (µS/µT )2. Go´mez and Lagakos’ method compares the
logrank statistics: Z and Z∗ derived for two different set of hypotheses H0 versus Ha
and H∗0 versus H∗a and do so using, as definition of the ARE, the ratio (µ∗/µ)2 where µ
and µ∗ are, respectively, the asymptotic means of Z and Z∗, under alternative contiguous
hypotheses to H0 and H∗0 .
This paper is organized as follows. In Section 2 the notation, assumptions and
main results from Go´mez and Lagakos’ paper are introduced. Section 3 establishes
Guadalupe Go´mez and Moise´s Go´mez-Mateu 75
the limiting relationship between ARE and sample sizes and proves that the usual
interpretation of the ARE as the ratio of sample sizes holds. Section 4 presents a
simulation to study under which conditions and for finite sample sizes, the relationship
ARE(Z∗,Z) = (µ∗/µ)2 = n/n∗ holds where n and n∗ are the needed sample sizes for Z
and Z∗, respectively, to attain the same power for a given significance level. Section 5
concludes the paper with a discussion.
2. Notation, the logrank test and the asymptotic relative efficiency
2.1. The logrank tests for the relevant and for the composite endpoints
Assume that we have a two-arm study involving random assignment to an active (X = 1)
or control treatment (X = 0) aiming to prove the efficacy of the new active treatment.
The effect of treatment is to be evaluated on the time T ( j)1 to a relevant event E1, where
the superscript j indicates the treatment group ( j = 0 for the control group and j = 1 for
the treatment group). Let λ( j)1 (t) denote the hazard function of T ( j)1 ( j = 0,1). The null
hypothesis of no effect is given by H0 : HR1(t) = λ(1)1 (t)/λ
(0)
1 (t) = 1 and the alternative
that the new treatment improves survival by Ha : HR1(t)< 1. The logrank test Z is used
to test that the new treatment improves survival.
Assume now that an additional endpoint E2 is considered as component of the
primary endpoint and the composite endpoint E∗ = E1 ∪ E2 is to be used, instead, to
prove the efficacy of the new treatment. The effect of treatment would then be evaluated
on the time T ( j)∗ to E∗ where T ( j)∗ = min{T ( j)1 ,T ( j)2 } and T ( j)2 stands for the time to E2
( j = 0,1). Let λ( j)2 (t) and λ( j)∗ (t) denote, respectively, the hazard functions of T ( j)2 and
T ( j)∗ ( j = 0,1). The treatment effect on E∗ would then be tested with the logrank test Z∗
to compare H∗0 : HR∗(t) = λ
(1)
∗ (t)/λ
(0)
∗ (t) = 1 versus H∗a : HR∗(t)< 1.
Observation of endpoints E1 and E2 depends on whether or not they include a
terminating event and yield four different situations referred, in Go´mez and Lagakos
(2013), as Cases 1, 2, 3 and 4. In this paper we assume that the additional endpoint does
not include a terminating event, which corresponds to Case 1 when neither the relevant
nor the additional endpoint includes a terminating event, and Case 3, when the relevant
endpoint includes a terminating event.
Schoenfeld (1981) studies the asymptotic behaviour of the logrank statistic and proves
that under the null hypothesis of no treatment difference, the logrank is asymptotically
N(0,1) and, under a sequence of alternatives contiguous to the null, the logrank is
asymptotically normal with unit variance and finite mean. Go´mez and Lagakos apply
Schoenfeld’s results and proceed as follows. They consider λ(0)1 (t) as fixed and define a
sequence of alternatives Ha,n consisting of instantaneous hazard functions close enough
to λ(0)1 (t), for instance taking λ
(1)
1,n(t) = λ
(0)
1 (t)e
g(t)/
√
n for some g(t) function. These
sequence of alternatives, formulated equivalently as HR1,n(t) = eg(t)/
√
n
, include pro-
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portional hazard alternatives, i.e, taking g(t) = β for a fixed real value β . Logrank Z
is asymptotically N(0,1) under the null hypothesis of no treatment difference (H0 :
HR1(t) = 1) and asymptotically normal with unit variance and mean µ given in equation
(1) under the sequence of alternatives Ha,n : HR1,n(t) = eg(t)/
√
n < 1. Analogously, fix
λ
(0)
∗ (t) and define H∗0 : HR∗(t) = 1 and the sequence of alternatives H∗a,n : HR∗,n(t) =
eg∗(t)/
√
n < 1 for a given function g∗(t). It follows that Z∗ is asymptotically N(0,1) under
H∗0 and asymptotically normal with unit variance and mean µ∗ given in equation (2)
under the sequence H∗a,n. The asymptotic means of Z and Z∗ are given by
µ=
∫
∞
0 g(t)p(t)[1− p(t)]PrH0{U ≥ t}λ(0)1 (t)dt√∫
∞
0 p(t)[1− p(t)]PrH0{U ≥ t}λ(0)1 (t)dt
, (1)
µ∗ =
∫
∞
0 g∗(t))p∗(t)[1− p∗(t)]PrH∗0 {U∗ ≥ t}λ
(0)
∗ (t)dt√∫
∞
0 p∗(t)[1− p∗(t)]PrH∗0 {U∗ ≥ t}λ
(0)
∗ (t)dt
, (2)
where U = min{T1,C} (in Cases 1 and 3) and U∗ = min{T∗,C} denote the observed out-
come; C denotes the censoring time; p(t) = PrH0{X = 1|U ≥ t} and p∗(t) = PrH∗0 {X =
1|U∗ ≥ t} are the null probabilities that someone at risk at time t is in treatment group 1;
PrH0{U ≥ t} and PrH∗0 {U∗ ≥ t} are the null probabilities that someone is still at risk at
time t and PrH0{U ≥ t}λ(0)1 (t) and PrH∗0 {U∗ ≥ t}λ
(0)
∗ (t) correspond to the probabilities,
under the null hypothesis, of observing events E1 and E∗, respectively, by time t.
2.2. Asymptotic relative efficiency
Efficiency calculations throughout the paper will assume that end-of-study censoring at
time τ (τ = 1 without loss of generality) is the only non-informative censoring cause
for both groups; this assumption indirectly implies that the censoring mechanism is
the same for both groups. It is as well assumed that the hazard functions λ( j)1 (t) and
λ
( j)
2 (t) ( j = 0,1) are proportional, that is, HR1(t) = HR1 and HR2(t) = HR2, for all
t, where HR1(t) = λ(1)1 (t)/λ
(0)
1 (t) and HR2(t) = λ
(1)
2 (t)/λ
(0)
2 (t) are the hazard ratios
between T (0)1 and T
(1)
1 and between T
(0)
2 and T
(1)
2 , respectively. Note that although we
are assuming that the hazard functions λ( j)1 (t) and λ
( j)
2 (t) ( j = 0,1) are proportional,
this does not imply the proportionality of hazards λ(0)∗ (t) and λ(1)∗ (t) for the composite
endpoint T∗ (see Figure 1).
To assess the difference in efficiency between using logrank test Z, based on the
relevant endpoint E1, and logrank test Z∗, based on the composite endpoint E∗, Go´mez
and Lagakos base their strategy on the behaviour of the asymptotic relative efficiency
(ARE) of Z∗ versus Z. The ARE is a measure of the relative power of two tests that can
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Figure 1: Survival and hazard ratio for the relevant endpoint (RE), T1, for the additional endpoint (AE),
T2 and for the composite endpoint (CE), T∗ = min{T1,T2}. T1 ∼ Weibull with shape parameter β1 = 2
(increasing hazard) for treatment groups 0 and 1 and T2 ∼ Weibull with shape parameter β2 = 1 (constant
hazard) for treatment groups 0 and 1. Scale parameters for T1 and T2 have been calculated such that Pr{T1
observed in group 0}=0.1, Pr{T2 observed in group 0}=0.25, HR1 = 0.5, HR2 = 0.9 and Spearman’s
ρ(T1,T2) = 0.45 assuming Frank’s copula between T1 and T2. Considering the RE as a terminating event
(case 3), in this setting ARE(Z∗,Z) = 0.21.
be interpreted, when the two tests are for the same null and alternative hypothesis, as
the ratio of the required sample sizes to detect a specific treatment effect to attain the
same power for a given significance level (Lehmann and Romano, 2005). In this case,
a value of ARE= 0.6 would mean that we only need 60% as many cases to reach a
given power if we use E1 as we would need if we used E∗. Whenever the tests under
consideration, Z and Z∗, are asymptotically N(0,1) under H0 and H∗0 , respectively, and
asymptotically normal with variance 1 under a sequence of contiguous alternatives to
the null hypothesis, a different definition for Pitman’s relative efficiency as the square
of the ratio of the non-centrality parameters µ and µ∗ is appropriate
ARE(Z∗,Z) =
(
µ∗
µ
)2
, (3)
where µ and µ∗ are to be replaced by expressions (1) and (2).
Before providing the expression that is being used to evaluate the ARE, and for the
sake of clarity, we enumerate the assumptions that have been taken into account:
• End-of-study censoring at time τ is the only non-informative censoring cause for
both groups.
• The additional endpoint does not include a terminating event.
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• The hazard ratios between T (0)1 and T (1)1 and between T (0)2 and T (1)2 are propor-
tional, that is, HR1(t) = λ(1)1 (t)/λ
(0)
1 (t) = HR1 and
HR2(t) = λ
(1)
2 (t)/λ
(0)
2 (t) = HR2 for all t.
• Effect of treatment on E1 is tested establishing H0 : HR1 = 1 versus a sequence
of alternatives Ha,n : λ(1)1,n(t) = λ
(0)
1 (t)e
g(t)/
√
n for some g(t) function. Note that
g(t)/
√
n = log{λ(1)1,n(t)/λ(0)1 (t)}.
• Effect of treatment on E∗ is tested establishing H∗0 : HR∗(t) = 1 versus a sequence
of alternatives H∗a,n : HR∗,n(t) = eg∗(t)/
√
n < 1 for a given function g∗(t). Note that
g∗(t)/
√
n = log{HR∗,n(t)}.
Under the above assumptions expression (3) becomes
ARE(Z∗,Z) =
(∫ 1
0 log
{
λ
(1)
∗ (t)/λ
(0)
∗ (t)
} f (0)∗ (t)dt)2(
log
{
HR1
})2
(
∫ 1
0 f (0)∗ (t)dt)(
∫ 1
0 f (0)1 (t)dt)
, (4)
where f (0)1 (t) and f (0)∗ (t) are the density functions of T (0)1 and T (0)∗ , respectively.
Remark The density function f (0)∗ (t) is the density of the T (0)∗ = min{T (0)1 ,T (0)2 },
computed from the joint density between T (0)1 and T (0)2 , which itself is built from the
marginals of T (0)1 and T
(0)
2 by means of a bivariate copula.
3. Relationship between ARE and sample sizes
We start establishing that if the hazard ratios for T ( j)1 ( j = 0,1) and for T ( j)2 ( j = 0,1)
approach the unity as n gets large, so does the hazard ratio of the minimum T ( j)∗ between
T ( j)1 and T
( j)
2 ( j = 0,1).
Lemma 1 Given two sequences of hazard ratios {HR1,n(t) = λ(1)1,n(t)/λ(0)1 (t)} and
{HR2,n(t) = λ(1)2,n(t)/λ(0)2 (t)}, both converging uniformly to 1 as n → ∞, the sequence
corresponding to the hazard ratio of T ( j)∗ = min{T ( j)1 ,T ( j)2 }, namely {HR∗,n(t) =
= λ
(1)
∗,n(t)/λ
(0)
∗ (t)}, tends to 1 as n → ∞. In particular, this lemma holds whenever
log(λ(1)k,n(t)/λ
(0)
k (t)}) = O(n−1/2), which in turn, is true if log(λ(1)k,n(t)/λ(0)k (t)}) =
= gk(t)/
√
n, for any bounded real function gk(t) (k = 1,2).
Proof 1 It follows immediately that for fixed t, limn→∞λ(1)1,n(t) = λ(0)1 (t) and
limn→∞λ(1)2,n(t) = λ
(0)
2 (t). Furthermore, it follows that the corresponding densities and
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survival functions f (1)1,n (t), f (1)2,n (t), S(1)1,n(t) and S(1)2,n(t), converge to f (0)1 (t), f (0)2 (t), S(0)1 (t)
and S(0)2 (t), respectively. Taking into account that the survival function of the minimum,
S(1)∗,n(t) is expressed in terms of the marginal survival functions S(1)1,n(t) and S
(1)
2,n(t) of T
(1)
1
and T (1)2 via a copula C, that is,
S(1)∗,n(t) =C(S(1)1,n(t),S
(1)
2,n(t)), it remains to prove that limn→∞ S
(1)
∗,n(t) = S(0)∗ (t). This result
will imply that
limn→∞ f (1)∗,n (t)= f (0)∗ (t), limn→∞λ(1)∗,n(t)=λ(0)∗ (t) and hence the sequence HR∗,n(t)→
1 as n→ ∞, as we wanted to prove.
The convergence of S(1)∗,n(t) to S(0)∗ (t) is guaranteed by the convergence of S(1)1,n(t) and
S(1)2,n(t) to S
(0)
1 (t) and S
(0)
2 (t), respectively, together with the fact that bivariate copulas
C are bivariate distribution functions with uniform marginals. The reader is referred to
Lindner and Szimayer (2005) for the corresponding technical proofs. 
Proposition 1 Consider two test procedures φn and φ∗n to test H0 : HR1(t) = 1 against
Ha,n : HR1,n(t)< 1 and H∗0 : HR∗(t) = 1 against H∗a,n : HR∗,n(t)< 1, respectively. Let n
and n∗ be the sample sizes required for φn and φ∗n , respectively, to have power at least
Π at level α. Assume the sequences φ = {φn} and φ∗ = {φ∗n} are based on the logrank
statistics Z and Z∗, respectively, converging, to Normal (µ,1) and Normal (µ∗,1) with
µ and µ∗ given in (1) and (2), under sequences of local alternatives HRk,n(t) (k = 1,2)
converging uniformly to 1 as n→ ∞. Given 0 < α< Π < 1,
lim
HR1,n(t)→1
HR2,n(t)→1
n
n∗
= ARE(Z∗,Z).
The usual interpretation of the ARE as the reciprocal ratio of the sample sizes holds even
when two different sets of hypotheses (H0 versus Ha,n and H∗0 versus H∗a,n) are tested.
As a consequence of this proposition, the interpretation of the ARE is the following. If
ARE(Z∗,Z) = 0.7, then, asymptotically, we only need 70% as many cases to attain a
given power if we use Z as we would need if we used Z∗.
Proof 2 By Lemma 1, uniform convergence to 1 of {HR1,n(t)} and {HR2,n(t)} imply
that limHR∗,n(t)→ 1. Under the sequence of contiguous alternatives to the null Ha,n :
{HR1,n(t) = λ(1)1,n(t)/λ(0)1 (t)} → 1 and H∗a,n : {HR∗,n(t) = λ(1)∗,n(t)/λ(0)∗ (t)} → 1, both Z
and Z∗ are asymptotically N(µ,1) and N(µ∗,1), respectively. The power function for a
one-sided test with size α is therefore given, respectively, by
Π1 = lim
n→∞ Prob{Z < z1−α|Ha,n}= 1−Φ(−z1−α+µ)
Π∗ = lim
n→∞ Prob{Z∗ < z1−α|H
∗
a,n}= 1−Φ(−z1−α+µ∗) (5)
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where Φ is the distribution function of the standard normal and z1−α is the standard
normal quantile corresponding to the left tail probability α. It immediately follows that
Π1 = Π∗ is equivalent to µ= µ∗.
The equivalence of powers (Π1 = Π∗) implies that µ = µ∗, given by (1) and (2).
Equivalently
(
µ∗
µ
)2
= 1 ⇐⇒

∫
∞
0 g(t)p(t)[1−p(t)]PrH0{U≥t}λ
(0)
1 (t)dt√∫
∞
0 p(t)[1−p(t)]PrH0{U≥t}λ
(0)
1 (t)dt∫
∞
0 g∗(t)p∗(t)[1−p∗(t)]PrH∗0 {U∗≥t}λ
(0)
∗ (t)dt√∫
∞
0 p∗(t)[1−p∗(t)]PrH∗0 {U∗≥t}λ
(0)
∗ (t)dt

2
= 1. (6)
Since
p(t) =
PrH0{U ≥ t|X = 1}pi
PrH0{U ≥ t}
=
PrH0{U ( j) ≥ t}pi
PrH0{U ≥ t}
where pi= PrH0{X = 1}, we have
p(t)(1− p(t))PrH0{U ≥ t}=
PrH0{U (1) ≥ t}piPrH0{U (0) ≥ t}(1−pi)
PrH0{U (0) ≥ t}(1−pi)+PrH0{U (1) ≥ t}pi
.
Based on the stated assumptions, because T ( j)1 is right-censored by the end-of-study
at time τ, and under the null hypothesis of no effect (S(0)1 (t) = S(1)1 (t)), we have
PrH0{U ( j) ≥ t} = S(0)1 (t)1{[0,1]}(t), for j = 0,1. Replacing in (1), the noncentrality
parameter µ becomes
µ=
√
pi(1−pi)∫ 10 g(t)S(0)1 (t)λ(0)1 (t)dt√∫ 1
0 S
(0)
1 (t)λ
(0)
1 (t)dt
=
√
pi(1−pi)∫ 10 g(t) f (0)1 (t)dt√∫ 1
0 f (0)1 (t)dt
where f (0)1 (t) is the marginal density function for T (0)1 . Analogously, it can be seen that
µ∗ =
√
pi(1−pi)∫ 10 g∗(t) f (0)∗ (t)dt√∫ 1
0 f (0)∗ (t)dt
where f (0)∗ (t) is the density function for T (0)∗ . The reader is addressed to the online
supporting material of Go´mez and Lagakos paper for other technical details.
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If we would replace g(t) and g∗(t) by
√
n log
(
λ
(1)
1,n(t)
λ
(0)
1 (t)
)
=
√
n log(HR1) and
√
n∗ log
(
λ
(1)
∗,n(t)
λ
(0)
∗ (t)
)
,
respectively, equality (6), after cancelling pi(1−pi), becomes equal to
lim
HR1,n(t)→1
HR2,n(t)→1
√
n∗√
n
∫ 1
0 log
{
λ
(1)
∗ (t)/λ
(0)
∗ (t)
}
f (0)∗ (t)dt√∫ 1
0 f (0)∗ (t)dt
log(HR1)
√∫ 1
0 f (0)1 (t)dt
= 1
which in turn is equivalent to
lim
HR1,n(t)→1
HR2,n(t)→1
n
n∗
=
(∫ 1
0 log
{
λ
(1)
∗ (t)/λ
(0)
∗ (t)
} f (0)∗ (t)dt)2
(log(HR1))2 (
∫ 1
0 f (0)∗ (t)dt)(
∫ 1
0 f (0)1 (t)dt)
(7)
and it follows that ARE(Z∗,Z) = lim
HR1,n(t)→1
HR2,n(t)→1
n
n∗
, as we wanted to prove. 
Note that (7) implies
(∫ 1
0 log
{
λ
(1)
∗ (t)/λ
(0)
∗ (t)
} f (0)∗ (t)dt)2
(log(HR1))2
(∫ 1
0 f (0)∗ (t)dt
)2 = limHR1,n(t)→1
HR2,n(t)→1
n(
∫ 1
0 f (0)1 (t)dt)
n∗(
∫ 1
0 f (0)∗ (t)dt)
≈ expected number E1
expected number E∗
and whenever λ(1)∗ (t)/λ(0)∗ (t) is approximately constant and equal to HR∗, we would
have (
1
log(HR1)
)2
(
1
log(HR∗)
)2 = limHR1,n(t)→1
HR2,n(t)→1
n(
∫ 1
0 f (0)1 (t)dt)
n∗(
∫ 1
0 f (0)∗ (t)dt)
≈ expected number E1
expected number E∗
4. Simulation
4.1. Simulation
Our next aim is to simulate data to empirically check how close we are to the limiting
relationship n/n∗ = ARE(Z∗,Z) when Π1 = Π∗ for different finite sample sizes. To
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conduct the simulations we will assume, as Go´mez and Lagakos did, that T ( j)1 and
T ( j)2 follow Weibull distributions. Weibull distributions are chosen for their wide use
in the field of survival analysis due to its flexibility, allowing decreasing, constant and
increasing hazard rates. The corresponding shape and scale parameters are denoted by
βk and b( j)k ( j = 0,1, k = 1,2) (shape parameters for both groups are taken equal so
that the assumption of the proportionality of the hazard ratios holds). To establish the
bivariate distribution of (T (0)1 ,T
(0)
2 ) we consider Frank’s Archimedean survival copula,
again as Go´mez and Lagakos did. Other choices of copulas would be possible, although
main conclusions and recommendations will not differ (Plana-Ripoll and Go´mez, 2014).
Frank’s copula depends on an association parameter θ between T (0)1 and T
(0)
2 which
is biunivocally related to Spearman’s rank correlation ρ. Different scenarios will be
simulated according to several choices of (β1,β2, p(0)1 , p
(0)
2 ,HR1,HR2,ρ) where p
(0)
1
and p(0)2 are the probability of observing events E1 and E2, respectively, for treatment
group 0, HR1 and HR2 are relative treatment hazard ratios for T (1)j versus T
(0)
j ( j = 1,2,
respectively) and ρ is Spearman’s rank correlation between T (0)1 and T (0)2 .
Given a set of values for (β1,β2, p(0)1 , p
(0)
2 ,HR1,HR2,ρ), for a given power Π and a
significance level α, the simulation steps are the following:
1. Computations for the relevant endpoint E1. The scale parameters b(0)1 and b
(1)
1
and the probability p(1)1 of observing the relevant endpoint in group 1 are derived
as:
b(0)1 =
1
(− log(1− p(0)1 ))1/β1
b(1)1 =
b(0)1
HR(1/β1)1
p(1)1 = 1− e−(1/b
(1)
1 )
β1
2. Computations for the additional endpoint E2. The scale parameters b(0)2 and b
(1)
2
and the probability p(1)2 of observing the additional endpoint in group 1 are derived
as:
b(0)2 =

1
(− log(1−p(0)2 ))1/β2
for Case 1
∗ for Case 3
b(1)2 =
b(0)2
HR(1/β2)2
p(1)2 = 1− e−(1/b
(1)
2 )
β2
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∗ For Case 3, b(0)2 is found as the solution of equation p(1)2 =
∫ 1
0
∫ 1
u f (0)(1,2)(u,v;ρ)dvdu,
where f (0)(1,2)(·, ·;ρ) is the joint density between T (0)1 and T (0)2 and ρ is Spearman’s
ρ coefficient between T (0)1 and T
(0)
2 .
3. Computation of sample sizes n and n∗
(a) Compute n (per group) following Freedman (1982) formulas as follows
n =
E
p(0)1 + p
(1)
1
(8)
where
E =
(HR1 +1)2(z1−α+ zΠ)2
(HR1−1)2 (9)
(b) Compute ARE(Z∗,Z) based on (β1,β2, p(0)1 , p(0)2 ,HR1,HR2,ρ).
(c) Compute n∗ = n/ARE(Z∗,Z).
(d) Compute N = max{n,n∗}.
4. Simulation of T (0)1 ,T
(1)
1 ,T
(0)
2 ,T
(1)
2 ,T
(0)
∗ ,T
(1)
∗
Simulate 1000 samples of size N for the 4 endpoints T ( j)k from Weibull (b
( j)
k ,βk)
( j = 0,1, k = 1,2). Compute T ( j)∗ = min{T ( j)1 ,T ( j)2 }.
5. Computation of empirical powers ˆΠ1 and ˆΠ∗
For each sample of size n (n∗), compute the logrank statistic Z (Z∗) to compare the
treatment effect between T (0)1 and T
(1)
1 ( T (0)∗ and T (1)∗ ). For a given significance
level α, the rejection region comprises all observed Z (Z∗) such that Z < z1−α
(Z∗ < z1−α) where z1−α is the standard normal quantile corresponding to the left
tail probability α. The empirical powers, denoted by ˆΠ1 ( ˆΠ∗ ), are calculated as
the proportion of samples for which Z < z1−α (Z∗ < z1−α).
We note here that whenever n∗ < n, we only use, for each sample, the first n∗
simulated values to compute ˆΠ∗, while when n < n∗, we only use the first n
simulated values to compute ˆΠ1.
6. Comparison between ˆΠ1 and ˆΠ∗
For each scenario (β1,β2, p(0)1 , p
(0)
2 ,HR1,HR2,ρ), we compare the differences
between the two empirical powers ˆΠ1 and ˆΠ∗ obtained from the 1000 simulations.
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Table 1: Values of parameters β1, β2, p1, p2, HR1, HR2 and ρ used for the simulations. There are 624
different configurations, excluding those yielding sample sizes larger than 1100 and ARE(Z∗,Z)> 10.
Parameters
β1 = β2 0.5 1 2
(p1, p2) (0.05, 0.01) (0.05, 0.15) (0.05,0.35) (0.1, 0.01) (0.1, 0.15) (0.1,0.35)
(p1, p2) (0.15, 0.01) (0.15, 0.15) (0.15,0.35) (0.35, 0.01) (0.35, 0.15) (0.35,0.35)
ρ 0.15 0.45 0.75
(HR1,HR2) (0.5, 0.3) (0.5, 0.7) (0.5, 0.9) (0.6, 0.3) (0.6, 0.7) (0.6, 0.9)
(HR1,HR2) (0.7, 0.3) (0.7, 0.7) (0.7, 0.9) (0.8, 0.3) (0.8, 0.7)
Total number
of cases 624
4.2. Results
We have set Π = 0.9 and α= 0.05 (other values would not provide additional informa-
tion). We have chosen meaningful values for (β1,β2, p(0)1 , p(0)2 ,HR1,HR2,ρ), based on
those arising in cardiovascular clinical trials (Go´mez, Go´mez-Mateu, Dafni, 2014) (see
Table 1). We restrict our simulation study to 624 scenarios corresponding to ARE(Z∗,Z)
≤ 10 and sample sizes smaller than 1100 patients per group. These scenarios yield
ARE(Z∗,Z) values between 0.20 and 9.93, sample sizes, n, for the relevant endpoint
between 142 and 1081, and, n∗, for the composite endpoint between 53 and 1077 (see
Table 2). Similar results were obtained for Case 1, when neither the relevant nor the
additional endpoint includes a terminating event, and for Case 3 when the relevant end-
point includes a terminating event, and we only discuss here Case 1.
Table 2: Computed values of n, n∗ and ARE(Z∗,Z) in step 3 of the simulation
based on the parameter values given in Table 1.
min median max
n 142 509 1081
n∗ 53 398 1077
ARE(Z∗,Z) 0.2 1.04 9.93
The empirical powers ˆΠ1 in our simulation study resulted in powers between 0.87
and 0.94, with a median of 0.91. A slightly higher median was found for scenarios with
low hazard ratios. This finding is acknowledged as well by Freedman (1982).
Table 3 provides the percentiles for the absolute value differences between ˆΠ∗ and
ˆΠ1. We observe that in 75% of the cases the difference is smaller than 2.3%, and among
cases with ARE as large as 3 the difference shrinks to 1.9%. There are, however, few
instances, where this difference can be as large as 6%, and they deserve a closer look.
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Table 3: Percentiles of | ˆΠ∗− ˆΠ1| as a function of ARE values,
where wi indicates the corresponding percentile.
min w0.1 w0.25 w0.5 w0.75 w0.9 max
For all ARE 0 0.002 0.004 0.010 0.023 0.036 0.062
ARE(Z∗,Z)≤ 3 0 0.002 0.004 0.008 0.019 0.033 0.062
ARE(Z∗,Z)> 3 0.001 0.009 0.016 0.026 0.038 0.046 0.062
Figure 2 plots the differences ˆΠ∗− ˆΠ1 as a function of the ARE(Z∗,Z) values. The
behaviour is remarkably different when ARE(Z∗,Z)≤ 3 or ARE(Z∗,Z)> 3. Whenever
ARE(Z∗,Z) ≤ 3, ˆΠ∗ fluctuates around ˆΠ1, within a range of 4%. However, when
ARE(Z∗,Z) > 3, corresponding mostly to scenarios where treatment has an stronger
effect on the additional endpoint than on the relevant endpoint (HR2 ≤ HR1 − 0.2)
and the anticipated number of events in the control group is larger for the additional
endpoint than for the relevant (p(0)2 ≥ p(0)1 ), the empirical power ˆΠ∗ of the logrank test
based on the CE never achieves the same power as the logrank test for the relevant
endpoint would get. In these cases the interpretation of the ARE(Z∗,Z) as the ratio of
the sample sizes, n/n∗, is not as straightforward. Nevertheless, this does not mean that
the recommendation of using the CE does not have to be followed since larger values
for n∗ needed to attain the same power as n does, would reduce the ARE value but not
as much as to cross the “1” border that would imply to use the relevant endpoint instead
of the CE.
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Figure 2: Differences between empirical powers ˆΠ∗ − ˆΠ1 as function of ARE(Z∗,Z) and in terms of
HR2−HR1.
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If we analyze the differences between ˆΠ∗ and ˆΠ1 as a function of the differences
between the two hazard ratios (HR2 −HR1), we observe that when the two hazard
ratios are very close, the two empirical powers are as well very close. Whenever
HR2−HR1 ≤ −0.2, not only ARE(Z∗,Z) values tend to be higher, but also ˆΠ∗ < ˆΠ1.
(see Figure 2).
Taking into account that absolute differences between powers smaller than 5% could
be considered irrelevant, we conclude that the asymptotic relationship ARE(Z∗,Z) =
n/n∗ is valid in the majority of scenarios.
All computations in this paper have been implemented in R and are available on
request to either author.
5. Discussion
Pitman’s relative efficiency is defined as the limiting ratio of sample sizes to give the
same asymptotic power under sequences of local alternatives. Given two asymptotically
standard normal tests Sn and Tm under the same null and alternative hypotheses, the
alternative definition ARE = (µS/µT )2 where
√
nµS and
√
mµT are the respective
means under local alternatives, can be used because the equality of the powers holds
if m
n
= ( µSµT )
2
.
Go´mez and Lagakos’ method uses the alternative definition of ARE to develop all
the computations for the two corresponding logrank tests. Our goal has been to check
that the relationship between (µS/µT )2 and the ratio of sample sizes still held when the
two hypotheses under test were not the same (H0 versus Ha and H∗0 versus H∗a ).
It is important to keep in mind that these two hypotheses tests are by no means
equivalent, for instance, to check whether treatment has a beneficial effect, we might
use E1 or we might add endpoint E2 and use E∗. As it is shown in Go´mez (2011), even if
we assume that the times to E1 and to E2 are independent, a beneficial effect on E∗ can
occur simultaneously with a beneficial effect on E1 and a harmful effect on E2 and not
finding a beneficial effect on the composite event E∗ is no guarantee of not having some
effect on the individual events E1 or E2.
The main result of this paper proves that ARE(Z∗,Z) coincides with n/n∗, being n
and n∗ the sample sizes needed to detect specific alternatives HR1 and HR2 to attain
power Π and for the same significance level α. Therefore, we can use and interpret ARE
in its usual way.
The simulation study has been conducted in such a way that for fixed values n
and ARE(Z∗,Z), the sample size n∗ is calculated as n∗ = n/ARE(Z∗,Z). Hence an
approximate equality of the empirical powers ˆΠ1, of logrank test Z for H0 versus
Ha,n, and of ˆΠ∗ of logrank test Z∗ for H∗0 versus H∗a,n, indicates that the relationship
ARE(Z∗,Z) = n/n∗ holds. Main results from our simulations show that the absolute
differences between ˆΠ1 and ˆΠ∗ are most of the times less than 2.5%, hence the usual
interpretation between (n,n∗) and ARE(Z∗,Z) holds for finite sample sizes.
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For those scenarios under which ARE(Z∗,Z) > 3, we observe that the empirical
power of the test based on E∗ never achieves the empirical power that the logrank
test based on E1 would get. Consequently, larger values of n∗ would be needed to
attain the same power as n does. In these instances, even though the relationship
ARE(Z∗,Z) = n/n∗ is not necessarily true, the recommendation to use the composite
endpoint E∗ instead of the relevant endpoint E1 will still be valid because very rarely a
value of ARE(Z∗,Z)> 3 would go down to less than 1. However, caution will be needed
if one wants to use the relationship ARE(Z∗,Z) = n/n∗ to compute the required sample
size n∗ if ARE(Z∗,Z)> 3. In these cases, a different formulation should be seek.
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1. Introduction
The paper by Sankoh et al. [1] reviews the use of composite endpoints (CE) in randomized clinical trials
and advocates for its use because it leads to higher event rates. They also claim that ‘highly correlated
components do not add trial efficiency regarding gain in the overall event rate compared with disparate
or independent components’.
The purpose of this letter is to illustrate several situations where, in the presence of highly correlated
events, the more efficient primary endpoint (PE) is not always based on one single component. The
efficiency of the CE versus one of its components can be quantified by means of the Asymptotic Relative
Efficiency (ARE) [2] and with the aid of CompARE [3], a new web-based platform. We will base this
illustration on the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) trial [4].
Assume that the PE could be based either on a relevant endpoint (RE) or on a union of a RE and an
additional endpoint (AE). Let TR and TA be the times from randomization to RE and AE, respectively.
Under reasonable assumptions, the ARE, equivalent to the ratio of the sample sizes needed to attain the
same power for a fixed significance level [5], is expressed as a function of the following: (i) the marginal
laws of TR and TA; (ii) the probabilities pR and pA of observing RE and AE in the control group; (iii) the
treatment effects given by the hazard ratios HRR and HRA between the two treatment groups; and (iv) the
correlation between TR and TA. Whenever anticipated values for the aforementioned parameters can be
provided, the ARE can be evaluated and can guide the choice of the PE.
In the LIFE trial, the PE was composed of two clinically important outcomes, cardiovascular death
(CVD) and myocardial infarction (MI), and a softer outcome, stroke (ST). We use the values in Table I
(Table 3 of the original paper [4]) as the feasible anticipated values to study which would have been the
most efficient PE. Assume that, within the Atenolol group, the probability of observing CVD or MI is
pR = 0.06 (note that the probability of observing CVD and MI are, respectively, 0.05 and 0.04) and of
observing ST is pA = 0.07. The plots in Figure 1, which have been computed for the aforementioned
parameter values, illustrate how much more efficient it would be to add ST to CVD or MI. The plots
assume anticipated hazard ratios for CVD or MI equal to HRR = 0.89 (left) or HRR = 0.76 (right),
hazard ratios on ST varying from 0.75 to 0.89, and all possible correlations between (CVD or MI) and
ST. Observe that the ARE value heavily depends on the correlation between CVD or MI and ST, with
highly correlated situations leading to smaller ARE values. When HRR = 0.89, the ARE values are
always larger than 1, even when stroke is highly correlated with CVD or MI, and the recommendation
should have been to include ST into the definition of the PE. If a stronger treatment effect on CVD or MI
is anticipated (HRR = 0.76), and the hazard ratio on ST is smaller than 0.80, the ARE is still > 1 and,
again, ST should be included as part of the PE. However, for hazard ratios larger than 0.80 and moderate
or strong correlation between (CVD or MI) and ST, ARE is smaller than 1 and it would be much wiser
not to include ST into the definition of the PE.
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